

# Evidenztabelle der S3-Leitlinie Prostatakarzinom

Version 7.0 – Mai 2024

AWMF-Registernummer: 043-0220L

## Evidenztabelle

# Inhalt

<b>1</b>	<b>Informationen zu dieser Leitlinie.....</b>	<b>3</b>
1.1	Herausgeber .....	3
1.2	Federführende Fachgesellschaft.....	3
1.3	Finanzierung der Leitlinie .....	3
1.4	Kontakt.....	3
1.5	Zitierweise .....	3
1.6	Abkürzungsverzeichnis .....	4
<b>2</b>	<b>Leitliniensynopse .....</b>	<b>9</b>
2.1	AG Aktive Überwachung .....	11
2.2	AG Pathologie .....	22
2.3	Welche Bildgebung/Kriterien ist für die Indikationsstellung für Pluvicto notwendig?.....	23
2.4	Wann sollte die Indikation für eine Therapie mit Lutetium-177-PSMA beim mCRPC gestellt werden? .....	38
2.5	Schlüsselfrage: Welche neu zugelassenen Medikamente/Medikamentenkombinationen sind der Androgendeprivationstherapie oder Docetaxel+Androgendeprivationstherapie in der Therapie des mHSPC überlegen? .....	89
2.6	Schlüsselfrage: Welchen Stellenwert hat Relugolix im Vergleich zu anderen Androgendeprivationstherapien? .....	153
2.7	Welchen Stellenwert hat die molekulare Diagnostik auf HRR- Mutationen auf das Ergebnis der Therapie mit diesen neu zugelassenen Medikamenten/Medikamentenkombinationen für Patienten mit mCRPC? .....	158
2.8	Welche neu zugelassenen Medikamente/Medikamentenkombinationen sind den Standardtherapien in der Therapie des mCRPC überlegen? .....	178
<b>3</b>	<b>Literaturverzeichnis .....</b>	<b>209</b>

# 1 Informationen zu dieser Leitlinie

## 1.1 Herausgeber

Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF), Deutschen Krebsgesellschaft e. V. (DKG) und der Stiftung Deutsche Krebshilfe (DKH).

## 1.2 Federführende Fachgesellschaft



## 1.3 Finanzierung der Leitlinie

Diese Leitlinie wurde von der Deutschen Krebshilfe im Rahmen des Leitlinienprogramms Onkologie gefördert.

## 1.4 Kontakt

Office Leitlinienprogramm Onkologie  
c/o Deutsche Krebsgesellschaft e. V.  
Kuno-Fischer-Straße 8  
14057 Berlin

[leitlinienprogramm@krebsgesellschaft.de](mailto:leitlinienprogramm@krebsgesellschaft.de)

[www.leitlinienprogramm-onkologie.de](http://www.leitlinienprogramm-onkologie.de)

## 1.5 Zitierweise

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Evidenztabelle 7.0, 2024, AWMF-Registernummer: 043-022OL <https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/>; Zugriff am [tt.mm.jjj]

## 1.6 Abkürzungsverzeichnis

**Tabelle 1: Abkürzungsverzeichnis**

Abkürzung	Erläuterung
ACP	American College of Physicians
AD	Androgendeprivation
AE	Adverse Events
AHB	Anschlussheilbehandlung
AP	Anteroposterior
AR	Androgen Receptor
AS	Active Surveillance (aktive Überwachung)
AS	Androgen Suppression
ASAP	Atypical Small Acinar Proliferation
AUA	American Urological Association
BMV	Bundesmantelverträge
BOO	Bladder outlet (oder: orifice) obstruction
BSC	Best Supportive Care
CCI	Charlson Comorbidity Index
CTCAE	Common Terminology Criteria for Adverse Events
DCE-MRI	Dynamic contrast-enhanced magnetic resonance imaging
DES	Diethylstilbestrol
DRU	Digital-Rektale Untersuchung
DWI	Diffusion-weightend imaging
EAU	European Association of Urology
EBRT	External Beam Radiotherapy = perkutane Strahlentherapie
ECOG	Eastern Cooperative Oncology Group

<b>Abkürzung</b>	<b>Erläuterung</b>
EK	Expertenkonsens
EKG	Elektrokardiogramm
EMA	European Medicines Agency
EORTC	European Organisation for Research and Treatment of Cancer
ePLND	Extended Pelvic Lymph Node Dissection
FDA	Food and Drug Administration
FDG	Fluordesoxyglucose
fPSA	freies Prostata-spezifisches-Antigen
G-BA	Gemeinsamer Bundesausschuss
GKV	Gesetzliche Krankenversicherung
GnRH	Gonadotropin-Releasing-Hormone
GS	Gleason-Score
Gy	Kurzbezeichnung für die Maßeinheit der Energiedosis Gray
HDR	high dose rate
HIFU	Hochintensiver Fokussierter Ultraschall
HR	Hazard Ratio
HRR	homologen Rekombinationsreparatur
HT	Hormontherapie
HTA	Health Technology Assessment
ICI	Intrakavernöse Injektionen
ICRU	International Commission in Radiation Units and Measurement
IGeL	individuelle Gesundheitsleistungen
IGF	Insulin-like Growth Factors (insulinähnliche Wachstumsfaktoren)

Abkürzung	Erläuterung
IGRT	Image-guided radiation therapie (bildgesteuerte Strahlentherapie)
IMRT	Intensitätsmodulierte Radiotherapie
IPSS	International Prostate Symptom Score
IQWiG	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
KHK	Koronare Herzkrankheit
KI	Konfidenzintervall
KM	Knochenmetastase
LDR	Low-Dose Rate
LH-RH	Luteinisierendes Hormon Releasing Hormon
LK	Lymphknoten
LL	Leitlinie
LND	lymphonodectomy
LoE	Level of Evidence
mCRPC	metastasiertes, kastrationsresistentes Prostatakarzinom
mHSPC	hormonsensitives, metastasierten Prostatakarzinoms
MRS	Magnetresonanztomographie
MRSI	Magnet Resonance Spectroscopy Imaging
MRT	Magnetresonanztomographie
NICE	National Institute for Health and Care Excellence
nmCRPC	nicht-metastasiertes, kastrationsresistentes Prostatakarzinom
NNT	number needed to treat
NW	Nebenwirkungen
OL	Leitlinienprogramm Onkologie

Abkürzung	Erläuterung
OR	Quotenverhältnis (Odds-Ratio)
OS	Gesamtüberleben (Overall Survival)
PCa	Prostatakarzinom
PCTCC	Prostate Cancer Trialists Collaborative Group
PET/CT	Positronen-Emissionen-Tomographie/Computertomographie
PIN	Prostatische Intraepitheliale Neoplasie
PLCO	Prostate, Lung, Colorectal and Ovarian Cancer Screening
PPW	Positive prädikativer Wert
PSA	Prostata-spezifisches Antigen
PSADT	PSA-Doubling-Time
PSMA	Prostata-spezifisches Membranantigen
QoL	Lebensqualität (Quality of Life)
RCT	Randomized Controlled Trial
RPE	Radikale Prostatektomie
rPFÜ	radiologischen progressionsfreies Überleben
RT	radiotherapy = Radiotherapie
RTOG	Radiation Therapy Oncology Group
SEER	Surveillance, Epidemiology, and End Results (USA)
SGB	Sozialgesetzbuch
SIGN	Scottish Intercollegiate Guidelines Network
SPECT	Single-Photon-Emissionscomputertomographie
SRE	Skeletal related event, Skelett-bezogenes Ereignis
SRT	Salvagestrahlentherapie

<b>Abkürzung</b>	<b>Erläuterung</b>
SUV	Standardized uptake value
TED	Tele-Dialog
TRUS	Transrektale Ultraschalluntersuchung
TTP	Time To Progression
TURP	Transurethrale Resektion der Prostata
UAW	Unerwünschte Arzneimittelwirkungen
UICC	Union Internationale Contre le Cancer (eng.: Union for International Cancer Control)
UTI	Urinary Tract Infections
V.a.	Verdacht auf
VACURG	Veterans Administration Cooperative Urology Research Group
WHO	World Health Organization (Welt-Gesundheitsorganisation)
WW	Watchful Waiting
zVT	zweckmäßige Vergleichstherapie

## 2 Leitliniensynopse

### Evidenzlevel

Leitlinie	Empfehlungsgrad/ LoE	Erläuterung
AUA/ASTRO, 2022 [1]	LoE A	high we are very confident that the true effect lies close to that of the estimate effect
	LoE B	moderate we are moderately confident in the effect estimate the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
	LoE C	low our confidence in the effect is limited the true effect may be substantially different from the estimate of the effect very low we have very little confidence in the effect estimate the true effect is likely to be substantially different from the estimate of effect
	Strong Recommendation	directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is substantial
	Moderate Recommendation	directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is moderate

Leitlinie	Empfehlungsgrad/ LoE	Erläuterung
	Conditional Recommendation	non-directive statements used when the evidence indicates that there is no apparent net benefit or harm or when the balance between benefits and risks/burden is unclear.
EAU/EANM/ ESTRO/ESUR/ ISUP/SIOG 2023 [2]	LoE	based on the 2009 Oxford Centre for Evidence-Based Medicine (CEBM) Levels of Evidence
	Strong Recommendation	These principles follow the well-established GRADE methodology.
	Weak Recommendation	
NCCN 2023 [3]	Category 1	Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
	Category 2A	Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
	Category 2B	Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
	Category 3	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
NICE 2021 [4]	Evidence profile	These principles follow the well-established GRADE methodology. The evidence profiles were not assigned to the specific recommendations.

## 2.1 AG Aktive Überwachung

Leitlinie	Empfehlungen	AGREE II- Bewertung
AUA/ASTRO, 2022 [1]	<p>Risk-Based Management</p> <p>For patients with low-risk prostate cancer, clinicians should recommend active surveillance as the preferred management option. (Strong Recommendation; Evidence Level: Grade A)</p> <p>For patients with favorable intermediate-risk prostate cancer, clinicians should discuss active surveillance, radiation therapy, and radical prostatectomy. (Strong Recommendation; Evidence Level: Grade A)</p> <p><i>Clinicians should inform patients with intermediate-risk prostate cancer considering whole gland or focal ablation that there are a lack of high-quality data comparing ablation outcomes to radiation therapy, surgery, and active surveillance. (Expert Opinion)</i></p> <p>Principles of Active Surveillance</p> <p><i>Patients managed with active surveillance should be monitored with serial PSA values and repeat prostate biopsy. (Expert Opinion)</i></p> <p><i>In patients selecting active surveillance, clinicians should utilize mpMRI to augment risk stratification, but this should not replace periodic surveillance biopsy. (Expert Opinion)</i></p>	<p>Scope and Purpose (Domain 1): 17/21</p> <p>Rigour of Development (Domain 3): 31/56</p> <p>Editorial Independence (Domain 6): 9/14</p>
EAU/EANM/ESTRO/ESUR/ISUP/SIOG 2023 [2]	<p>Summary of evidence and guidelines for follow-up during active surveillance</p> <p><u>Summary of evidence</u></p> <p>Serial magnetic resonance imaging can improve the detection of aggressive cancers during follow-up. (LoE 3)</p> <p>A progression on magnet resonance imaging mandates a repeat biopsy before a change in treatment strategy. (LoE 3)</p>	<p>Scope and Purpose (Domain 1): 11/21</p> <p>Rigour of Development (Domain 3): 38/56</p>

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>A stationary magnet resonance imaging does not make repeat biopsy superfluous. (LoE 3) (S. 79)</p> <p><u>Recommendations</u></p> <p>Base follow-up during active surveillance on a strict protocol including digital rectal examination (at least once yearly), prostate-specific antigen (at least once every 6 months) and repeated biopsy every 2 to 3 years. (strong)</p> <p>Perform magnetic resonance imaging and repeat biopsy if prostate-specific antigen is rising (prostate-specific antigen doubling time &lt; 3 years). (strong)</p> <p>Re-classify patients with low-volume ISUP grade group 2 disease included in active surveillance protocols, if repeat non-magnetic resonance imaging-based systematic biopsies performed during monitoring reveal &gt; 3 positive cores or maximum core involvement &gt; 50%/core of ISUP 2 disease.</p> <p>Base change in treatment on biopsy progression, not on progression on MRI and/or prostate-specific antigen. (weak)</p> <p>Patients with a PI-RADS 1-2 findings on MRI and a low PSA density (&lt; 0.15) may be excepted from repeat biopsy. (weak) (S. 79)</p> <p>Summary of evidence and guidelines for the management of low-risk disease</p> <p><u>Summary of evidence</u></p> <p>Active surveillance or watchful waiting is standard of care, based on life expectancy. (LoE 2a)</p> <p>All active treatments options present a risk of over-treatment. (LoE 1a) (S. 79)</p> <p><u>Recommendations</u></p> <p>Manage patients with a life expectancy &gt; 10 years and low-risk disease by active surveillance. (strong) (S. 80)</p>	<p>Editorial Independence (Domain 6): 11/14</p>

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p><i>Selection of patients</i></p> <p>Patients with intraductal histology on biopsy should be excluded from active surveillance. (strong)</p> <p>Perform magnetic resonance imaging before a confirmatory biopsy if no magnetic resonance imaging has been performed before the initial biopsy. (strong)</p> <p>Take both targeted biopsy (of any PI-RADS <math>\geq 3</math> lesion) and systematic biopsy if a confirmatory biopsy is performed. (strong)</p> <p>If magnetic resonance imaging is not available, per-protocol confirmatory prostate biopsies should be performed. (weak)</p> <p>If a patient has had upfront magnetic resonance imaging followed by systematic and targeted biopsies there is no need for confirmatory biopsies. (weak) (S. 80)</p> <p><i>Follow-up of patients</i></p> <p>Repeat biopsies should be performed at least once every 3 years for 10 years. (weak)</p> <p>In case of prostate-specific antigen progression or change in digital-rectal examination or magnetic resonance imaging findings, do not progress to active treatment without a repeat biopsy. (strong) (S. 80/S. 129f.)</p> <p><i>Guidelines for the treatment of intermediate-risk disease</i></p> <p>Offer active surveillance to highly selected patients with ISUP grade group 2 disease (i.e. &lt; 10% pattern 4, prostate-specific antigen &lt; 10 ng/mL, <math>\leq</math> cT2a, low disease extent on imaging and low biopsy extent [defined as <math>\leq 3</math> positive cores and cancer involvement <math>\leq 50\%</math> core involvement/per core]), or another single element of intermediate-risk disease with low disease extent on imaging and low biopsy extent, accepting the potential increased risk of metastatic progression. (weak)</p> <p>Patients with ISUP grade group 3 disease should be excluded from active surveillance protocols. (strong)</p>	

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>Re-classify patients with low-volume ISUP grade group 2 disease included in active surveillance protocols, if repeat non- magnetic resonance imaging -based systematic biopsies performed during monitoring reveal &gt; 3 positive cores or maximum core involvement &gt; 50%/core of ISUP 2 disease. (weak) (S. 82/S. 130)</p> <p>Guidelines for quality of life in men undergoing local treatments</p> <p>Advise eligible patients for active surveillance that global quality of life is equivalent for up to 5 years compared to radical prostatectomy or external beam radiotherapy. (strong) (S. 145)</p>	
NCCN 2023 [3]	<p><b>PRINCIPLES OF ACTIVE SURVEILLANCE AND OBSERVATION</b></p> <p>The NCCN Prostate Cancer Panel and the NCCN Prostate Cancer Early Detection Panel (See NCCN Guidelines for Prostate Cancer Early Detection) remain concerned about overdiagnosis and overtreatment of prostate cancer. The Prostate Cancer Panel recommends that patients and their physicians carefully consider active surveillance based on the patient’s prostate cancer risk profile and estimated life expectancy. In settings where the patient’s age and comorbidities suggest a shorter life expectancy, observation may be more appropriate. Shared decision-making, after appropriate counseling on the risks and benefits of the various options, is critical.</p> <p><b>ACTIVE SURVEILLANCE</b></p> <p>Active surveillance involves actively monitoring the course of disease with the expectation to intervene with curative intent if the cancer progresses.</p> <p>Life Expectancy:</p> <p>Life expectancy is a key determinant for the choice between observation, active surveillance, and definitive treatment.</p> <p>Consider incorporating a validated metric of comorbidity such as the Adult Comorbidity Evaluation-27 Index (ACE-27) to differentiate between recommendations for observation versus active surveillance. Prior studies</p>	<p>Scope and Purpose (Domain 1): 21/21</p> <p>Rigour of Development (Domain 3): 40/56</p> <p>Editorial Independence (Domain 6): 13/14</p>

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>did not incorporate a validated metric of comorbidity to estimate life expectancy, which is a potential limitation when interpreting the data for a patient who is in excellent health.</p> <p>Life expectancy can be challenging to estimate for individual patients (see Principles of Life Expectancy Estimation, PROS-A).</p> <p>Candidacy for Active Surveillance:</p> <p>Active surveillance is preferred for patients with very-low-risk prostate cancer (See Risk Group Criteria [PROS-2]) and a life expectancy <math>\geq 10</math> years. (Observation is preferred for patients with a life expectancy <math>&lt; 10</math> years and very-low-risk disease.)</p> <p>Active surveillance is preferred for most patients with low-risk prostate cancer (See Risk Group Criteria [PROS-2]) and a life expectancy <math>\geq 10</math> years. The panel recognizes that there is heterogeneity across this risk group, and that some factors may be associated with an increased probability of near-term grade reclassification including high PSA density, a high number of positive cores (eg, <math>\geq 3</math>), and high genomic risk (from tissue-based molecular tumor analysis). In some of these cases, upfront treatment with RP or prostate RT may be preferred based on shared decision-making with the patient.</p> <p>Patients with favorable intermediate-risk prostate cancer (See Risk Group Criteria [PROS-2]) and a life expectancy <math>&gt; 10</math> years may also consider active surveillance. Particular consideration for active surveillance may be appropriate for those patients with a low percentage of Gleason pattern 4 cancer, low tumor volume, low PSA density, and/or low genomic risk (from tissue-based molecular tumor analysis).</p> <p>Confirmatory Testing to Establish Appropriateness of Active Surveillance:</p> <p>Goals of confirmatory testing are to help facilitate early identification of those patients who may be at a higher risk of future grade reclassification or cancer progression.</p> <p>Since an initial prostate biopsy may underestimate tumor grade or volume, confirmatory testing is strongly recommended within the first 6 to 12 months of diagnosis for patients who are considering active surveillance.</p>	

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>Options for confirmatory testing include prostate biopsy, mpMRI with calculation of PSA density (and repeat biopsy as indicated), and/orp molecular tumor analysis, see Principles of Risk Stratification (PROS-D).</p> <p>Early confirmatory testing may not be necessary in patients who have had an mpMRI prior to diagnostic biopsy.</p> <p>All patients should undergo a confirmatory prostate biopsy within 1–2 years of their diagnostic biopsy.</p> <p>Active Surveillance Program:</p> <p>Patients who choose active surveillance should have regular follow-up, and key principles include:</p> <p>PSA no more often than every 6 months unless clinically indicated.</p> <p>DRE no more often than every 12 months unless clinically indicated.</p> <p>Repeat prostate biopsy no more often than every 12 months unless clinically indicated. While the intensity of surveillance may be tailored on an individual basis, most patients should have prostate biopsies incorporated as part of their monitoring.</p> <p>Consider repeat mpMRI no more often than every 12 months unless clinically indicated.</p> <p>In patients with a suspicious lesion on mpMRI, MRI-ultrasound fusion biopsy improves the detection of higher grade (Grade Group <math>\geq 2</math>) cancers.</p> <p>Patients should be transitioned to observation when life expectancy is &lt;10 years.</p> <p>Repeat molecular tumor analysis is discouraged.</p> <p>The intensity of surveillance may be tailored based on patient life expectancy and risk of reclassification.</p> <p>Considerations for Treatment of Patients on Active Surveillance:</p> <p>Grade reclassification on repeat biopsy is the most common factor influencing a change in management from active surveillance to treatment.</p>	

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>Other factors affecting decisions to actively treat include: increase in tumor volume, a rise in PSA density, and patient anxiety.</p> <p>Considerations for a change in management strategy should be made in the context of the patient's life expectancy.</p> <p>Advantages of active surveillance:</p> <p>Between 50% and 68% of those eligible for active surveillance may safely avoid treatment for at least 10 years.</p> <p>Patients will avoid possible side effects of definitive therapy that may be unnecessary while on active surveillance.</p> <p>Quality of life/normal activities will be less affected while on active surveillance.</p> <p>Risk of unnecessary treatment of small, indolent cancers will be reduced.</p> <p>Limitations of active surveillance:</p> <p>Between 32% and 50% of patients will undergo treatment by 10 years,4-6 although treatment delays do not seem to impact cure rate.</p> <p>Although the risk is very low (&lt;0.5% in most series), it is possible for a cancer to progress to a regional or metastatic stage.</p> <p><b>OBSERVATION</b></p> <p>Observation involves monitoring with a history and physical exam no more often than every 12 months (without surveillance biopsies) until symptoms develop or are thought to be imminent.</p> <p>Observation is recommended for:</p>	

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>Asymptomatic patients in very-low-, low-, and intermediate-risk groups with life expectancy <math>\leq 5</math> years.</p> <p>Asymptomatic patients with very-low- and low-risk prostate cancer with a life expectancy 5–10 years.</p> <p>Observation is preferred for:</p> <p>Asymptomatic patients with favorable and unfavorable intermediate-risk prostate cancer and a life expectancy between 5–10 years.</p> <p>Observation may be considered for:</p> <p>Asymptomatic patients with high-risk, very-high-risk, regional, and metastatic prostate cancer and life expectancy <math>\leq 5</math> years.</p> <p>Life expectancy can be challenging to estimate for individual patients (see Principles of Life Expectancy Estimation, PROS-A). Consider incorporating a validated metric of comorbidity (see Life Expectancy, above).</p> <p>If patients under observation become symptomatic, an assessment of disease burden can be performed, and treatment or palliation can be considered (see PROS-12).</p> <p>Advantages of observation:</p> <p>Patients will avoid possible side effects of unnecessary confirmatory testing and definitive therapy.</p> <p>Limitation of observation:</p> <p>There may be a risk of local or systemic symptoms (eg, urinary retention, pathologic fracture), without prior symptoms or concerning PSA levels.</p> <p>PROS-A: PRINCIPLES OF LIFE EXPECTANCY ESTIMATION</p>	

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>Life expectancy estimation is critical to informed decision-making in prostate cancer early detection and treatment.</p> <p>Estimation of life expectancy is possible for groups of patients but challenging for individuals.</p> <p>Life expectancy can be estimated using:</p> <p>The Social Security Administration tables (<a href="http://www.ssa.gov/OACT/STATS/table4c6.html">www.ssa.gov/OACT/STATS/table4c6.html</a>)</p> <p>The WHO's Life Tables by country (<a href="http://apps.who.int/gho/data/view.main.60000?lang=en">http://apps.who.int/gho/data/view.main.60000?lang=en</a>)</p> <p>The Memorial Sloan Kettering Male Life Expectancy tool <a href="https://www.mskcc.org/nomograms/prostate">https://www.mskcc.org/nomograms/prostate</a></p> <p>If using a life expectancy table, life expectancy should be adjusted using the clinician's assessment of overall health as follows:</p> <p>Best quartile of health - add 50%</p> <p>Worst quartile of health - subtract 50%</p> <p>Middle two quartiles of health - no adjustment</p> <p>Example of upper, middle, and lower quartiles of life expectancy at selected ages are included in the NCCN Guidelines for Older Adult Oncology for life expectancy estimation.</p>	
NICE 2021 <a href="#">[4]</a>	<p>Localised and locally advanced prostate cancer</p> <p>1.3.8 For people with CPG 1 localised prostate cancer:</p> <p>offer active surveillance</p> <p>consider radical prostatectomy or radical radiotherapy if active surveillance is not suitable or acceptable to the person.</p> <p>1.3.9 For people with CPG 2 localised prostate cancer, offer a choice between active surveillance, radical prostatectomy or radical radiotherapy if radical treatment is suitable.</p>	<p>Scope and Purpose (Domain 1): 13/14</p> <p>Rigour of Development (Domain 3): 39/56</p> <p>Editorial Independence (Domain 6): 8/14</p>

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>1.3.10 For people with CPG 3 localised prostate cancer: offer radical prostatectomy or radical radiotherapy and consider active surveillance (in line with recommendation 1.3.14) for people who choose not to have immediate radical treatment.</p> <p>1.3.11 Do not offer active surveillance to people with CPG 4 and 5 localised and locally advanced prostate cancer. (S. 20)</p> <p>Multiparametric magnetic resonance imaging and protocol for active surveillance</p> <p>1.3.13 Offer multiparametric magnetic resonance imaging to people having active surveillance who have not had an magnetic resonance imaging previously. If the magnetic resonance imaging results do not agree with the biopsy findings, offer a new magnetic resonance imaging -influenced biopsy.</p> <p>1.3.14 Consider using the protocol in table 2 for people who have chosen active surveillance. (S. 21)</p> <p><u>Table Protocol for active surveillance</u></p> <p><u>Year 1 of active surveillance</u></p> <p>Every 3 to 4 months: measure prostate-specific antigen (could be carried out in primary care if there are agreed shared-care protocols and recall systems)</p> <p>Throughout active surveillance: monitor prostate-specific antigen kinetics (could include prostate-specific antigen density and velocity)</p> <p>At 12 months: digital rectal examination (should be done by a healthcare professional with expertise and confidence in performing digital rectal examination. In a large United Kingdom trial that informed this protocol, digital rectal examinations were carried out by a urologist or a nurse specialist)</p>	

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>At 12 to 18 months: multiparametric magnetic resonance imaging</p> <p><u>Year 2 and every year thereafter until active surveillance ends</u></p> <p>Every 6 months: measure prostate-specific antigen (could be carried out in primary care if there are agreed shared-care protocols and recall systems)</p> <p>Throughout active surveillance: monitor prostate-specific antigen kinetics (could include PSA density and velocity)</p> <p>Every 12 months: digital rectal examination (should be done by a healthcare professional with expertise and confidence in performing digital rectal examination. In a large United Kingdom trial that informed this protocol, digital rectal examinations were carried out by a urologist or a nurse specialist) (S. 22)</p> <p>1.3.15 If a person wishes to move from active surveillance to radical treatment at any stage in their care, make a shared decision to do so based on the person's preferences, comorbidities and life expectancy.</p> <p>1.3.16 Offer radical treatment to people with localised prostate cancer who had chosen an active surveillance regimen and who now have evidence of disease progression. (S. 22)</p>	

## 2.2 AG Pathologie

Leitlinie	Empfehlungen	AGREE II- Bewertung
AUA/ASTRO, 2022 <a href="#">[1]</a>	<p><b>Staging</b></p> <p>In patients with prostate cancer at high risk for metastatic disease with negative conventional imaging, clinicians may obtain molecular imaging to evaluate for metastases. (Expert Opinion) (S. 2)</p> <p><b>Risk Assessment</b></p> <p>Clinicians should use clinical T stage, serum prostate-specific antigen (PSA), Grade Group (Gleason score), and tumor volume on biopsy to risk stratify patients with newly diagnosed prostate cancer. (Strong Recommendation; Evidence Level: Grade A) (S. 1)</p> <p>Clinicians may selectively use tissue-based genomic biomarkers when added risk stratification may alter clinical decision-making. (Expert Opinion)</p> <p>Clinicians should not routinely use tissue-based genomic biomarkers for risk stratification or clinical decision-making. (Moderate Recommendation; Evidence Level: Grade B) (S. 2)</p> <p>Clinicians should perform an assessment of patient and tumor risk factors to guide the decision to offer germline testing that includes mutations known to be associated with aggressive prostate cancer and/or known to have implications for treatment. (Expert Opinion) (S. 3)</p>	<p>Scope and Purpose (Domain 1): 17/21</p> <p>Rigour of Development (Domain 3): 31/56</p> <p>Editorial Independence (Domain 6): 9/14</p>
EAU/EANM/ESTRO/ESUR/ISUP/SIOG 2023 <a href="#">[2]</a>	<p><b>Classification and staging systems</b></p> <p><u>Recommendations</u></p> <p>Use the Tumour, Node, Metastasis (TNM) classification for staging of prostate cancer. (strong)</p>	<p>Scope and Purpose (Domain 1): 11/21</p>

Leitlinie	Empfehlungen	AGREE II- Bewertung
	<p>Clinical stage should be based on digital rectal examination only; additional staging information based on imaging should be reported separately. (strong)</p> <p>Use the International Society of Urological Pathology 2019 system for grading of prostate cancer. (strong)</p> <p>Use the EAU risk group stratification for prognostic subgrouping of patients. (strong) (S. 24)</p> <p><b>Guidelines for germline testing</b></p> <p><u>Recommendations</u></p> <p>Consider germline testing in men with metastatic prostate cancer. (weak)</p> <p>Consider germline testing in men with high-risk prostate cancer who have a family member diagnosed with PCa at age &lt; 60 years. (weak)</p> <p>Consider germline testing in men with multiple family members diagnosed with PCa at age &lt; 60 years or a family member who died from prostate cancer. (weak)</p> <p>Consider germline testing in men with a family history of high-risk germline mutations or a family history of multiple cancers on the same side of the family. (weak) (S. 27)</p>	<p>Rigour of Development (Domain 3): 38/56</p> <p>Editorial Independence (Domain 6): 11/14</p>

1. Systematische Recherchen

AG mCRPC/mHSPC

## 2.3 Welche Bildgebung/Kriterien ist für die Indikationsstellung für Pluvicto notwendig?

Literaturreferenzen: [\[437\]](#), [\[438\]](#), [\[439\]](#), [\[440\]](#)

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
<b>Systematische Übersichtsarbeiten</b>								
<a href="#">[437]</a>	Systematic review with meta-analysis  study protocol: CRD42020206349  2++	We performed a systematic review and meta-analysis to assess the concordance between response evaluation using PSMA PET and PSA after systemic treatment and the association between	n=10 retrospective studies  n=247 men with mCRPC  Austria, Germany, India, Turkey  Search date: 27 August 2020	PSMA  PET, PET/CT or PET/MRI	PSA	<b>177Lu-PSMA</b> (n=5 studies)  0.78 (95% CI 0.71-0.85), p=0.69, I <sup>2</sup> =0%	PSA and PSMA PET response assessments are discordant in nearly a fourth of patients  with mCRPC undergoing systemic treatments. Results were consistent across different therapeutic agents and PET response criteria.	sources of funding of the included studies were not reported  The authors declare no conflict of interest.  This research was funded in part through the NIH/NCI Cancer Center Support Grant.

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		PSMA PET and other robust endpoints of overall and radiologic PFS in patients with mCRPC.						
[438]	Systematic review 2-	We present a comprehensive overview of the current literature covering retrospective studies, prospective	men with mCRPC n=40 studies retrospective studies (n=16) phase I/II trials (n=9) phase III trial (n=1)	Lutetium-177-PSMA-617		<b>Imaging/Biomarkers</b> PSMA-PET: has shown heterogeneity in PSMA expression among metastases suggesting its use as a biomarker of PSA response to 177Lu-PSMA-617	Amongst the studies, there is also inherent variation in measurement/biomarkers of response, PSMA imaging modalities used, retrospective vs. prospective designs, and small recruitment size.	no study protocol, no information if efforts were made to minimise errors in the data extraction, no summary (e. g. Table 1) of included studies, wrong risk of bias tool for included studies

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		<p>ve studies, and clinical trials that established 177Lu-PSMA-617 for the treatment of mCRPC.</p>	<p>clinical trials (n=11)                      real-world studies (n=3)                      Search date: February 1, 2023</p>			<p>FDG-PET: It provided the measure of tumor glycolysis, and in conjunction with PSMA-PET identified sites of disease that were FDG-positive but PSMA-negative</p> <p>high ALP and LDH have been associated with worse PFS and OS</p> <p>Androgen receptor mutations have been shown to be associated with worse prognosis in mCRPC and may be a way to predict resistance to</p>		<p>used, sources of funding of the included studies were not reported</p> <p>Detailed list of conflict of interest reported in the paper.</p> <p>This paper received no funding.</p>

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>177Lu PSMA-617 treatment</p> <p>PSMA expression in circulating tumor cells has been studied as a novel prognostic biomarker</p> <p>SUVmean of PSMA has shown to be a predictive biomarker for response to 177Lu-PSMA-617</p> <p>Nomograms: it was noted that tumors with high PSMA expression were associated with more favorable outcomes while bone disease was less likely to be adequately</p>		

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						controlled with Lu-PSMA		
[439]	Systematic Review 2-	To review current data in the literature regarding the impact of antiandrogen therapy on PSMA expression of metastatic sites and the role of serial (baseline and at least 1 follow-up scan) PSMA PET	n=36 studies (animal experiment/case reports, prospective and retrospective cohort studies) men with metastatic prostate cancer Search period: 2010- July 2022	antiandrogen therapy		<b>Role of serial PSMA PET/CT in assessing treatment responses in advanced PC (n=5)</b> <u>177Lu-PSMA-617 &amp; mCRPC</u> Substudies of the TheraP and VISION trials recently found that SUVmean at baseline PSMA PET was predictive of a favourable response to 177Lu-PSMA-617 RLT Prognostic significance of	PSMA PET imaging is essential in selecting patients for 177Lu-PSMA RLT. Growing evidence favors its use in assessing treatment responses after RLT. Preliminary evidence indicates the value of PSMA PET for assessment of the treatment response in patients receiving systemic treatment other than RLT for metastatic prostate cancer.	in the tables are 38 studies included, unclear which studies were identified via literature search, reference 15 are not included in the tables, only one database used and no additional hand search reported, only keywords reported, no information if efforts were made to minimise errors in the data extraction, no risk of bias assessment of the included

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		to assess treatment response in patients with metastatic prostate cancer.				<p>changes in PSMA PET parameters at followup scan has also been demonstrated</p> <p>Prognostic PET Parameter:</p> <p>PSMA-TV and PSMA-TL decrease had significantly longer OS than those without a decrease</p> <p>Progression according to PPP criteria was a significant prognostic marker for OS</p> <p>At early response assessment: OS was significantly higher in complete/partial response/stable</p>		<p>studies, sources of funding of the included studies were not reported</p> <p>Ken Herrmann has received personal fees from Bayer, Sofie Biosciences, SIRTEX, Adacap, Curium, Endocyte, Boston Scientific, Ipsen, Siemens Healthineers, GE Healthcare, Amgen, Novartis, ymabs, Aktis Oncology, Pharma15, Theragnostics Ltd., Janssen, Telix, Debiopharm,</p>

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						disease than in progressive disease according to modified PERCIST/EORTC criteria		Bain Capital, and Eco1R, other fees from Sofie Biosciences, nonfinancial support from ABX, and grants from Boston Scientific, all outside the submitted work. Obtaining funding: None.
<b>Health Technology Assessment</b>								
[441]	SR Includes: 3 RCTs Literature search: December 2018 to December 2022	Male patients (≥18 years old) with PSMA-positive mCRPC (ICD-10	177Lu-labelled PSMA inhibitor therapy administered intravenously	Best standard of care: Chemotherapy, e.g.: - Docetaxel (Docefrez/Taxotere®) + prednisone - Cabazitaxel (Jevtana®) + prednisolone +/- carboplatin		<b>OS:</b> 1 RCT (n=831): difference 15.3 vs. 11.3 mo, HR 0.62 <b>PFS:</b>	hinsichtlich des Gesamtüberlebens: bei vorbehandelten mCRPC eine Überlegenheit von 177Lu-PSMA-617 in Kombination	<b>GRADE:</b> sehr niedrige bis moderate Vertrauenswürdigkeit der Evidenz zur Wirksamkeit; niedrige

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		Code: Z19.2) total 1071 patients (age range: 68-72 yrs) ECOG Status $\leq 2$ Follow up range Range 18.4-20.3 months <b>Diagnosis, imaging procedure</b> <b>Used for initial tumor</b>	The active substance is the radionuclide $^{177}\text{Lu}$ -Lutetium ( $^{177}\text{Lu}$ ) Available agents of the RLT with PSMA: - $^{177}\text{Lu}$ -PSMA-617 (Pluvicto®, Endocyte, a Novartis company, USA) - $^{177}\text{Lu}$ -PSMA-I&T (Scintomics GmbH, Germany) - Agents synthesized by	- Mitoxantrone (Novantrone®) + prednisolone - Estramustine (Emcyt®) + docetaxel + prednisolone Hormonal agents, e.g: - Enzalutamide (Xtandi®) - Abiraterone (Zytiga®) Radiopharmaceuticals, e.g.: - Radium 223 (Xofigo®) PARP inhibitors for HRRm, e.g.: - Olaparib		1 RCT (n=581) 8.7 vs. 3.4 mo, HR 0.40 2 RCTs (n=280) no difference $^{177}\text{Lu}$ -PSMA-617 Vs Chemo <b>ORR:</b> 3 RCTs, nur 1 RCT (n=200) zeigte Unterschied nach 18,4 Mo: 49 % vs. 24 %, RR 2,12 <b>HRQL:</b> 1 RCT (n=581) berichtete längere Dauer bis HRQoL & Schmerz-	mit der Standardbehandlung (ohne zytotoxische Chemotherapie) gegenüber der Standardbehandlung alleine. mögliche Überlegenheit der $^{177}\text{Lu}$ -PSMA-617 Kombinationstherapie hinsichtlich des progressionsfreien Überlebens und der gesundheitsbezogenen Lebensqualität. Für weitere randomisierte Evidenz zur klinischen Wirksamkeit und Sicherheit	Vertrauenswürdigkeit der Evidenz zur Sicherheit Begründung: open-label Studiendesigns, fehlenden Daten, etc.

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		<b>evaluatio n:</b> 1 RCT not reported, 1 RCT CT, MRI, or bone- scan imaging, 1 RCT Ga-PSMA- 11 PET/CT, biopsy	radiophar macists			Verschlechterung in Pat. mit <sup>177</sup> Lu-PSMA- 617 + Standardbehandl ung keine Evidenz zur allgemeinen Lebensqualität <b>Unerwünschte            Ereignisse:</b> 1 RCT (n=183) keine Therapie- bedingten Todesfälle, in 2 RCTs (n=774) starben etwas mehr Pat. in der <sup>177</sup> Lu-PSMA-617	sind die Ergebnisse der längeren Nachbeobachtung der TheraP-Studie und laufende RCTs abzuwarten.	

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						(+ Standardbehandlung) Gruppe 2 RCTs (n=223) weniger Grad $\geq 3$ AEs in 177Lu-PSMA-617- vs. Chemotherapie- Gruppen, 1 RCT (n=734) mehr Grad $\geq 3$ AEs in Pat. mit 177Lu-PSMA-617 + Standardbehandlung		
<b>Randomisierte kontrollierte Studien</b>								

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[440]	RCT NCT03392428 (TheraP) 1+	We aimed to analyse gallium-68 [ <sup>68</sup> Ga]Ga-PSMA-11 PET (PSMA-PET) and 2-[ <sup>18</sup> F]fluorodeoxy-D-glucose PET (FDG-PET) imaging parameters as predictive and prognostic biomarkers in this patient	n=200 men with mCRPC 2018-2019 Australia (11 centres) Median follow-up: 18.4 mo (IQR 12.8-21.8 mo)	[ <sup>177</sup> Lu]Lu-PSMA-617  (intravenously, every 6 weeks for a maximum of six cycles)  n=99  Median age: 72.1 y (66.9-76.7 y)	Cabazitaxel  (20 mg/m <sup>2</sup> intravenously, every 3 weeks for a maximum of ten cycles)  n=101  Median age: 71.8 y (66.7-77.3 y)	<b>Cabazitaxel vs. [<sup>177</sup>Lu]Lu-PSMA-617</b> <b>PSA response</b> <u>PSMA SUVmean &lt;10</u>  OR: 2.22 (95% CI 1.11-4.51) <u>PSMA SUVmean ≥10</u>  OR: 12.19 (95% CI 3.42-58.76) <b>Radiographic PFS</b> <u>PSMA SUVmean &lt;10</u>  HR: 0.85 (95% CI 0.59-1.24) <u>PSMA SUVmean ≥10</u>  HR: 0.46 (95% CI 0.25-0.84) <b>PSA PFS</b>	In men with metastatic castration-resistant prostate cancer, PSMA-PET SUVmean was predictive of higher likelihood of favourable response to [ <sup>177</sup> Lu]Lu-PSMA-617 than cabazitaxel, which provides guidance for optimal [ <sup>177</sup> Lu]Lu-PSMA-617 use. High FDG-PET MTV was associated with lower responses regardless of randomly assigned treatment, warranting further research for treatment intensification.	Neither participants nor investigators were masked to group assignment, funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report, PET-CT images that were obtained as part of the eligibility assessment were centrally reviewed by three expert nuclear medicine physicians  OS is not yet published  Detailed list of conflict of

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		population.				<p><u>PSMA SUVmean &lt;10</u></p> <p>HR: 0.77 (95% CI 0.53-1.12)</p> <p><u>PSMA SUVmean ≥10</u></p> <p>HR: 0.45 (95% CI 0.25-0.80)</p> <p><b>PSA response</b></p> <p><u>FDG MTV &lt;200 mL</u></p> <p>Reference</p> <p><u>FDG MTV ≥200 mL</u></p> <p>OR: 0.44 (0.23-0.84)</p> <p><b>Radiografic PFS</b></p> <p><u>FDG MTV &lt;200 mL</u></p> <p>Reference</p> <p><u>FDG MTV ≥200 mL</u></p>		<p>interest reported in the paper.</p> <p>Funding Prostate Cancer Foundation of Australia, Endocyte (a Novartis company), Australian Nuclear Science and Technology Organization, Movember, The Distinguished Gentleman's Ride, It's a Bloke Thing, and CAN4CANCER.</p>

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						HR: 1.79 (1.28-2.52) <b>PSA PFS</b> <u>FDG MTV &lt;200 mL</u> Reference <u>FDG MTV ≥200 mL</u> HR: 1.44 (1.03-2.02) There was no evidence that other PET parameters (PSMA-PET SUVmax, PSMA-PET MTV, FDG-PET SUVmax, and FDG-PET SUVmean) were more valuable markers of response or prognosis than PSMA-PET		

Referenz	Studiencharakteristika	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						SUVmean or FDG-PET MTV.		

## 2.4 Wann sollte die Indikation für eine Therapie mit Lutetium-177-PSMA beim mCRPC gestellt werden?

Literaturreferenzen: [\[439\]](#), [\[442\]](#), [\[443\]](#), [\[444\]](#), [\[445\]](#), [\[446\]](#), [\[447\]](#), [\[448\]](#), [\[449\]](#), [\[450\]](#), [\[440\]](#), [\[451\]](#)

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
<b>Systematische Übersichtsarbeiten</b>								
<a href="#">[439]</a>	Systematic Review 2-	To review current data in the literature regarding the impact of antiandrogen therapy on PSMA expression of metastatic sites and the role of serial	n=36 studies men with metastatic prostate cancer Search period: 2010- July 2022	antiandrogen therapy		<b>Role of serial PSMA PET/CT in assessing treatment responses in advanced PC (n=5)</b> <u><a href="#">177Lu-PSMA-617 &amp; mCRPC</a></u> 177Lu-PSMA-617 RLT prolonged OS and imaging-based PFS	PSMA PET imaging is essential in selecting patients for 177Lu-PSMA RLT. Growing evidence favors its use in assessing treatment responses after RLT. Preliminary evidence indicates the value of PSMA PET for assessment of the treatment response in patients receiving systemic treatment other than RLT for metastatic prostate cancer.	in the tables are 38 studies included, unclear which studies were identified via literature search, reference 15 are not included in the tables, only one database used and no additional hand search reported, only keywords reported, no

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		(baseline and at least 1 follow-up scan) PSMA PET to assess treatment response in patients with metastatic prostate cancer.				when added to the standard of care (VISION 3)  nomograms to predict outcomes after <sup>177</sup> Lu-PSMA-617 therapy found that tumor SUVmax was an independent predictor of OS, PSA-PFS, and a PSA decline of ≥50%.  Substudies of the TheraP and VISION trials recently		information if efforts were made to minimise errors in the data extraction, no risk of bias assessment of the included studies, sources of funding of the included studies were not reported  Ken Herrmann has received personal fees from Bayer, Sofie Biosciences, SIRTEX, Adacap, Curium, Endocyte,

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>found that SUVmean at baseline PSMA PET was predictive of a favourable response to 177Lu-PSMA-617 RLT</p> <p>Prognostic significance of changes of PSMA PET parameters at followup scan has also been demonstrated</p>		<p>Boston Scientific, Ipsen, Siemens Healthineers, GE Healthcare, Amgen, Novartis, ymabs, Aktis Oncology, Pharma15, Theragnostics Ltd., Janssen, Telix, Debiopharm, Bain Capital, and Eco1R, other fees from Sofie</p> <p>Biosciences, nonfinancial support from ABX, and grants from Boston Scientific,</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
								all outside the submitted work.  Obtaining funding: None.
[442]	Systematic Review N=17  prospective or retrospective clinical (dosimetry) studies  between January 2014 and July 2021  LoE: 2-	To assess the organs at risk and the absorbed dose received by tumor lesions in 177Lu-PSMA therapy:  (1) assess the organs at risk and maximum tolerance limit in 177Lu-PSMA therapy and	N= 263 patients with mCRPC of any age received 177Lu-PSMA therapy pre- or post-therapeutic dosimetry in a single cycle or multiple cycles	177Lu-PSMA systemic radiation therapy (SRT)		<b>Median cumulative absorbed dose received</b> by lacrimal, salivary glands and kidneys were found 9.04 Gy (range: 2.8–28.12 Gy), 4.66 Gy (range: 1.74–9.88 Gy) and 3.08 Gy (range:	177Lu-PSMA systemic radiation therapy  (SRT) is a well-tolerated and reliable treatment option against the management of the mCRPC stage of prostate carcinoma.  Tumors receive 3–6 times higher absorbed doses compared to organs at risk.  BUT:	<b>Conflicts of interest:</b> None  <b>Funding:</b> ?  <b>ROB:</b>  No risk of bias assessment (at all!); no explanation of the selection of the study designs for inclusion in the review; no list of excluded studies or justification of exclusions; no report on the sources of

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		(2) assess the dose received by tumor lesions.				<p>1.68–5.32 Gy).</p> <p><i>maximum tolerance doses:</i></p> <p>~ 40 Gy for lacrimal,</p> <p>~ 20 Gy for salivary,</p> <p>~ 23 Gy for kidneys.</p> <p><b>Median absorbed dose per unit of administered activity for:</b></p> <p>kidneys, salivary, liver, spleen, lacrimal and bone marrow</p>	<p>Lacrimal gland (especially), salivary gland and kidneys are the organs that receive a significant amount of dose in <sup>177</sup>Lu-PSMA therapy.</p> <p>It is well-tolerated to</p> <p>achieve a number of treatment cycles of <sup>177</sup>Lu-PSMA SRT before surpassing the tolerance limit of lacrimal glands, salivary glands and kidneys.</p> <p>Individualized patient dosimetry is required to determine the maximum administered activity and number of treatment cycles</p>	<p>funding; no heterogeneity-discussion;</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						0.55, 0.81, 0.1, 0.1, 2.26 and 0.03 Gy/GBq. <b>Median absorbed dose per unit of activity for tumor lesions:</b> in a range of 2.71–10.94 Gy/GBq. <b>Assumption</b> : <u>no variation in the tracer uptake during 3-4 treatment cycles with <sup>177</sup>Lu-PSMA in normal organs</u>	before <sup>177</sup> Lu-PSMA therapy to prevent organ toxicity.	

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						estimated absorbed dose between: <b>lacrimal glands:</b> 27.12 and 36.16 Gy, <b>salivary glands:</b> 13.98 and 18.64 Gy <b>kidneys:</b> 9.24 and 12.32 Gy. àabsorbed doses for the kidneys: far below the dose tolerance limits. àlacrimal glands & salivary		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>glands: critical organs for 177Lu-PSMA SRT since the predicted absorbed dose limit after four treatment cycles* are very near to tolerance dose limit and will probably surpass it after five or six therapy cycles.</p> <p>*a cumulative activity of 20–21 GBq of 177Lu- PSMA can be</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						safely administered in 3–4 treatment cycles after considering the tolerance limit of these organs.		
[443]	Systematic Review and Meta-analysis N=24 (n= 3 prospective studies, n= 21 retrospective studies) LoE: 2-	To evaluate the efficacy and toxicity of PRLT.	N= 1192 patients with metastatic CRPC prior to PRLT (expect 1 study)	177Lu-PSMA or/and 177Lu-PSMA-I&T 177Lu-PSMA-617 (N=20 studies; 927 patients), 177Lu-PSMA-I&T (n=3 studies - 133 patients) a mix of 177Lu-PSMA-617 and 177Lu-PSMA- (1 study - 132 patients and reported aggregate data)		<b>PSA decrease of <math>\geq 50\%</math>:</b> <b>177Lu-PSMA-617 vs. 177Lu-PSMA-I&amp;T:</b> (after therapy; n=23 studies)	<b>aggregate data:</b> ~ 46% of CRPC patients being treated with more than one cycle of PRLT with either 177Lu-PSMA-I&T or 177Lu-PSMA-617 have PSA reductions of $\geq 50\%$ , indicating that these agents are objectively effective for this patient population.	<b>Funding/Support:</b> supported by: the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under award number T32EB006351;

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>0.41(0.36; 0.47); I<sup>2</sup>=67%</p> <p><b>PSA response</b> ≥50% (after more than one cycle of with 177Lu-PSMA-I&amp;T or 177Lu-PSMA-617; n=16 studies):</p> <p>0.46 (0.41; 0.51); I<sup>2</sup>=45%</p> <p><b>177Lu-PSMA-617</b> (after therapy at least an 8-wk interval between therapy and</p>	<p><b>Higher proportion of responders with therapy in the ≥8-wk interval group.</b></p> <p>PRLT: associated with ≥50% reduction in:</p> <ul style="list-style-type: none"> <li>prostate-specific antigen level in a large number of patients</li> <li>low rate of toxicity</li> <li>àpotential in treating castration-resistant prostate cancer</li> </ul> <p>Extraction of:</p> <ul style="list-style-type: none"> <li>≥50% serum prostate-specific antigen</li> <li>any PSA decrease,</li> <li>any PSA increase</li> </ul> <p>Ultimate utility of this treatment</p>	<p>the statistical analysis by the National Center for Research Resources and the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health through grant number 1UL1TR001079 ;</p> <p>funding from CA134675, CA183031, CA184228, EB024495, the Prostate Cancer Foundation</p> <p>Young Investigator</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>PSA measurements; n= 17 studies): 0.44 (0.39; 0.50); I<sup>2</sup>=52%</p> <p><b>177Lu-PSMA-I&amp;T</b>(after therapy with 177Lu-PSMA-I&amp;Tà ≥50% PSA reduction; n=3 studies) 0.36(0.26; 0.47); I<sup>2</sup>=18%</p> <p><b>Any decrease in PSA after therapy with:</b></p>	<p>modality will become clearer as multiple prospective studies continue to accrue.</p>	<p>Award, and the European Union's Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement 701983.</p> <p><b>Conflicts of interest:</b> None</p> <p><b>Limitations:</b> single-arm designs of the included studies heterogeneity between the studies 15 of the included</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>177Lu-PSMA-I&amp;T or 177Lu-PSMA-617</b></p> <p>(after therapy n= 17 studies)</p> <p>0.71(0.66; 0.75); I<sup>2</sup>=42%</p> <p><b>177Lu-PSMA-617</b></p> <p>(after therapy; n=17 studies)</p> <p>0.70(0.66; 0.75); I<sup>2</sup>=43%</p> <p><b>Any increase in PSA after therapy with:</b></p>		<p>studies were ongoing trials</p> <p>supplement is incomplete</p> <p>no comprehensive search strategy</p> <p>Numbers of reviewers: unclear</p> <p>Exclusion list: no information</p> <p>Risk of bias: just for publication bias</p> <p>pooled, but no information on the risk of bias</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>177Lu-PSMA-I&amp;T or 177Lu-PSMA-617</b> (after therapy; n=6 studies)</p> <p>0.27(0.20; 0.35); I<sup>2</sup>= 0%</p> <p>-----</p> <p><b><u>≥50% PSA decline</u></b> <b>after radioligand therapy, vs. the time interval between PRLT and PSA measurement (≥8 vs &lt;8 wk interval)</b></p> <p>2.20, p &lt; 0.001, 95%</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						CI [1.30; 3.10] → higher proportion of responders with therapy in the ≥8-wk interval group <b>One cycle vs more than one cycle of PRLT:</b> 0.84, $p < 0.001$ , 95% CI [0.36; 1.32] → more than one cycle: greater proportion of patients with ≥50%		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						PSA reduction  <b>Grade 3 and 4 toxicities</b> (were uncommon) nausea, fatigue, diarrhea, elevated aspartate transaminas e  0.01 (0.00;0.04) anemia  0.08 (0.05; 0.12)  <b>Overall survival (pooled HRs):</b>  for any PSA decline		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						0.29 (0.18; 0.46) for >50% PSA reduction 0.67 (0.43; 1.07) for >50% PSA decline 0.53 (0.32- 0.86) for the PFS of >50% PSA decline <b>Progression -free survival</b> (pooled HR of >50% PSA reduction): 0.53 (0.32; 0.86)		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[444]	Systematic review N= 12 (11 retrospective and 1 prospective study) articles up to May 2020, LoE: 2-	To precisely evaluate the impact of visceral metastases on biochemical response and survival outcomes in patients of mCRPC treated with Lu-PSMA RLT.	N= 1504 mCRPC-patients with progressive disease despite prior treatments with antiandrogens and/or chemotherapy and administered 177Lu-PSMA RLT as salvage/compassionate treatment.	177Lu-PSMA-617 or 177Lu-PSMA-I&T		<b>Visceral metastases and low biochemical response rate:</b> <b>(pooled univariate)</b> OR: 0.38, 95% CI, 0.22–0.66 <b>Visceral metastases and prognosticator of worse progression-free survival</b> <b>(pooled univariate)</b>	Presence of visceral metastases was associated with poor response and survival outcomes in patients of mCRPC treated with 177Lu-PSMA RLT. The results are clinically significant for pretreatment risk stratification of such patients and to guide optimal treatment strategies.	<b>Funding:</b> ? <b>Conflict of interest:</b> ? Individual regression estimates for biochemical response, PFS, and OS were not available in all of these studies, and consequently, pooled analysis of the ORs and HRs was feasible only in a limited number of studies. Most studies were retrospective and single-arm in nature and

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						HR, 1.85; 95% CI, 1.39–2.46  (pooled multivariate)  HR, 1.48; 95% CI, 1.15–1.92  <b>Visceral                      metastases                      and OS</b>  (pooled univariate)  HR, 1.77; 95% CI, 1.29–2.44  (pooled multivariate)  HR, 2.22; 95% CI, 1.82–2.70		thus had an inherent high risk of bias. Pooled estimates of univariate ORs and HRs could have been affected by other clinical variables;  however, the corresponding multivariate estimates, wherever available, were not markedly different. The impact of liver metastasis vis- à-vis lung metastasis on treatment outcomes was

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
								also not investigated  in most of the studies and needs further research.
<a href="#">[445]</a>	Systematic Review with meta-analysis  2++	This study was conducted to precisely evaluate the impact of prior taxane chemotherapy on response and survival outcomes in mCRPC patients after [177Lu]Lu-PSMA-RLT.	n=13 articles (11 single-arm interventional studies, 2 retrospective studies)  n=2068 patients with mCRPC  Median age: 71.6 y (range 30-92 y)  Median follow-up: 9.9 mo	Taxane-Naïve patients  n=590	Taxane-Treated Patients  n=1477	<b>Taxane-naïve vs. taxane-treated patients after 177Lu-PSMA-RLT</b>  <b>PSA Response</b> (n=6 studies)  OR 1.82 (95% CI, 1.21-2.71; p=0.004) I <sup>2</sup> =0%	mCRPC patients with no prior taxanes had significantly better outcomes after [177Lu]Lu-PSMA-RLT than did taxane-treated patients.	sources of funding of the included studies were not reported  No potential conflict of interest relevant to this article was reported.  Funding not reported.

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			(range 0.5-72 mo)  search date: December 19, 2022			<b>PFS</b> (n=5 studies)  HR 0.6 (95% CI, 0.51-0.69; P<0.001), I <sup>2</sup> =0%  <b>OS</b> (n=8 studies)  HR 0.54 (95% CI, 0.43-0.68; P<0.001), I <sup>2</sup> =0%		
[446]	systematic review and meta-analysis  N= 36 (all types of study design)  Search for publications up to 31 September 2020	To evaluate patient and treatment characteristics for patients with metastatic castration-resistant	N= 2346 patients above 18 with multi-resistant mCRPC	PRLT (177Lu PRLT or 225 Act PRLT)	Comparative analyses evaluated whether characteristics differed in impact on	<b>OS in general:</b>  Patients with PSA decline ≥ 50% vs. with less PSA decline  <u>median 20 months vs.</u>	<b>OS:</b>  177Lu PSMA I&T and 177Lu PSMA-617 had a similar rates of PSA decline ≥ 50%.  More patients treated with an intensive schedule	<b>Conflicts of Interest:</b> None  <b>Funding:</b> None  Some publications did not state whether they reported consecutive

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
	LoE: 2-	<p>prostate cancer (mCRPC) treated with PSMA radioligand therapy (PRLT) associated with above-average outcome.</p> <p>associated with an <b>above-average overall survival (OS)</b>.</p> <p>proportion of patients with <b>severe adverse effects (SAE)</b></p>			the outcome	<p><u>12 months</u>, p = 1.6 × 10<sup>-6</sup></p> <p>Relevant characteristics of patients regarding OS:</p> <p><b><u>Metastases / cancer</u></b></p> <p><b><u>PSA decline ≥ 50% after PRLT:</u></b> <b><u>(patients with lymph node metastases (LNM) vs. patients with bone metastases):</u></b></p> <p>36 of 45 versus 38 of</p>	<p>for 177Lu PRLT in the first series had a PSA decline ≥ 50% than those treated with a conventional schedule</p> <p>Patients treated with an intensified schedule of 177Lu PRLT lived longer than those treated with a conventional* schedule.</p> <p>*Conventional schedule mostly: 6 GBq 177Lu for each cycle of PRLT and ≥8 weeks between cycle.</p> <p>Characteristics regarding the patients, art of cancer/ metastases, restaging and PLRT</p>	<p>patients, other publications reported preliminary results, and a third group of publications did not report on all outcomes our systematic review aimed to address.</p> <p>Only a few patients with favorable patient characteristics were reported, only a few patients treated with intensified 177Lu PRLT, and only two radioligands</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>100, p &lt; 0.0005.</p> <p>Patients with cancer lesions with a high uptake of 177Lu lived longer than patients with a low uptake.</p> <p><b><u>Restaging - PET/CT:</u></b></p> <p><u>PSA decline ≥ 50% after 1<sup>st</sup> series of PLRT</u></p> <p><u>(PSMA based radioligand therapy)</u></p> <p><b>First series of PRLT</b></p>	<p>contribute to an above-average OS after PLRT</p> <p>of patients with mCRPC (= highly significant findings).</p> <p>Only hepatic metastases caused the negative impact visceral metastases to have an outcome after PTRLT relative to that of bone metastases.</p> <p>PSMA PET/CT resulted in a better staging of patients with PC than conventional imaging such as bone and CT scans</p> <p><b>Chemotherapy-naïve patients were treated at an earlier phase</b> in the</p>	<p>used as monotherapy for patients with mCRPC. No report in the combined effect of all characteristics that determine the response after PRLT and OS.</p> <p>No list of excluded studies; risk of bias only regarding publication bias; heterogeneity between publications but no separate summary</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>Intensive 177 LU</b></p> <p>N= 2 studies (Rasul, Seifert)</p> <p>56(46-66); 95% CI</p> <p><b>lymph node metastases</b></p> <p>N= 1 study (Von Eyben)</p> <p>80(67-92); 95% CI</p> <p>255 Act</p> <p>N=2 (Sathekge, Yadav)</p> <p>75(59-89); 95% CI</p> <p><b>Conventional 177LU</b></p>	<p>sequence of treatments of mCRPC than patients resistant to chemotherapy. For many cancers in addition to PC, asymptomatic patients with good performance status live longer than patients with symptoms and poor performance status</p> <p><b><u>Severe Adverse Effects (SAE)</u></b></p> <p>Treatment with 177Lu PRLT=safe; none died of SAE; none developed leukemia.</p> <p>In the treatment of mCRPC, PRLT is an optimal candidate</p>	<p>estimates for RCTs and NRSI</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>N=18 studies 44(39-49); 95% CI</p> <p><b>TOTAL:</b> 48(43-54); 95% CI</p> <p><u>PSA decline</u> <u>≥ 50% after</u> <u>2<sup>nd</sup> series of</u> <u>PRLT</u></p> <p><b>225</b> <b>Actinium</b> <b>PLRT</b></p> <p>N=3 studies 46(19-75) 95% CI</p> <p><b>177 LU</b> <b>PLRT</b></p> <p>55(44-66); 95% CI</p> <p><b>TOTAL:</b></p>	for being combined with established drugs.	

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						50(36-56) 95% CI SUVaverage/ min <u>SAE:</u> rare and mailly hematologic SAE grade 3* (of the treated patients, a median of 10% had anemia grade 3, median 3% had leucopenia grade 3, median 2%, thrombocytopenia grade 3 *similar rates of		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						grade 3 hematologic SAE between 225 Act PRLR or 177Lu PRLT		
<b>Randomisierte kontrollierte Studien</b>								
[447]	RCT NCT03511664, (VISION) 1-	We report additional HRQOL, pain, and symptomatic skeletal event results.	n=831 men with mCRPC 2018-2019 84 sites in nine countries 52 in North America 32 in Europe	177Lu- PSMA-617 (maximum of six cycles every six weeks) plus standard care n=385 Median age: 71 y (range 65-75 y)	standard care n=196 Median age: 72 y (range 66- 76 y)	<b>177Lu- PSMA-617 vs. standard care</b>  <b>Median time to first symptomatic skeletal event</b>  <i>Median follow-up: 17 mo</i>  11.5 vs. 6.8 mo; HR 0.5 (95% CI 0.4-	[ <sup>177</sup> Lu]Lu-PSMA-617 plus standard of care delayed time to worsening in HRQOL and time to skeletal events compared with standard of care alone. These findings support the use of [ <sup>177</sup> Lu]Lu- PSMA-617 in patients with metastatic castration-resistant prostate cancer who received previous androgen receptor pathway inhibitor	open-label study  The funder of the study had a role in study design, data analysis, data interpretation, and writing of the report, but had no role in data collection.  Detailed list of conflict of interest

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>0.62) p&lt;0.001</p> <p><b>Time to worsening (FACT-P score)</b></p> <p><i>Median follow-up: 4.37 mo (IQR: 1.02-8.08 mo)</i></p> <p>5.7 vs. 2.2 mo; HR 0.54 (95% CI 0.45-0.66) p&lt;0.001</p> <p><b>EQ-5D-5L utility score</b></p> <p>1 vs. 0.5 mo; HR 0.65 (95% CI 0.54-0.78) p&lt;0.001</p>	and taxane treatment.	<p>reported in the paper.</p> <p>Supported by Endocyte, a Novartis company</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>Pain intensity (BPI-SF)</b></p> <p><i>Median follow-up: 4.14 mo (IQR: 1.64-8.77 mo)</i></p> <p>6.9 vs. 2.6 mo; HR 0.52 (95% CI 0.42-0.63) p&lt;0.001</p> <p><b>Treatment-related adverse events</b></p> <p><u>Death</u></p> <p>177Lu-PSMA-617: 5 (pancytopenia [n=2], bone marrow failure [n=1],</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						subdural haematoma [n=1], and intracranial haemorrhage [n=1]) standard care: 0		
[448]	RCT CTRI/2019/12/022282 1-	We report the final analysis of OS for a phase 2 RCT.	n=40 men with chemotherapy-naïve patients with mCRPC Mean follow-up: 33.4 mo	[177Lu]Lu-PSMA-617 (6.0–7.4 GBq/cycle intravenously, up to 4 cycles, 8–12 wk apart) n=20	docetaxel (75 mg/m <sup>2</sup> /cycle intravenously, up to 10 cycles, 3 wk apart) n=20	<b>Median OS</b> Lutetium: 15.0mo (95% CI, 9.5–20.5 mo) docetaxel: 15 mo(95% CI, 8.1–21.9 mo)	Long-term outcomes with [177Lu]Lu-PSMA- 617 administered earlier in the prechemotherapy setting are comparable to those with docetaxel.	The study sample size was based on the primary endpoint of prostate-specific antigen response rate and was not adequately powered for other analyses.  Randomisation process not clearly described,

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
								open-label study, important patient characteristics not described (e. g. age)  No potential conflict of interest relevant to this article was reported.  Funding: not reported
[449]	randomized, controlled, phase 2 non-inferiority trial  CTRI/2019/12/022282  LoE: 1-	To prospectively compare the efficacy and safety of <sup>177</sup> Lu-PSMA-617 and docetaxel in chemothera	N= 40 men with chemotherapy-naïve patients with mCRPC and high PSMA-expressing	N=20 patients  177 Lu-PSMA-617 (6.0–7.4 GBq/cycle, every 8	N=20 patients  docetaxel (75 mg/m <sup>2</sup> /cycle, every 3 weeks, up	<b>per-protocol analysis:</b>  <u>best PSA-RR</u>  177 Lu-PSMA-617: (9/15) (60%, 95% CI: 35–85)	<b><sup>177</sup>Lu-PSMA-617=</b> safe and non-inferior to docetaxel in the treatment of mCRPC  regarding achieving PSA response in chemotherapy-naïve mCRPC with an	<b>Conflict of interest:</b> none  <b>Funding:</b> ?  <b>Limitations:</b> open-label nature of the study; lack of a baseline <sup>18</sup> F-

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		<p>py-naïve mCRPC patients.</p> <p>Primary outcome: best prostate-specific antigen response rate (PSA-RR)</p>	<p>lesions on 68 Ga-PSMA-11 PET/CT</p> <p>2019-2021</p>	<p>weeks, up to 4 cycles)</p> <p>high-grade prostate cancer</p> <p>14 (70%)</p> <p>15/20 = treatment per protocol</p> <p><b>49 cycles - median cumulative activity:</b></p> <p>of 15 GBq (range 6-30 GBq) over 1-4 cycles at intervals of 8-16 weeks</p> <p>àIntervals were disturbed by COVID-19</p>	<p>to 10 cycles)</p> <p>high-grade prostate cancer</p> <p>12 (60%)</p> <p>20/20= treatment per protocol</p> <p><b>5 cycles:</b></p> <p>all the patients;</p> <p><b>10 cycles:</b></p> <p>11 patients (55%)</p> <p><b>discontinued further cycles due to</b></p>	<p>docetaxel: (8/20) (40%, 95% CI: 19-61)</p> <p><u>Difference (PSA-RRs):</u></p> <p>177 Lu-PSMA-617 vs. docetaxel</p> <p>20% (95% CI: -12-47, P = 0.25)</p> <p><b>ITT analysis</b></p> <p><u>Best PSA-RR</u>(defined according to Prostate Cancer Clinical Trials Working Group-3 as proportion</p>	<p>acceptable safety profile.</p> <p>Could be potentially employed earlier in the disease course rather than being solely reserved for advanced end-stage disease. Further large-scale trials are required to validate our observations and determine the specific sequence of treatment options for these patients.</p>	<p>FDG-PET/CT; unavoidable delays in the treatment administration and follow-up in few patients during the COVID-19 pandemic; calculated sample size was adequate for PSA-RR as the primary end-point and not for the other observations.</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
				<b>at least one cycle:</b> all patients <b>at least two cycles:</b> 15 pat. (75%) <b>3 cycles</b> 2 pat. (10%) <b>4 cycles</b> 6 pat. (30%) <b>not completing four cycles</b> (disease progression) 7 pat. (35%) <b>disease-related deaths:</b>	<b>progressive disease:</b> 7 patients (35%); <b>did not complete treatment (chemotherapy-related interstitial pneumonitis)</b> 1 patient <b>8 cycles:</b> 1 patient died	of patients achieving $\geq$ 50% decline in PSA from baseline): 177 Lu-PSMA-617: (50%, 95% CI: 28-72) (10/20) Docetaxel: (40%, 95% CI: 19-61) (8/20) <u>Difference - 177 Lu-PSMA-617 vs. docetaxel</u> 10% (95% CI: -19-37, P = 0.53)		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
				3 pat. (15%) <b>persistent treatment (myelosuppression) (≥ grade 3)</b> 2 pat. (10%) <b>exceptional response</b> 2 patients (10%)		<b>Per-protocol analysis</b> <u>best objective response</u> 177Lu-PSMA-617 (5/11) (46%, 95% CI: 16-75) docetaxel (6/19) (32%, 95% CI: 11-52) <u>difference</u> 14% (95% CI: -19-45, P = 0.45) <u>best molecular response rates</u>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>177 Lu-PSMA-617</p> <p>50% (95% CI: 22-78)</p> <p>docetaxel</p> <p>32% (95% CI: 11-52)</p> <p><u>difference</u></p> <p>18%, (95% CI: - 14-48, P = 0.31)</p> <p><b>ITT analysis:</b></p> <p><u>best objective response</u></p> <p>177 Lu-PSMA-617</p> <p>(5/13) (39%, 95% CI: 12-65)</p> <p>docetaxel</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>(6/19) (32%, 95% CI: 11- 52)</p> <p><u>Difference:</u></p> <p>(7%, 95% CI: - 24-38, P = 0.69)</p> <p><u>best molecular responses:</u></p> <p>177 Lu- PSMA-617</p> <p>(6/14) (43%, 95% CI: 17- 69)</p> <p>docetaxel</p> <p>(6/19) (32%, 95% CI: 11- 52)</p> <p><u>Difference</u></p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						11%, 95% CI: - 19-41, P = 0.51) <b>Per-protocol</b> <u>median PFS</u> <u>durations</u> 177 Lu- PSMA-617 5.0 months (95% CI: 3.3- 6.7) <u>docetaxel</u> <u>arms</u> 4.0 months (95% CI: 3.6- 4.4) (P = 0.30) <u>Corresp. PFS</u> <u>rate at 6</u> <u>months</u>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>177Lu-PSMA-617: 30%</p> <p>Docetaxel: 20%</p> <p><u>difference</u></p> <p>10%, 95% CI: - 18-38, P = 0.50)</p> <p><u>progression-free survival rates at 6 months:</u></p> <p>177 Lu-PSMA-617 and docetaxel arms respectively: 30% and 20%</p> <p><u>Difference:</u></p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						10% (95% CI: - 18-38, P = 0.50)  <b>ITT analysis</b>  <u>PFS 4.0                      months</u>  177 Lu- PSMA-617  (95% CI: 1.8- 6.2 months)  docetaxel  (95% CI: 3.6- 4.4 months)  (P = 0.98)  <u>PFS rate at 6                      months</u>  177Lu- PSMA-617 vs. docetaxel  23% vs. 20%		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>difference</u></p> <p>3%, 95% CI: - 22-28, P = 0.82</p> <p><u>disease progression or death</u></p> <p>177 Lu- PSMA-617 versus docetaxel</p> <p>HR:0.90 (95% CI: 0.46-1.77)</p> <p>----- --</p> <p><b><u>treatment- emergent grade ≥ 3adverse events:</u></b></p> <p>177 Lu- PSMA-617</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						6/20, (30%, 95% CI: 10- 50)  docetaxel  10/20, (50%, 95% CI: 28- 72)  P = 0.20  <u>Difference</u>  20%, (95% CI: - 10-45, P = 0.20)  <u>Quality-of- life outcomes:</u>  177 Lu- PSMA-617 compared to  docetaxel arm:  P < 0.01		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[450]	RCT NCT0351166 (VISION) 1-	We report the results of VISION, a phase 3 trial investigating the efficacy and safety of 177Lu-PSMA-617 plus protocol-permitted standard care in a specific population of previously treated patients with mCRPC who were selected for PSMA positivity on	n=831 men with mCRPC 2018-2019 84 sites 52 in North America 32 in Europe Median follow-up: 20.9 mo	177Lu-PSMA-617 (maximum of six cycles every six weeks) plus standard care n=551 Median age: 70 y (range 48-94 y)	standard care n=280 Median age: 71.5 y (range 40-89 y)	<b>177Lu-PSMA-617 vs. standard care</b> <b>Median imaging-based PFS</b> (n=581) 8.7 vs. 3.4 mo; HR 0.40 (99.2% CI 0.29-0.57) p<0.001 <b>Median OS</b> (n=831) 15.3 vs. 11.3 mo; HR 0.62 (95% CI, 0.52-0.74) p<0.001 <b>Median time to first</b>	Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer.	open-label study, objective response and disease control not reported, conflict of interest not clearly described Standard-care therapy that was permitted by the trial protocol had to be agreed on and assigned by the physician-investigator before randomization,

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		the basis of PSMA positron-emission tomographic imaging.				<p><b>symptomatic skeletal event</b> (n=581)</p> <p>11.5 vs. 6.8 mo; HR 0.5 (95% CI 0.4-0.62) p&lt;0.001</p> <p><b>Complete response</b> (n=248)</p> <p>9.2% (17/184) vs. 0% (0/64)</p> <p><b>Partial response</b> (n=248)</p> <p>41.8% (77/184) vs. 3% (2/64)</p> <p><b>Incidence of adverse events of</b></p>		<p>but it could be modified at the discretion of the treating physician. Standard-care therapies could not include cytotoxic chemotherapy, systemic radioisotopes (e.g. radium-223), immunotherapy, or drugs that were investigational when the trial was designed (e.g. olaparib). Supported by Endocyte, a Novartis company.</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<b>grade 3 or above</b> (n=831)  52.7% vs. 38.0%		
[440]	RCT NCT03392428 (TheraP)  1+	We aimed to analyse gallium-68 [ <sup>68</sup> Ga]Ga-PSMA-11 PET (PSMA-PET) and 2-[ <sup>18</sup> F]fluoro-2-deoxy-D-glucose PET (FDG-PET) imaging parameters as predictive and prognostic biomarkers in this patient population.	n=200 men with mCRPC  2018-2019  Australia (11 centres)  Median follow-up: 18.4 mo (IQR 12.8-21.8 mo)	[ <sup>177</sup> Lu]Lu-PSMA-617 (intravenously, every 6 weeks for a maximum of six cycles)  n=99  Median age: 72.1 y (66.9-76.7 y)	Cabazitaxel I (20 mg/m <sup>2</sup> intravenously, every 3 weeks for a maximum of ten cycles)  n=101  Median age: 71.8 y (66.7-77.3 y)	<b>Cabazitaxel vs. [<sup>177</sup>Lu]Lu-PSMA-617</b>  <b>PSA response</b>  <u>PSMA SUVmean</u> $\leq 10$  OR: 2.22 (95% CI 1.11-4.51)  <u>PSMA SUVmean</u> $\geq 10$  OR: 12.19 (95% CI 3.42-58.76)	In men with metastatic castration-resistant prostate cancer, PSMA-PET SUVmean was predictive of higher likelihood of favourable response to [ <sup>177</sup> Lu]Lu-PSMA-617 than cabazitaxel, which provides guidance for optimal [ <sup>177</sup> Lu]Lu-PSMA-617 use. High FDG-PET MTV was associated with lower responses regardless of randomly assigned treatment,	Neither participants nor investigators were masked to group assignment, funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report, PET-CT images that were obtained as part of the eligibility assessment

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>Radiografic PFS</b></p> <p><u>PSMA SUVmean</u> <u>&lt;10</u></p> <p>HR: 0.85 (95% CI 0.59-1.24)</p> <p><u>PSMA SUVmean</u> <u>≥10</u></p> <p>HR: 0.46 (95% CI 0.25-0.84)</p> <p><b>PSA PFS</b></p> <p><u>PSMA SUVmean</u> <u>&lt;10</u></p> <p>HR: 0.77 (95% CI 0.53-1.12)</p>	warranting further research for treatment intensification.	<p>were centrally reviewed by three expert nuclear medicine physicians</p> <p>OS is not yet published</p> <p>Detailed list of conflict of interest reported in the paper.</p> <p>Funding Prostate Cancer Foundation of Australia, Endocyte (a Novartis company), Australian Nuclear Science and Technology Organization, Movember, The</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>PSMA SUVmean</u> ≥10</p> <p>HR: 0.45 (95% CI 0.25-0.80)</p> <p><b>PSA response</b></p> <p><u>FDG MTV</u> &lt;200 mL</p> <p>Reference</p> <p><u>FDG MTV</u> ≥200 mL</p> <p>OR: 0.44 (0.23-0.84)</p> <p><b>Radiographic PFS</b></p> <p><u>FDG MTV</u> &lt;200 mL</p> <p>Reference</p> <p><u>FDG MTV</u> ≥200 mL</p>		Distinguished Gentleman's Ride, It's a Bloke Thing, and CAN4CANCER.

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						HR: 1.79 (1.28-2.52)  <b>PSA PFS</b>  <u>FDG MTV</u> <u>&lt;200 mL</u>  Reference  <u>FDG MTV</u> <u>≥200 mL</u>  HR: 1.44 (1.03-2.02)  There was no evidence that other PET parameters (PSMA-PET SUVmax, PSMA-PET MTV, FDG-PET SUVmax, and FDG-PET SUVmean) were more		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						valuable markers of response or prognosis than PSMA-PET SUVmean or FDG-PET MTV.		
[451]	RCT NCT03392428 (TheraP) 1+	We aimed to compare [ <sup>177</sup> Lu]Lu-PSMA-617 with cabazitaxel in patients with metastatic castration-resistant prostate cancer.	n=200 men with mCRPC 2018-2019 Australia (11 centres) Median follow-up: 18.4 mo (IQR 12.8-21.8 mo)	[ <sup>177</sup> Lu]Lu-PSMA-617 (intravenousl y, every 6 weeks for a maximum of six cycles) n=99 Median age: 72.1 y (66.9-76.7 y)	Cabazitaxel (20 mg/m <sup>2</sup> intravenously, every 3 weeks for a maximum of ten cycles) n=101 Median age: 71.8 y (66.7-77.3 y)	[ <sup>177</sup> Lu]Lu-PSMA-617 vs. Cabazitaxel <b>PSA responses</b> 65/99 (66%) vs. 37/101 (37%), difference: 29% (16-42%), p<0.001	[ <sup>177</sup> Lu]Lu-PSMA-617 compared with cabazitaxel in men with metastatic castration-resistant prostate cancer led to a higher PSA response and fewer grade 3 or 4 adverse events. [ <sup>177</sup> Lu]Lu-PSMA-617 is a new effective class of therapy and a potential alternative to cabazitaxel.	Neither participants nor investigators were masked to group assignment, funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report, PET-CT images that were obtained

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>radiographic Progression</b></p> <p>HR 0.64 [0.46-0.88]; p=0.0070</p> <p><b>PSA PFS</b></p> <p>HR 0.60 [0.44-0.83]; p=0.0017</p> <p><b>PFS at 12 mo</b></p> <p>19% (95% CI 12-27%) vs. 3% (1-9%)</p> <p><b>Median PFS</b></p> <p>5.2 mo (3.4-5.7 mo) vs. 5.1 mo (2.8-6 mo)</p> <p><b>Pain PFS</b></p> <p>HR 0.72 (95% CI</p>		<p>as part of the eligibility assessment were centrally reviewed by three expert nuclear medicine physicians</p> <p>OS is not yet published</p> <p>Detailed list of conflict of interest reported in the paper.</p> <p>Funding Prostate Cancer Foundation of Australia, Endocyte (a Novartis company), Australian Nuclear Science and</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						0.53-0.97) p=0.033  <b>Patient-reported outcomes</b> <i>(with clinical meaningful improvement of QoL)</i>  diarrhoea: 9 [95% CI 6-11] vs. 16 [13-19] p<0.0001  fatigue: 34 [31-38] vs. 40 [36-43]; p=0.027  social functioning: 79 [75-82] vs 73 [69-77]; p=0.030)		Technology Organization, Movember, The Distinguished Gentleman's Ride, It's a Bloke Thing, and CAN4CANCER.

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						insomnia: 23 [20-27] vs 29 [25-33]; p=0.023  <b>Deterioration-free survival for global health status</b>  29% [95% CI 21-38] vs 13% [95% CI 7-21]; p=0.0002  <b>Grade 3-4 adverse</b>  32/98 (33%) vs. 45/85 (53%)  No deaths were attributed to		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						[ <sup>177</sup> Lu]Lu-PSMA-617		

## 2.5 Schlüsselfrage: Welche neu zugelassenen Medikamente/Medikamentenkombinationen sind der Androgendeprivationstherapie oder Docetaxel+Androgendeprivationstherapie in der Therapie des mHSPC überlegen?

Literaturreferenzen: [\[452\]](#), [\[453\]](#), [\[454\]](#), [\[455\]](#), [\[456\]](#), [\[457\]](#), [\[458\]](#), [\[459\]](#), [\[460\]](#), [\[461\]](#), [\[462\]](#), [\[463\]](#), [\[464\]](#), [\[349\]](#), [\[348\]](#), [\[347\]](#)

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
<b>Systematische Reviews</b>								
<a href="#">[452]</a>	Systematic review 1++	We performed a systematic review to evaluate if HRQoL is affected by the combination therapy of ADT and ARSIs in	n = 6 RCTs (ARCHES, ENZAMET, TITAN, LATITUDE, STAMPEDE, ARASENS)  n = 6397 patients ≥18 years of age and with a histologically or clinically confirmed	<u>I. ARCHES</u> ENZ +ADT <u>II. ENZAMET</u> ENZ +ADT <u>III. TITAN</u> APA + ADT <u>IV. LATITUDE</u> AAP + ADT	<u>I. ARCHES</u> Placebo + ADT <u>II. ENZAMET</u> Nonsteroidal first generation antiandrogens + ADT <u>III. TITAN</u> Placebo + ADT	Overall HRQoL <u>I. ARCHES</u> TTFD: 11.14 vs 8.38 mo; HR = 0.80 (95% CI: 0.67-0.94; p = 0.007)  no significant mean change in HRQoL score over time	<b>The addition of ARSIs to ADT in mHSPC tends to increase overall HRQoL and prolong time to first deterioration of pain/fatigue compared with ADT alone, ADT with first generation nonsteroidal</b>	PROSPERO protocol not found (registration number: 334849), sources of funding and potential heterogeneity of the included studies were not reported  <b>We identified a large methodological heterogeneity among studies as different</b>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		mHSPC patients.	<p>mPCa (only the STAMPEDE trial included also patients with high-risk localized or relapsing disease after initial local therapy)</p> <p><u>Median age</u> 66 - 70 y</p> <p>Search: January 2011-April 2022</p> <p>Median follow-up: 14 mo - 43.7 mo</p>	<p><u>V. STAMPEDE</u> AAP + ADT</p> <p><u>VI. ARASENS</u> DAR + DOC + ADT</p>	<p><u>IV. LATITUDE</u> Placebo +ADT</p> <p><u>V. STAMPEDE</u> DOC + ADT</p> <p><u>VI. ARASENS</u> Placebo + DOC + ADT</p>	<p><u>II. ENZAMET</u> deterioration-free survival: 31% vs 17%; p &lt; 0.001</p> <p>no significant mean change in HRQoL score over time</p> <p><u>III. TITAN</u> No difference in terms of HRQoL outcomes</p> <p><u>IV. LATITUDE</u> TTFD: HR = 0.85 (95% CI: 0.74-0.99, p = 0.03)</p> <p><u>V. STAMPEDE</u> MD at 3 mo: 7.0</p>	<p><b>anti-androgens, and ADT with docetaxel. ARSIs show a complex interaction with remaining HRQoL domains. We advocate a standardization of HRQoL measurement and reporting to allow further comparisons.</b></p>	<p><b>questionnaires and time points have been used to measure HRQoL and its subdomains, as well as diversity regarding outcome reporting, which has prevented a direct comparison between different regimens.</b></p> <p><b><u>Conflict of interest</u></b> RC: Advisory role for Astellas, Janssen, Bayer, Sanofi, MSD, Roche, BMS, Merck, Pfizer, Ipsen; honoraria from Astellas, Janssen, Merck. The remaining authors</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						MD at 6 mo: 8.3 MD at 24 mo:4.8 overall MD: 3.9 p < 0.05 <u>VI. ARASENS</u> No difference in terms of HRQoL outcome		declare no competing interests. <b>Funding</b> no information the STAMPEDE trial included also patients with high-risk localized or relapsing disease after initial local therapy
[453]	Systematic Review and Multivariate Network Meta-analysis PROSPERO: CRD42021272306 1++	To systematically evaluate the literature regarding adverse events (AEs) between the ARSi drugs	mCSPC: n=4 RCTs (LATTITUDE [Fizazi 2019], Chi 2019, ARASENS [Smith 2022], ARCHES ([Armstrong 2019]))	<u>I. LATTITUDE</u> ABI + PRED <u>II. Chi (2019)</u> APA <u>III. ARASENS</u> DAR + ADT + DOC	<u>I. LATTITUDE</u> Placebo + ADT <u>II. Chi (2019)</u> Placebo + ADT <u>III. ARASENS</u> Placebo + ADT + DOC	Abiraterone was ranked as the most toxic treatment regarding grade 3 + 4 AEs (RR=1.36, 95% CI 1.22-3.62; SUCRA 3%) and sAEs (RR 1.28, 95% CI 1.15-1.43; SUCRA 6%)	<b>High-risk mCSPC</b> the disease volume or risk in the mCSPC setting may affect AE profiles, particularly for grade 3 + 4 AEs and sAEs, to a greater	Abiraterone was the only drug studied in a double-blind mCSPC setting (LATTITUDE) involving strictly high-risk disease; all other studies for mCSPC had mixed high/low risk/volume disease

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		abiraterone, apalutamid e, darolutamide, and enzalutamide in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic CRPC (nmCRPC), and metastatic castration-sensitive prostate cancer (mCSPC).	n= 4703 patients with mCSPC  Search: up until September 1, 2022	<u>IV. ARCHES</u> ENZ + ADT	<u>IV. ARCHES</u> Placebo + ADT	(abiraterone was studied strictly in the context of high-risk mCSPC. The other three double-blind RCTs had inclusion criteria that did not differentiate between high/low volume/risk mCSPC.)  Enzalutamide was ranked as the most toxic regarding headache (RR 2.10, 95% CI: 1.22–3.62)  <u>Subgroup analysis of high-risk mCSPC</u>	<b>extent than the specific agent used; however, comparisons are difficult to make as no other double-blind RCT evaluating ARSi therapy in this specific setting was included</b>	Registered protocol did not report the search strategy. It was however reported in the published article.  No information on the use of additional literature search methods. No justification on the restriction on English papers and study designs. No information on the source of funding of the included studies.  <b><u>Conflict of interest</u></b> None.  <b><u>Funding</u></b> None.

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>SUCRA curves consistently ranked abiraterone (used for high-risk disease) as the worst treatment with respect to:</p> <p>grade 3 + 4 AEs (RR=1.36, 95% CI: 1.30-1.42)</p> <p>sAEs (RR=1.28, 95% CI: 1.18-1.40)</p> <p><u>Subgroup analysis of low-risk mCSPC</u></p> <p>grade 3 + 4 AEs (RR=1.04, 95% CI: 1.00-1.08)</p> <p>sAEs (RR=1.05, 95% CI: 0.98-1.11)</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[454]	Systematic review and network meta-analyses 1+	Given the lack of head-to-head randomized trials, we performed this updated meta-analysis to conduct indirect comparison for the efficacy and safety of darolutamide with other new-generation ARTAs.	n = 9 RCTs (ARCHES, TITAN, ENZAMET, PEACE1, LATITUDE, Stampede (arms: C, G), ARASENS, CHARTED, Getug-AFU)  n=11058 patients with mHSPC  Search: up until July 2022	Darolutamide combination	other androgen receptor targeted agents	OS (n=9 trials)  <u>Compared with Docetaxel</u>  Apalutamide: HR 0.84 (95% CI 0.67, 1.1)  Darolutamide+DOC: HR 0.68 (95% CI 0.57, 0.81)  Abiraterone+DOC: HR 0.75 (95% CI 0.59, 0.95)  Abiraterone: HR 0.84 (95% CI 0.7, 1.0)  Enzalutamide: HR: 0.86 (95% CI 0.7, 1.1)  ADT: HR 1.3 (95% CI 1.1, 1.5)	<b>Darolutamide appears to be an optional androgen receptor inhibitor for mHSPC patients, especially for patients with Gleason score ≥ 8. Its well-tolerated characteristic may provide a preferred drug option for patients with poor cardiovascular function and bone health.</b>	<b>no study protocol, unclear if efforts were made to minimize errors in the data extraction, sources of funding of the included studies were not reported</b>  <b>no significant heterogeneity in the analysis and no evidence of a significant publication bias</b>  <b>This study was supported by the National Natural Science Foundation of China, the Tai Shan Scholar Foundation</b>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>OS for ARTA+ Docetaxel+ADT (n=5 trials)</p> <p><u>Compared with DOC+ADT</u></p> <p>DAR+DOC+ADT: OR 0.63 (95% CI 0.5, 0.78)</p> <p>ABI+DOC+ADT: OR 0.7 (95% CI 0.51; 0.95)</p> <p>ENZ+DOC+ADT: OR 0.84 (95% CI 0.59; 1.2)</p> <p>APA+DOC+ADT: OR 1.3 (95% CI 0.58; 2.8)</p> <p>Progression to CRPC (n=5 trials)</p>		<p>and Primary Research &amp; Development Plan of Shandong Province.</p> <p><b>Conflicts of interest: The authors declare no conflict of interest.</b></p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>Compared with Docetaxel</u></p> <p>Enzalutamide: HR 0.64 (95% CI 0.56, 0.73)</p> <p>Apalutamide: HR 0.56 (95% CI 0.49, 0.63)</p> <p>Darolutamide+D OC: HR 0.36 (95% CI 0.33, 0.39)</p> <p>Abiraterone+DOC : HR 0.38 (95% CI 0.34, 0.42)</p> <p>ADT: HR 1.6 (95% CI 1.5, 1.8)</p> <p>Subgroup analysis</p> <p>Darolutamide showed the lowest mortality risk in all subgroups (ECOG</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>and Gleason score)</p> <p>Gleason score (<math>\geq 8</math>) were likely to obtain significant survival benefits when treated with darolutamide (HR = 0.71, 95% CrI = 0.59-0.86)</p> <p>Adverse events (<math>\geq</math> Grade 3)</p> <p>abiraterone was significantly associated with a higher incidence</p> <p>Darolutamide, enzalutamide, and apalutamide provided a non-significant likelihood of toxicity</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						SUCRA: apalutamide had the highest rank associated with the lowest rate of $\geq$ Grade 3 adverse events, followed by darolutamide and enzalutamide		
[455]	Systematic review and network meta-analysis PROSPERO: CRD42022375347 1++	To conduct a systematic review and network meta-analysis to compare the efficacy of currently available combination therapies in patients	n=12 RCTs (GETUG-AFU 15, CHAARTED, STAMPEDE (arms: B, C, E, G), ENZAMET LATITUDE, TITAN, ARCHES, PEACE1, ARASENS, CHART)	ADT Abiraterone Androgen receptor antagonist drugs used in combination with abiraterone or androgen receptor antagonist		Overall population <u>OS</u> Ranking in comparison with ADT with or without SNA: triplet therapy (HR: 0.57, 95% CrI: 0.48-0.67)	<b>Overall population:</b> Triplet therapy was the best treatment. <b>High-volume mHSPC:</b> triplet therapy and ADT plus rezvilutamide had the greatest potential to	Due to the trial design, some volume stratification data were not available. Data maturities of the included trials may have affected the results.  The protocols for triplet therapies are not uniform and standardized.

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		with mHSPC. We indirectly compared the efficacy of specific therapies in patients with mHSPC with the high- and low-volume disease.	n= 11.386 mHSPC-patients high-volume disease (n=6043) low-volume disease (n=3471) Median follow-up: 29-84 mo Search date: published before November 2022			doublet therapy of ADT plus ARTA doublet therapy ADT plus docetaxel <u>Radiographic PFS</u> Ranking in comparison with ADT with or without SNA: triplet therapy (HR: 0.33, 95% CrI: 0.26–0.41) doublet therapy of ADT plus ARTA doublet therapy ADT plus docetaxel High-volume mHSPC	benefit patients. <b>Low-volume mHSPC:</b> most likely to benefit from ADT plus androgen receptor-targeted agents. Triplet therapy was associated with a higher risk of adverse events than the other therapies.	The proportion of different races in trials may limit comparability between studies. Trials with high heterogeneity were excluded to ensure that I2 values were <50%. <b>Funding</b> supported by Jilin Scientific and Technological Development Program, and Bethune Urological Oncology Special Grant, Beijing Bethune Charitable Foundation. <b>Conflict of interest</b>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>OS</u></p> <p>Ranking in comparison with ADT with or without SNA:</p> <p>triplet therapy (HR: 0.57; 95% CrI: 0.44-0.75)</p> <p>ADT plus ARTA</p> <p>ADT plus docetaxel</p> <p>Best combinations:</p> <p>abiraterone triplet therapy (HR, 0.52; 95% CrI: 0.38-0.72)</p> <p>ADT plus rezvolutamide (HR, 0.58; 95% CrI: 0.44-0.77)</p>		<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>Radiographic PFS</u></p> <p>Ranking in comparison with ADT with or without SNA:</p> <p>triplet therapy (HR: 0.29; 95% CrI: 0.23-0.37)</p> <p>ADT plus ARTA</p> <p>ADT plus docetaxel</p> <p>Best combination:</p> <p>abiraterone triplet therapy (HR, 0.28; 95% CrI: 0.21-0.38)</p> <p>ADT plus rezvolutamide (HR, 0.44; 95% CrI: 0.33-0.58)</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>Low-volume mHSPC</p> <p><u>OS</u></p> <p>Ranking in comparison with ADT with or without SNA: doublet and triplet therapies (HR: 0.68, 95% CrI:0.58–0.80)</p> <p>Best combination: ADT plus apalutamide (0.53, 95% CrI:0.35–0.79)</p> <p><u>Radiographic PFS</u></p> <p>Ranking in comparison</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>with ADT with or without SNA:</p> <p>doublet and triplet therapies (HR: 0.37, 95% CrI: 0.25-0.55)</p> <p>Best combination:</p> <p>enzalutamide triplet therapy (HR: 0.27, 95% CrI:0.15-0.51)</p> <p>Adverse Events:</p> <p>Comparison with ADT with or without SNA:</p> <p>none of the doublet therapies with ADT and ARTA had an increased risk</p> <p>docetaxel-based doublet or triplet</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						therapies significantly increased the risk  ADT plus rezvilutamide lowest incidence (OR: 1.00, 95% CrI: 0.31-3.15)  All combination therapies increased the risk of grade $\geq 3$ adverse events.		
[456]	Systematic review and network meta-analysis  1++	We aimed to determine which oral chemotherapeutic agents with ADT combination therapy could most	n= 18 RCTs (ARASENS, ARCHES, ENZAMET, LATITUDE, PEACE-1, CHART, TITAN, MANSMED, STAMPEDE)	treatment group  n=6753	control group  n=6756	total mHPSC OS comparison  more effective than SOC:  ADT+abiraterone  ADT+abiraterone +docetaxel	Novel oral chemotherapeutic agent combination therapies must replace current ADT monotherapy and	additional hand search, PROSPERO number and sources of funding of the included studies were not reported  The funnel plot does not suggest a publication bias in eligible

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		benefit mHSPC patients.	n=13509 patients search date: November 12, 2022			ADT+apalutamide ADT+bicalutamide ADT+darolutamide+docetaxel ADT+enzalutamide ADT+orteronel ADT+rezvilutamide ADT+abiraterone was more effective than ADT+abiraterone+docetaxel ADT+bicalutamide ADT+bicalutamide nilutamide	ADT+docetaxel SOC. ADT+docetaxel with ARTA triplet therapy still is not the best mHSPC treatment and requires further study.	studies. The authors declare no conflicts of interest. supported by the Korean Urological Association in 2022 and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning.

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						flutamide ADT+flutamide SOC high-volume mHSPC OS comparison more effective than SOC: ADT+abiraterone ADT+abiraterone +docetaxel ADT+apalutamide ADT+enzalutamide low-volume mHSPC OS comparison ADT+apalutamide was more		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						effective than SOC Total mHSPC OS SUCRA value ranking ADT+rezvilutamide (98%) ADT+enzalutamide (77%) ADT+abiraterone (76%) High-volume mHSPC OS SUCRA value ranking ADT+abiraterone (84%) ADT+enzalutamide (70%) ADT+apalutamid e (58%)		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>Low-volume mHSPC OS SUCRA value ranking</p> <p>ADT+apalutamide (91%)</p> <p>ADT+enzalutamide (70%)</p> <p>ADT+abiraterone (62%)</p> <p>total mHPSC PFS comparison</p> <p>most treatments were more effective than SOC, except:</p> <p>ADT+bicalutamide</p> <p>nilutamide</p> <p>flutamide,</p> <p>ADT+bicalutamide+palbociclib</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						ADT+nilutamide more effective than ADT+abiraterone: ADT+apalutamide ADT+darolutamide+docetaxel ADT+orterone ADT+rezvilutamide Total mHSPC PFS SUCRA value ranking ADT+rezvilutamide (95%) ADT+metformin+bicalutamide (88%) ADT+orterone (81%)		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[457]	Systematic review with network meta-analysis PROSPERO: CRD42022332079 1++	To compare directly and indirectly combination therapies among older and younger patients for mHSPC.	n= 9 RCTs (ARASENS, ARCHES, ENZAMET, TITAN, LATITUDE, STAMPEDE (arms: B, C, E, G) CHAARTED, GETUG-AFU15) n= 9183 patients with mHSPC The cut-off for age stratification was 70 years (±5 years, depending on the threshold	doublet combination therapies (docetaxel plus ADT) (n=3 RCTs) ARSI plus ADT (n=3 RCTs) Triplet combination therapy with ARSI plus docetaxel plus ADT (n=1 RCT)		OS Docetaxel plus ADT significantly improved OS with no differences according to age. <u>Younger patients</u> (n=3 RCTs) HR 0.79, 95% CI 0.69-0.90, p < 0.001 <u>Older patients</u> (n=3 RCTs) HR 0.79, 95% CI 0.63-0.99, p = 0.04 ARSI-based combination systemic therapies	Patients with mHSPC benefit from combination systemic therapies irrespective of age; the effect is, however, more evident in younger patients. Chronological age alone seems not to be a selection criteria for the administration of combination systemic therapies.	sources of funding of the included studies were not reported, no information to publication bias Authors have (strong) relation to pharmaceutical industries. Funding: EUSP Scholarship of the European Association of Urology

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			<p>provided in the RCTs)</p> <p>Date literature search: May 2022</p> <p>Median follow-up: 22.9 to 83.9 mo</p>			<p>significantly improved OS, younger patients did benefit more (p = 0.02)</p> <p><u>Younger patients</u> (n=5 RCTs)</p> <p>HR 0.58, 95% CI 0.51-0.66, p &lt; 0.001</p> <p><u>Older patients</u> (n=5 RCTs)</p> <p>HR 0.72, 95% CI 0.64-0.80, p &lt; 0.001</p> <p>Network treatment ranking showed that triplet therapy had the highest probability of OS benefit irrespective of</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						age group; in older patients, the benefit of triplet therapy compared to doublet was less expressed (Fig 4).		
[458]	Living Systematic Review and Network Meta-analysis registered at OSF ( <a href="https://osf.io/e2q3w">https://osf.io/e2q3w</a> ) 1+	To assess the comparative effectiveness of contemporary systemic treatment options for patients with mCSPC across clinically relevant subgroups.	n=10 RCTs (GETUG-AFU1, CHAARTED, STAMPEDE, LATITUDE, ENZAMET, ARCHES, TITAN, SWOG, PEACE-1, ARASENS)  n=11043 patients with mCSPC (except STAMPEDE,	contemporary treatment options (taxane-based chemotherapy, androgen pathway inhibitors)		<u>Direct Comparisons</u>  Doublet therapy (either API or DOC as add-on treatments to ADT) vs. ADT alone  (It was assumed that the relative efficacy of ADT to be similar to ADT+nonsteroidal antiandrogen which was the comparator in ENZAMET trial for	The findings of this systematic review and meta-analysis indicate that the decision of treatment intensification with triplet therapy for patients with mCSPC must be considered carefully by accounting for the volume of	The relative efficacy of the control group—nonsteroidal antiandrogen (including bicalutamide, flutamide, or nilutamide) and ADT—in 2 trials was considered equivalent to ADT for the purpose of pooling studies.  Registered protocol did not report the

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			<p>which included a small subset of patients with high-risk localized prostate cancer)</p> <p><u>Median age</u> Range: 63-70 y</p> <p>Search date: July 10, 2022</p>			<p>the purpose of pooling studies together for direct comparisons.)</p> <p>OS</p> <p><u>overall population</u> (n=8 RCTs; n=9069)</p> <p>HR=0.72 (95 % CI: 0.66-0.78)</p> <p><u>Subanalysis</u></p> <p>API doublet vs. ADT (n= 6808): HR=0.69 (95 % CI: 0.62-0.76)</p> <p>DOC doublet vs. ADT: HR=0.79 (95 % CI: 0.71-0.89)</p>	<p>disease, the timing of metastatic presentation, and API doublet options with significant survival benefit and fitness for chemotherapy.</p> <p>In summary, triplet therapy may be preferred for fit patients with synchronous (de novo) high-volume disease. The API doublet combinations may be preferred for patients with metachronous (recurrent) low-volume disease.</p>	<p>search strategy. It was however reported in the published article. No justification on the restriction on English papers and study designs. No information on the source of funding of the included studies.</p> <p>According to the authors the study is limited by an open network that did not allow to assess incoherence for most comparisons and precluded formal assessment of publication bias.</p> <p><u>Conflict of interest</u></p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>High volume</u> (n=7 RCTs; n=3793) HR=0.68 (95 % CI: 0.63-0.74)</p> <p><u>Low volume</u> (n=7 RCTs; n=2280) HR=0.69 (95 % CI: 0.57-0.84)</p> <p><u>Synchronous</u> (n=7 RCTs; n=4579) HR=0.68 (95 % CI: 0.62-0.74)</p> <p><u>Subanalysis</u> API doublet vs. ADT: HR=0.65 (95 % CI: 0.60-0.72)</p>	<p>The choice of treatment with metachronous (recurrent) high-volume disease and synchronous (de novo) low-volume disease requires an individualized risk-based approach, including consideration of patient comorbidities. Evidence in this regard is rapidly increasing, and the results of this living meta-analysis will be updated as new</p>	<p>A comprehensive list is stated in the publication.</p> <p><u>Funding</u> No detailed information stated.</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>DOC doublet vs. ADT: HR=0.78 (95 % CI: 0.58-1.06)</p> <p><u>Metachronous</u> (n=5 RCTs, n=1077) HR=0.70 (95 % CI: 0.54-0.91)</p> <p><u>Subanalysis</u> API doublet vs. ADT: HR=0.61 (95 % CI: 0.43-0.87)</p> <p>DOC doublet vs. ADT: HR=0.90 (95 % CI: 0.62-1.32)</p> <p>PFS</p>	data are published.	

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>overall population</u> (n=8 RCTs; n=9069) HR=0.55 (95 % CI: 0.49-0.62)</p> <p><u>High volume</u> (n=7 RCTs; n=4772) HR=0.51 (95 % CI:0.46-0.57)</p> <p><u>Low volume</u> (n=7 RCTs; n=3103) HR=0.49 (95 % CI: 0.36-0.67)</p> <p><u>Synchronous</u> (n=5 RCTs; n=4422)</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>HR: 0.48 (95 % CI: 0.40-0.58)</p> <p><u>Metachronous</u></p> <p>(n=3 RCTs, n=863)</p> <p>HR=0.42 (95 % CI: 0.33-0.54)</p> <p>Grade <math>\geq</math>3 adverse events <u>overall population</u></p> <p>(n=6 RCTs; n=9480)</p> <p>RR=1.42 (95 % CI: 1.19-1.69)</p> <p>Mixed treatment comparisons</p> <p>OS</p> <p><u>overall population</u></p> <p>rank 1: DARO + DOC + ADT</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>[DARO + DOC + ADT vs. DOC + ADT: HR=0.68 (95 % CI: 0.57-0.81)]</p> <p>rank 2: abiraterone + DOC + ADT</p> <p>[abiraterone + DOC + ADT vs. DOC + ADT: HR=0.75 (95 % CI: 0.59-0.95)]</p> <p>No statistically significant improvement in OS was observed with triplet regimes vs.:</p> <p>rank 3: APA + ADT</p> <p>rank 4: ENZ + ADT</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						rank 5: abiraterone + ADT  rank 6: DOC + ADT  rank 7:orterone1 + ADT  rank 8: non-steroidal antiandrogen + ADT  rank 9: ADT  PFS  <u>overall population</u>  rank 1: abiraterone + DOC + ADT  [abiraterone + DOC + ADT vs. abiraterone + ADT: HR=0.61		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						(95 % CI:0.41-0.91)]; rank 2: ENZ +ADT; rank 3: APA +ADT; rank 4: abiraterone + ADT rank 5: orteronel + ADT rank 6: DOC + ADT rank 7: non-steroidal antiandrogen + ADT rank 8: ADT Adverse Events (Grade 3 or higher)		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						rank 1: non-steroidal antiandrogen + ADT rank 2: ENZ +ADT rank 3: ADT rank 4: APA + ADT rank 5: abiraterone + ADT rank 6: DOC + ADT rank 7: DARO + DOC + ADT rank 8: abiraterone + DOC + ADT rank 9: orteronel + ADT		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[459]	Systematic review with network meta-analysis PROSPERO: CRD42022339754 1++	We conducted this systematic review, meta-analysis, and network meta-analysis to assess the impact of performance status on the efficacy of combination systemic therapies in patients with prostate cancer.	n=18 RCTs mHSPC: PEACE1, ARASENS, ARCHES, ENZAMET, LATITUDE, ENZAMET, CHAARTED, STAMPEDE (arm: G, B, C)  Search date: June 2022	Triplet therapy  Doublet therapy with ARSI + ADT  Doublet therapy with DOC + ADT		mHSPC OS <u>DOC + ADT vs ADT alone</u> (n=3 studies, 2261 patients)  Reduce the risk of patients with ECOG PS ≥ 1 (HR 0.70, 95% CI 0.56-0.87) vs. ECOG PS 0 (HR 0.81, 95% CI 0.71-0.93) p=0.3  <u>ARSI + SOC vs SOC</u> (n=5 studies, 6443 patients)  Reduce the risk of patients with ECOG PS ≥ 1 (HR 0.61, 95% CI	Among RCTs, novel systemic therapies seem to benefit the OS of patients with prostate cancer irrespective of performance status. Our findings suggest that worse performance status should not discourage treatment intensification across all disease stages.	sources of funding of the included studies were not reported, no information to publication bias  no significant heterogeneity among all analyses  Conflict of interest: Takahiro Kimura is a paid consultant/advisor of Astellas,  Bayer, Janssen and Sanofi. Shahrokh F. Shariat received  follows: Honoraria: Astellas, AstraZeneca, BMS, Ferring,

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>0.53-0.70) vs. ECOG PS 0 (HR HR 0.68, 95% CI 0.60-0.76) p=0.24</p> <p><u>ARSI + DOC + ADT vs</u></p> <p><u>DOC + ADT</u></p> <p>(n=2 studies, 2015 patients)</p> <p>Reduce the risk of patients with ECOG PS ≥ 1 (HR 0.63, 95% CI 0.50-0.79) vs. ECOG PS 0 (HR HR 0.75, 95% CI 0.63-0.90) p=0.2</p> <p><u>Network meta-analyses of the effect of combination therapies</u></p>		<p>Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, Takeda.</p> <p>Consulting or Advisory Role: Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Takeda.</p> <p>Speakers Bureau: Astellas, AstraZeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, Takeda.</p> <p>No external funding provided. EUSP Scholarship of the</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>stratified by performance status</u></p> <p>Compared to DOC + ADT, only the DAR + DOC +ADT combination resulted in significantly improved OS regardless of ECOG PS</p> <p>ECOG PS <math>\geq</math> 1 : DAR + DOC + ADT had the highest likelihood of providing the maximal OS benefit (94%)</p> <p>ECOG PS 0, ABI + DOC + ADT had the highest likelihood of</p>		European Association of Urology (PR).

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						providing the maximal OS benefit (79%), followed by DAR + DOC + ADT (73%)		
[460]	Systematic review with network meta-analysis  PROSPERO: CRD42022352440  1++	We aimed to analyze and compare the efficacy of combination systemic therapies in metastatic hormone-sensitive prostate cancer and metastatic castration-resistant	n=12 RCTs mHSPC: ARASENS, ARCHES, ENZAMET, TITAN, LATITUDE, CHARTED  Search date: July 2022	combination systemic therapy (androgen receptor signaling inhibitor and/or docetaxel	standard of care	mHSPC  Metaanalysis results for fixed effect model are reported  OS for ARSI-based systemic combination therapy incl. triplet therapy (n=5)  <u>Overall</u> HR 0.68 (CI 95% 0.63-0.74)  <u>Visceral metastasis</u>	The effectiveness of novel systemic therapies is similar in both mHSPC and mCRPC patients with and without visceral metastasis.	sources of funding of the included studies were not reported  No external funding was provided.  Detailed list of conflict of interest reported in the paper.  We did not find any heterogeneity in all analyses.

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		prostate cancer with or without visceral metastasis.		plus androgen deprivation therapy)		HR 0.77 (95% CI 0.64-0.94) <u>without visceral metastasis</u> HR 0.66 (95% CI 0.60-0.72) OS for ARSI-based doublet therapy (n=4) <u>Overall</u> HR 0.67 (95% CI 0.62-0.74) <u>Visceral metastasis</u> HR 0.77 (95% CI 0.61-0.96) <u>without visceral metastasis</u> HR 0.66 (95% CI 0.59-0.73)		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						PFSfor ARSI-based doublet therapy (n=3)  <u>Overall</u> HR 0.45 (95% CI 0.41-0.51)  <u>Visceral metastasis</u> HR 0.58 (95% CI 0.45-0.75)  <u>without visceral metastasis</u> HR 0.43 (95% CI 0.38-0.48)  SUCRA analysis OS <u>Visceral metastasis</u> DAR+DOC+ADT (90%)		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						DOC+ADT (76%) ABI+ADT (63%) <u>without visceral metastasis</u> DAR+DOC+ADT (98%) all combination regimens significantly reduced the risk of death inwhen compared to ADT alone PFS for mHSPC SUCRA analysis: <u>Visceral metastasis</u> ABI+ADT (82%) <u>without visceral metastasis</u>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>ENZ+ADT (91%)</p> <p>all combination regimens</p> <p>significantly reduced the risk of disease progression in patients without visceral metastasis compared to ADT alone</p>		
[461]	<p>Systematic review with network meta-analysis</p> <p>PROSPERO: CRD42022359472</p> <p>1++</p>	<p>To analyze current data from RCTs that investigated first-line treatment of high-volume mHSPC to compare the</p>	<p>n = 11 RCTs (ENZAMET, ARCHES, TITAN, CHART, LATITUDE, STAMPEDE (arms: C, G), CHAARTED, GETUF AFU</p>	<p>ADT (<math>\pm</math>SOC: bicalutamide, nilutamide, or flutamide) alone</p> <p>doublet therapies (including DOC, ABI, APA, REZ, and ENZ on the basis of ADT)</p> <p>triplet therapies (including DAR+DOC, ENZ+DOC and</p>		<p>OS</p> <p><u>ADT compared with:</u></p> <p>ABI: HR 0.61 (95% CI 0.53, 0.71)</p> <p>DOC+ABI: HR 0.52 (95% CI 0.38, 0.71)</p>	<p>We did not find significant differences in OS and PFS</p> <p>between REZ+ADT and available doublet or triplet therapies in patients with high-volume</p>	<p>sources of funding and potential heterogeneity of the included studies were not reported, no information to publication bias</p> <p>No potential conflict of interest was reported by the author(s).</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		therapeutic effects of these drugs indirectly, to help clinicians and patients select the optimal individualized treatment.	15, PEACE1, ARASENS) n = 6708 high-volume mHSPC patients Search date: May 2023	ABI+DOC on the basis of ADT)		<p>APA: HR 0.70 (95% CI 0.56, 0.88)</p> <p>DOC: HR 0.72 (95% CI 0.63, 0.84)</p> <p>ENZ: HR 0.65 (95% CI 0.53, 0.80)</p> <p>DOC+ENZ: HR 0.70 (95% CI 0.45, 1.10)</p> <p>REZ: HR 0.58 (95% CI 0.44, 0.77)</p> <p>DOC+DAR: HR 0.49 (95% CI 0.39, 0.62)</p> <p><u>DOC compared with:</u></p> <p>ABI: HR 0.85 (95% CI 0.69, 1.00)</p>	mHSPC, except for superiority to DOC+ADT and inferiority to DAR+DOC+ADT in terms of PFS benefit. REZ+ADT were the highest ranked doublet therapy for improvement in OS of patients with high-volume mHSPC, second only to triplet therapy (DAR+DOC+ADT and ABI+DOC+ADT).	This study was partly funded by the Natural Science Foundation of Shandong Province Medical and health research program of Qingdao. The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						DOC+ABI: HR 0.72 (95% CI 0.55, 0.95) ADT: HR 1.4 (95% CI 1.2, 1.6) APA: HR 0.97 (95% CI 0.74, 1.3) ENZ: HR 0.9 (95% CI 0.7, 1.2) DOC+ENZ: HR 0.97 (95% CI 0.64, 1.5) REZ: HR 0.81 (95% CI 0.58, 1.1) DOC+DAR: HR 0.68 (95% CI 0.57, 0.82) PFS ABI: HR 0.46 (95% CI 0.36, 0.58)		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						DOC+ABI: HR 0.28 (95% CI 0.18, 0.44) APA: HR 0.53 (95% CI 0.41, 0.67) DOC: HR 0.60 (95% CI 0.52, 0.70) ENZ: HR 0.42 (95% CI 0.33, 0.52) DOC+ENZ: HR 0.31 (95% CI 0.22, 0.43) REZ: HR 0.44 (95% CI 0.33, 0.58) DOC+DAR: HR 0.25 (95% CI 0.19, 0.31)		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>DOC compared with:</u></p> <p>ABI: HR 0.76 (95% CI 0.57, 1.00)</p> <p>DOC+ABI: HR 0.46 (95% CI 0.30, 0.72)</p> <p>ADT: HR 1.70 (95% CI 1.40, 1.9)</p> <p>APA: HR 0.87 (95% CI 0.66, 1.2)</p> <p>ENZ: HR 0.69 (95% CI 0.53, 0.89)</p> <p>DOC+ENZ: HR 0.51 (95% CI 0.38, 0.69)</p> <p>REZ: HR 0.73 (95% CI 0.53, 0.99)</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						DOC+DAR: HR 0.41 (95% CI 0.34, 0.49)		
[462]	<b>Meta-analysis</b> 1+	To evaluate whether the addition of an ARSi to ADT improves outcomes of mCSPC patients treated with docetaxel.	n=5 RCTs (ARCHES; ENZAMET; TITAN; PEACE-1; ARASENS) n=2837 mCSPC patients Search: up until February 21, 2022	ARSi + ADT + DOC (n=1421 patients)	ADT + DOC (n=1416 patients)	OS (n=5 RCTs, n=2837 patients) <u>Triplet vs. ADT + DOC</u> <i>Fixed effect model</i> HR=0.73 (95% CI: 0.65-0.83; p < 0.00001) Stratified by schedule of ARSi administration with respect to chemotherapy (concomitant to DOC vs. sequential DOC)	In conclusion, our results support the survival advantage of adding an ARSi to ADT in patients with mCSPC treated with docetaxel; the OS benefit of this intensified strategy is particularly evident when the ARSi was administered concomitantly to chemotherapy, especially in the	No study protocol. No information on additional search methods and the study selection process. No justification on the restriction on English papers and study designs. No information on the source of funding of the included studies. No investigation concerning a potential publication bias. <u>Conflict of interest</u> CC: occasional consultant of IPSEN,

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>Triplet (sequential) vs. ADT + DOC</u></p> <p>(n=2 RCT, ARCHES and TITAN, n=318 patients)</p> <p><i>Fixed effect model</i></p> <p>HR=0.86 (95% CI: 0.59-1.26; p=0.44)</p> <p><u>Triplet (concomitant) vs. ADT + DOC</u></p> <p>(n=3 RCTs)</p> <p><i>Fixed effect model</i></p> <p>HR=0.72 (95% CI: 0.63-0.82; p &lt; 0.00001)</p>	<p>subgroup of metastatic de novo mCSPC patients.</p>	<p>Janssen, MSD, Merck, Pfizer, Astellas.</p> <p>RI: advisory board member for Astellas, BMS, Eisai, IPSEN, Janssen, MSD, Novartis, Pfizer, Sanofi. Consultant for Astellas, Eisai, MSD, Pfizer.</p> <p>CS: Served as a consultant for Astellas, Pharma, Sanofi Genzyme, Roche-Genentech, Novartis, Bayer, Pfizer, Merck, MSD, AstraZeneca, Immunomedics (now Gilead), Janssen, Foundation Medicine, Impact</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>Subgroup of men with de novo mCSPC</u></p> <p>(Triplet vs. ADT + DOC)</p> <p>n=2 RCTs</p> <p><i>Fixed effect model</i></p> <p>HR=0.72 (95% CI: 0.63-0.84;</p> <p>p &lt; 0.0001)</p>		<p>Pharma, UroToday and Medscape.</p> <p>SG: received (last 3 y) personal honoraria for participation in advisory boards from Amgen, MSD, Orion; other honoraria</p> <p>from Radio-televisione Svizzera Italiana (RSI), German-speaking European School of Oncology</p> <p>(DESO), Patent royalties and other intellectual property for a research method for biomarker WO2009138392. [further declarations in the</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
								corresponding paper]. GT: advisory board member for BMS and Novartis. KF: Participation to advisory boards and talks for: Amgen, Astellas, AstraZeneca, Bayer, Clovis, Janssen, MSD, Novartis/AAA, Pfizer, Sanofi Honoraria go to Gustave Roussy, my institution. Participation to advisory boards with personal honorarium for CureVac and Orion. <u>Funding</u>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
								None declared.
[463]	Systematic review with network meta-analysis PROSPERO: CRD42022324980 1+	Performed a systematic review of all docetaxel-based triplet therapies and indirectly compared the efficacy and safety of these therapies through network meta-analysis.	n=5 RCTs (TITAN, ENZAMET, ARCHES, PEACE1, ARASENS) n=2836 patients with mHSPC Search date: April 2022	systemic therapy containing ADT plus docetaxel with or without another agent		OS <u>Compared with ADT+Docetaxel</u> ADT+Docetaxel+ DarolutamideHR 0.68 (95% CrI 0.57, 0.8) ADT+Docetaxel+ EnzalutamideHR 0.74 (95% CrI 0.46, 1.2) ADT+Docetaxel+ Abiraterone HR 0.75 (95% CrI 0.59, 0.95) ADT+Docetaxel+ SNA HR 0.83 (95% CrI 0.45, 1.51)	Systemic triplet therapy was more effective than ADT plus docetaxel for mHSPC. Of the triplet therapy regimens, darolutamide ranked first in terms of improved OS. Abiraterone and enzalutamide triplet ranked first in terms of radiographic FPS, however, it did not confer a statistically difference among all	sources of funding of the included studies were not reported, high risk of bias studies (ENZAMET, PEACE1) were not excluded from the analysis  supported by Jilin Scientific and Technological Development Program, Natural Science Foundation of Jilin Province and Bethune Urological Oncology  Special Grant, Beijing Bethune Charity Foundation.

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						ADT+Docetaxel+ Apalutamide HR 1.12 (95% CrI 0.59, 2.12) radiographic PFS <u>Compared with ADT+Docetaxel</u> ADT+Docetaxel+ Apalutamide HR 0.47 (95% CrI 0.22, 1) ADT+Docetaxel+ Abiraterone HR 0.49 (95% CrI 0.39, 0.61) ADT+Docetaxel+ Enzalutamide HR 0.52 (95% CrI 0.3, 0.89) ADT+Docetaxel+ SNA HR 1.08	triplet regimens. The overall risk of adverse effects was comparable. More studies are required for current and potential combinations of systemic triplet therapy.	The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.  <i>same studies included in the Maiorano, 2022 paper</i>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>(95% CrI 0.59, 1.98)</p> <p>Time to PSA Progression</p> <p><u>Compared with ADT+Docetaxel</u></p> <p>ADT+Docetaxel+ EnzalutamideHR 0.22 (95% CrI 0.11, 0.45)</p> <p>ADT+Docetaxel+ SNA</p> <p>HR 0.48 (95% CrI 0.23, 1.01)</p> <p>Time to first skeletal event</p> <p><u>Compared with ADT+Docetaxel</u></p> <p>ADT+Docetaxel+ DarolutamideHR 0.71 (95% CrI 0.54, 0.94)</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						ADT+Docetaxel+ EnzalutamideHR 0.85 (95% CrI 0.39, 1.86)  Any adverse events  <u>Compared with                      ADT+Docetaxel</u>  ADT+Docetaxel+ DarolutamideOR 2.53 (95% CrI 0.68, 12.63)  ADT+Docetaxel+ Abiraterone OR 1.07 (95% CrI 0.03, 36.25)  Grade $\geq 3$ adverse events  <u>Compared with                      ADT+Docetaxel</u>  ADT+Docetaxel+ DarolutamideOR		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						1.13 (95% CrI 0.89, 1.43)  ADT+Docetaxel+ Abiraterone OR 1.56 (95% CrI 1.15, 2.11)		
[464]	Systematic review with meta-analysis 1+	We carried out a meta-analysis of RCTs to better define the benefit achieved with the use of the triplet in mHSPC.	n=5 RCTs (TITAN, ENZAMET, ARCHES, PEACE1, ARASENS)  n=2836 patients with mHSPC  search date: 10 April 2022	enzalutamide (n=2 studies)  abiraterone (n=1 study)  darolutamide (n=1 study)  apalutamide+ docetaxel+ ADT (n=1 study)  n=1415	placebo+ docetaxel+ ADT  n=1421	ARTA + docetaxel + ADT vs. docetaxel + ADT  OS (n=5)  HR 0.74 (95% CI 0.66-0.84) p<0.00001  OS: high volume (n=2)  HR 0.79 (95% CI 0.63-0.99) p=0.04  OS: low volume (n=2)	The addition of an ARTA to docetaxel and ADT significantly prolongs survival compared with docetaxel and ADT in patients with mHSPC and should be adopted in daily clinical practice.	PEACE1 was rated with Jadad Score 1, bias was not discussed and the study not excluded from the analysis, sources of funding of the included studies were not reported, no study protocol  no significant heterogeneity among all analyses  The review was not registered.

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>HR 0.79 (95% CI 0.50-1.23) p=0.29</p> <p>OS: <i>de novo</i>(n=2)</p> <p>HR 0.77 (95% CI 0.67-0.88) p=0.0002</p> <p>OS: metachronous (n=1)</p> <p>HR 0.61 (95% CI 0.35-1.06) p=0.08</p> <p>OS: concomitant ARTA+ docetaxel+ADT (n=3)</p> <p>HR 0.73 (95% CI 0.64-0.83) p&lt;0.00001</p>		<p>The publication bias or sensitivity analysis has not been carried out because of the low number of included trials.</p> <p>No conflict of interest.</p> <p>No funding received.</p> <p><i>same studies included in the Jian, 2022 paper</i></p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						OS: ARTA after docetaxel+ADT (n=2) HR 0.86 (95% CI 0.59-1.26) p=0.43 radiographic PFS (n=3) HR 0.50 (95% CI 0.42-0.60) p<0.00001 clinical PFS (n=3) HR 0.49 (95% CI 0.41-0.58) p<0.00001 All-grade adverseevents (n=2) RR 1 (95% CI 1-		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						1.01) p=0.45 All-grade adverse events (n=2) RR 1.13 (95% CI 0.99-1.29) p=0.07		
<b>Randomisierte kontrollierte Studien</b>								
[349]	RCT NCT01957436 (PEACE-1) Overall population: 1- Docetaxel population: 2+	We aimed to evaluate the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy	n=1173 patients with mHSPC Belgium, France, Ireland, Italy, Romania, Spain, and Switzerland	SOC (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m <sup>2</sup> )	SOC+ radiotherapy n=293 SOC+ abiraterone (oral 1000 mg abiraterone once daily plus oral 5	SOC+abiraterone with/without radiotherapy (n=583) vs. SOC with/without radiotherapy (n=589) <u>radiographic PFS</u>	Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer	Neither the investigators nor the patients were masked to treatment allocation, no randomization process for docetaxel, no separate results for all randomized

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		y, in addition to standard of care.	(n=77 hospitals) 2013-2018 Median follow-up radiographic PFS: 3.5 y (IQR 2.8-4.6 y) OS: 4.4 y (IQR 3.5-5.4 y)	once every 3 weeks) n=296	mg prednisone twice daily) n=292 SOC+ radiotherapy + abiraterone n=291	HR: 0.54 (99.9% CI 0.41-0.71) p<0.001 <u>OS</u> HR: 0.82 (95.1% CI 0.69-0.98) p=0.03 <u>ADT with docetaxel population</u> SOC+abiraterone with/without radiotherapy (n=355) vs. SOC with/without radiotherapy (n=355) <u>radiographic PFS</u> HR: 0.5 (99.9% CI 0.34-0.71) p<0.001 <u>OS</u>	improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension. This triplet therapy could become a standard of care for these patients.	groups, no results of adverse events for the overall population, the influence of radiotherapy remains unclear Funding Janssen-Cilag, Ipsen, Sanofi, and the French Government. Detailed list of conflict of interest reported in the paper.

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						HR: 0.75 (95.1% CI 0.59-0.95) p=0.017  <u>Grade 3 or worse adverse events</u>  abiraterone: 217/347 (63%)  no abiraterone: 181/350 (52%)		
[348]	post hoc analysis Smith 2022 NCT02799602 (ARASENS)	We present efficacy and safety outcomes from ARASENS in patients with mHSPC by disease volume and disease risk.	Patient subgroups on the basis of disease volume and disease risk were assessed:  <b>high-volume</b> (= visceral metastases and/or $\geq 4$	darolutamide (dose of 600 mg [two 300-mg tablets] twice daily) with ADT (Investigator's choice) and docetaxel (75 mg/m <sup>2</sup> )	placebo with ADT (Investigator's choice) and docetaxel (75 mg/m <sup>2</sup> Day 1 as 1 hour IV infusion every 21 days)	<b>Darolutamide vs. placebo OS</b>  <u>high-volume</u> HR: 0.69; 95% CI, 0.57 to 0.82  <u>low-volume</u> HR, 0.68; 95% CI, 0.41 to 1.13  <u>high-risk</u>	Patients with high-volume and high-risk/low-risk mHSPC, treatment intensification with darolutamide, androgen-deprivation therapy, and docetaxel increased OS	<b>Support</b>  Supported by Bayer AG and Orion Pharma  <b>Conflict of interests:</b>  The following represents disclosure information provided by authors of this manuscript. All relationships are

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			<p><i>bone metastases with <math>\geq 1</math> beyond the vertebral column/pelvis</i>):</p> <p>N=1005 patients (77%)</p> <p><b>low-volume</b></p> <p>N=300 patients (23%)</p> <p><b>high-risk</b>(<math>\geq 2</math> risk factors: <i>Gleason score <math>\geq 8</math>, <math>\geq 3</math> bone lesions, and presence of measurable visceral metastases</i>):</p>	<p>Day 1 as 1 hour IV infusion</p> <p>every 21 days)</p> <p><b>high-volume</b> (n=497)</p> <p>Median: 67 y (41-89 y)</p> <p><b>low-volume</b> (n=154)</p> <p>Median: 67 y (41-89 y)</p> <p><b>high-risk</b> (n=452)</p> <p>Median: 67 y (41-86 y)</p> <p><b>low-risk</b></p>	<p><b>high-volume</b> (n=508)</p> <p>Median: 67 y (44-86 y)</p> <p><b>low-volume</b> (n=146)</p> <p>Median: 67.5 y (42-81 y)</p> <p><b>high-risk</b> (n=460)</p> <p>Median: 67 y (44-86 y)</p> <p><b>low-risk</b> (n=194)</p> <p>Median: 67 y (42-85 y)</p>	<p>HR, 0.71; 95% CI, 0.58 to 0.86</p> <p><u>low-risk</u></p> <p>HR, 0.62; 95% CI, 0.42 to 0.90</p> <p><b>Prolonged time to castration resistance</b></p> <p><u>high-volume</u></p> <p>HR: 0.41; 95% CI, 0.34 to 0.49</p> <p><u>low-volume</u></p> <p>0.21; 95% CI, 0.14 to 0.33</p> <p><u>high-risk</u></p> <p>HR: 0.38; 95% CI, 0.32 to 0.46</p> <p><u>low-risk</u></p> <p>HR: 0.32; 95% CI, 0.23 to 0.45</p>	<p>with a similar adverse event profile in the subgroups, consistent with the overall population.</p>	<p>considered compensated unless otherwise noted. Relationships are self-held unless noted. I5Immediate Family Member, Inst5My Institution. Relationships may not relate to the subject matter of this manuscript. More information about ASCO's conflict of interest policy: <a href="http://www.asco.org/rwc">www.asco.org/rwc</a> or <a href="http://ascopubs.org/jco/authors/author-center">ascopubs.org/jco/authors/author-center</a>.</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			<p>N= 912 patients (70%) <b>low-risk</b></p> <p>N= 393 patients (30%)</p>	<p>(n=199) Median: 67 y (41-89 y)</p>		<p><b>Incidences of serious adverse events</b></p> <p><u>high-volume</u> 45.4% vs 43.5%</p> <p><u>low-volume</u> 42.9% vs. 38.2%</p> <p><u>high-risk</u> 45.3% vs 42.9%</p> <p><u>low-risk</u> 43.7% versus 40.9%</p> <p><b>Adverse events:</b> Similar between treatment groups across subgroups by disease volume and risk.</p> <p><b>Grade 3 or 4 Adverse events</b></p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<u>high-volume</u> 64.9% vs. 64.2%  <u>low-volume</u> 70.1% versus 61.1%  <u>high-risk</u> 67.5 % vs 64.3 %  <u>low-risk</u> 62.8% versus 61.7%		
[347]	RCT NCT02799602 (ARASENS) 1++	<b>Primary end point:</b> OS  <b>Secondary end points:</b> time to castration-resistant prostate cancer, time to	n= 1306 patients <65 y with mHSPC  286 centers in 23 countries  2016-2018  Median follow-up:	darolutamide (dose of 600 mg [two 300-mg tablets] twice daily) with ADT (Investigator's choice) and	placebo with ADT (Investigator's choice) and docetaxel (75 mg/m <sup>2</sup> Day 1 as 1 hour IV infusion	<b>OS at 4 y</b>  darolutamide: 62.7% (95% CI, 58.7 to 66.7)  placebo: 50.4% (95% CI, 46.3 to 54.6)  <b>Darolutamide vs. Placebo</b>	OS was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus	international, phase 3 trial  Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)  1 patient was randomly assigned to the placebo group but received

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		<p>pain progression, symptomatic skeletal event-free survival, time to a first symptomatic skeletal event, time to initiation of subsequent systemic antineoplastic therapy, time to worsening of disease-related physical symptoms, time to</p>	<p>Darolutamide : 43.7 mo placebo group: 42.4 mo</p>	<p>docetaxel (75 mg/m<sup>2</sup> Day 1 as 1 hour IV infusion every 21 days) n=651 Median: 67 y (41-89 y)</p>	<p>every 21 days) n=655 Median: 67 y (42-86 y)</p>	<p><u>Time to castration-resistant prostate cancer</u> HR: 0.36 (0.30–0.42) p&lt;0.001 <u>Pain progression</u> HR: 0.79 (0.66–0.95) p=0.01 <u>Symptomatic skeletal event</u> HR: 0.71 (0.54–0.94) p=0.02 <u>Worsening of disease-related physical symptoms</u> HR: 1.04 (0.89–1.22) p=0.59 <u>Symptomatic skeletal event-free survival</u></p>	<p>androgendeprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points. The frequency of adverse events was similar in the two groups.</p>	<p>darolutamide was included in the placebo group in the full analysis set. The trial was designed by Bayer and the first and last authors, with support from the protocol steering committee. Funding: Bayer and Orion Pharma. Conflict of interests: unknown</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien- und Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		initiation of opioid treatment for 7 or more consecutive days, and safety.				HR: 0.61 (0.52–0.72) p<0.001 <b>Adverse events:</b> Similar in the two groups <u>Grade 3 or 4 adverse events:</u> darolutamide: 66.1% placebo: 63.5%		

## 2.6 Schlüsselfrage: Welchen Stellenwert hat Relugolix im Vergleich zu anderen Androgendeprivationstherapien?

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[465]	RCT (phase III) NCT03085095 (HERO) 155 centers (worldwide) 2017-2018 1-	The goals of the phase 3 HERO trial were to evaluate the efficacy and safety of oral relugolix as compared with leuprolide in men with advanced prostate cancer.	n=930 men with advanced prostate cancer presence of metastatic disease: 295/930 (31.7%) Median age: 71 y (47-97 y)	relugolix (120 mg once daily after a single oral loading dose of 360 mg) for 48 weeks n=622	leuprolide 22.5 mg* (injections every 3 months) for 48 weeks n=308 *11.25 mg in Japan/Taiwan	<b>Testosterone suppression to castrate levels (&lt;50 ng/dl) through 48 wk</b>  Relugolix: 96.7% (95% CI 94.9-97.9%)  Leuprolide: 88.8% (95% CI 84.6-91.8%)  relugolix was determined to be noninferior to leuprolide (between group difference, 7.9 percentage	In this trial involving men with advanced prostate cancer, relugolix achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascular events.	open label, randomisation process and allocation concealment not clearly described  testosterone values for the primary endpoint analysis were measured at a blinded central laboratory  Supported by Myovant Sciences.  Disclosure forms provided by

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						points; 95% CI, 4.1 to 11.8) <b>Cumulative            probability            of            testosterone            suppression            to (&lt;50            ng/dl)  <u>on day 4</u>            Relugolix:            56%            Leuprolide: 0            p&lt;0.001  <u>on day 15</u>            Relugolix:            98.7%            Leuprolide:            12%            p&lt;0.001         </b>		the authors are available.

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>PSA response at day 15 followed by confirmation at day 29</b></p> <p>Relugolix: 79.4%</p> <p>Leuprolide: 19.8%</p> <p>p&lt;0.001</p> <p><b>Cumulative probability of profound testosterone suppression to 50 ng/dl on day 15</b></p> <p>Relugolix: 78.4%</p> <p>Leuprolide: 1%</p> <p>p&lt;0.001</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>Mean FSH level at end of wk 24</b></p> <p>Relugolix: 1.72 IU/liter</p> <p>Leuprolide: 5.95 IU/liter</p> <p>p&lt;0.001</p> <p><b>Adverse events</b></p> <p><u>Grade 3 or 4</u> any adverse event:</p> <p>Relugolix: 112/622 (18%)</p> <p>Leuprolide: 63/308 (20.5%)</p> <p>serious adverse event:</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						Relugolix: 61/622 (9.8%)  Leuprolide: 35/308 (11.4%)  <u>Incidence of major adverse cardiovascular events</u>  Relugolix: 2.9%  Leuprolide: 6.2%  HR: 0.46 (95% CI 0.24-0.88)		

## 2.7 Welchen Stellenwert hat die molekulare Diagnostik auf HRR- Mutationen auf das Ergebnis der Therapie mit diesen neu zugelassenen Medikamenten/Medikamentenkombinationen für Patienten mit mCRPC?

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
<b>Systematische Reviews</b>								
[466]	Systematic review with meta-analysis 1+	We aim to better characterize the PFS and OS in mCRPC patients treated with PARPis and determine the subgroup of patients with this disease who can benefit from these medications at maximum.	n=7 RCTs patients with mCRPC Search date: 30 May 2023	PARP with or without ARPI (abiraterone acetate or enzalutamide)	standard care (ARPI or docetaxel)	<b>PARPi vs. Standard care</b> <b>PFS in patients without HRR gene mutation</b> (n=4) HR: 0.747 (95% CI 0.637-0.877) p=0.00 I <sup>2</sup> =0%	Our meta-analysis of clinical trials found that PARPis in combination with novel hormonal agents may improve PFS and OS in patients with mCRPC, regardless of their HRR gene mutation status.	The study protocol was not registered. No reported sources of funding for the studies included in the review. Results are reported from fixed-effect models, although random-effect models were planned. The authors declare no

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
								conflict of interest.  This research received no external funding.
<b>Randomisierte kontrollierte Studien</b>								
[467]	RCT NCT03395197 (TALAPRO-2) 1+	We aimed to compare the efficacy and safety of talazoparib plus enzalutamide versus enzalutamide alone in patients with mCRPC.	n= 805 patients with mCRPC  <u>HRR-deficient</u> : n= 169 (21%)  <u>HRR-non-efficient</u> : n= 636 (79%)  <u>BRCA alterations</u> : Talazoparib: n= 27 (7%) Placebo:	n= 402 patients (0.5mg  Talazoparib plus 160mg enzalutamide orally once daily)  <u>Mean age</u> : 71 y (66-76 y)  <b>Median duration of treatment</b> : <u>Talazoparib</u> :	n= 403 patients (placebo plus 160mg enzalutamide orally once daily)  <u>Mean age</u> : 71 y (65-76 y)  <b>Median duration of treatment</b> :	<b>Patients with HRR gene alteration status of deficient - median rPFS:</b>  <u>talazoparib plus enzalutamide</u>  (95% CI 27.9 (16.6-not reached)	Talazoparib plus enzalutamide resulted in clinically meaningful and statistically significant improvement in rPFS versus standard of care enzalutamide as first-line treatment for	Sponsor, patients, and investigators were masked to talazoparib or placebo, while enzalutamide was open-label.  <u>Conflicts of interest and funding</u> : NA has received an honorarium for consultancy since May, 2020, from diverse

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			<p>n= 32 (8%) 2019- 2020 223 hospitals, cancer centres, medical centres in 26 countries.</p> <p><u>Median follow-up:</u> rPFS:  Talazoparib:2 4.9 months (IQR 21.9– 30.2)  Placebo:  24.6 months (14.4–30.2)</p>	<p>19.8 mo (IQR 8.8–26.9 mo)  <u>Enzalutamide in the talazoparib group:</u> 22.2 mo (9.9–28.1 mo)</p>	<p><u>Placebo:</u> 16.1 mo (6.5–25.0 mo)  <u>Enzalutami de in the placebo group:</u> 16.6 mo (6.7–25.1 mo)</p>	<p><u>placebo plus enzalutami de</u>  16.4 (10.9– 24.6)  Stratified - HR: 0.46 (95% CI 0.30–0.70); p=0.0003  <b>Patients with HRR gene alteration status of non- deficient or unknown - median rPFS:</b>  <u>talazoparib plus</u></p>	<p>patients with mCRPC. Final  overall survival data and additional long-term safety follow- up will further clarify the clinical benefit of the treatment  combination in patients with and without tumour HRR gene alterations.</p>	<p>pharmaceutical companies (detailed list in the paper).  Study was sponsored by Pfizer. Astellas Pharma provided enzalutamide. Editorial and medical writing support was provided by Emily Messina and Annette Smith, on behalf of CMC AFFINITY, a division of IPG Health Medical Communications , and was funded by Pfizer.</p>

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>enzalutamide</u></p> <p>(95% CI Not reached (27.5-not reached)</p> <p><u>placebo plus enzalutamide</u></p> <p>22.5 (19.1-30.5)</p> <p>Stratified - HR: 0.70 (95% CI 0.54-0.89); p=0.0039</p> <p><b>Patients with HRR gene alteration status of non-deficient by</b></p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p>prospektive tumour tissue testing – median rPES:</p> <p><u>talazoparib plus enzalutamide</u></p> <p>(95% CI Not reached (25.8-not reached)</p> <p><u>placebo plus enzalutamide</u></p> <p>22.1 (16.6-not reached)</p> <p>Unstratified – HR: 0.66</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						(95% CI 0.49-0.91); p=0.0092 <b>BRCA gene alterations vs. placebo:</b> Talazoparib : HR 0.23; 95% CI 0.10-0.53; p=0.0002 <b>Non-BRCA gene alterations vs. placebo:</b> HR 0.66; 0.39-1.12; p=0.12 Talazoparib (n= 398):		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						most common treatment-emergent adverse events (grade >3): anaemia [46%], neutropenia [18%], fatigue [4%]. Treatment-related deaths:  Talazoparib : n= 0 pat.  Placebo: n= 2 pat. (<1%)		
[468]	RCT NCT03748641 (MAGNITUDE)	The phase III MAGNITUDE study	n=423 patients with mCRPC  HRR+ (n=423)	Niraparib (200 mg once daily with abiraterone acetate 1,000	Abiraterone acetate 1,000 mg once daily	<b>Niraparib vs. AAP HRR+ cohort</b>	Combination treatment with niraparib+AAP significantly	Randomisation process not clearly described, double-blind

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
	1+	prospectively enrolled patients into two cohorts on the basis of HRR biomarker status and compared the efficacy and safety of niraparib and abiraterone acetate plus prednisone (niraparib+AAP) versus placebo+AAP as first-line treatment for patients with mCRPC.	HRR- (n=247) Age: HRR+: 69.0 y (43-100 y) 2019-2021 worldwide (26 countries) Median follow-up: HRR+: 18.6 mo (range 0.3-29 mo)	mg once daily plus prednisone 5 mg twice daily n=212 patients with HRR+ n=123 patients with HRR-	plus prednisone 5 mg twice daily n=211 patients with HRR+ n=124 patients with HRR-	<u>radiographic PFS</u> 16.5 vs. 13.7 mo; HR 0.73 (95% CI, 0.56-0.96) p=0.022 <u>Time to PSA progression</u> 18.5 vs. 9.3 mo; HR 0.57 (95% CI 0.43-0.76) p<0.001 <u>OS</u> not estimable; HR 0.94 (95% CI 0.66-1.36) p=0.73 <u>ORR</u>	lengthened radiographic PFS in patients with HRR+ mCRPC compared with standard-of-care AAP.	study, radiographic progression assessed by blinded independent central review.  On the basis of the prespecified criteria, futility was declared for the HRR- cohort in August 2020, which was closed  to further enrollment on the basis of Independent Data Monitoring Committee recommendations.  supported by Janssen

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						RR: 2.13, p<0.001 <u>FACT-P</u> <u>total</u> <u>score</u> changes over time between treatment arms were similar as determined by FACT-P total score <b>Any TEAEs</b> <b>Grade 3</b> Niraparib: 119/212 (56.1%) AAP: 90/211 (42.7%) <b>Grade 4</b>		Research & Development, LLC. Disclosures provided by the authors are available with this article at DOI

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						Niraparib: 23/212 (10.8%)  AAP: 8/211 (3.8%)  <b>HRR- cohort</b>  <u>radiographi c PFS</u>  12 vs. not estimable; HR 1.03 (95% CI, 0.63-1.76)  <u>Time to PSA progression</u>  not estimable; HR 1.03 (95% CI 0.67-1.59)		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[469]	RCT NCT02975934 (TRITON3) 1-	We report the primary results of the trial.	n=405 patients who had mCRPC with a BRCA1, BRCA2, or ATM alteration and who had disease progression after treatment with a second-generation ARPI  2017-2022  143 sites in 12 countries	Rucaparib (600 mg oral twice daily) n=270 BRCA (n=201) ARM (n=69)  Median age: 70 y (45-90 y)	physician's choice of:  docetaxel (administered intravenously at a dose of 75 mg/m <sup>2</sup> every 3 weeks, up to a maximum of 10 cycles + prednisone or prednisolone 5 mg twice daily  abiraterone acetate (administered orally at a starting dose of	<b>Rucaparib vs. control</b>  <b>Imaging-based median PFS</b>  <u>Intention-to-treat</u>  10.2 mo vs 6.4 mo; HR 0.61 (95% CI 0.47-0.80), p<0.001  <u>BRCA subgroup</u>  11.2 mo vs 6.4 mo; HR 0.5 (95% CI 0.36-0.36) p<0.001  <u>ATM subgroup</u>	The duration of imaging-based progression-free survival was significantly longer with rucaparib than with a control medication among patients who had metastatic, castration-resistant prostate cancer with a BRCA alteration.	open label, allocation concealment not clearly described  conflict of interest and median follow-up not reported  Funded by Clovis Oncology. Dr. Abida's work is supported  by a grant from the National Cancer Institute.

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
					1000 mg once daily + prednisone 10 mg once daily enzalutamide (administered orally at a starting dose of 160 mg once daily) n=135 BRCA (n=101) ARM (n=34) Median age: 71 y (47-92 y)	8.1 mo vs 6.8 mo; HR 0.95 (95% CI 0.59- 1.52) <b>Time to                      PSA                      progression</b> <u>Intention-                      to-treat</u> 5.7 mo vs 3.6 mo; HR 0.63 (95% CI 0.49- 0.81) <u>BRCA                      subgroup</u> 6.6 mo vs 3.8 mo; HR 0.52 (95% CI 0.38- 0.70)		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<u>ATM subgroup</u> not reported <b>Objective response rate</b> <u>Intention-to-treat</u> 35% vs. 16% <u>BRCA subgroup</u> 45% vs. 17% <u>ATM subgroup</u> 0% vs. 14% <b>Median duration of response</b> <u>Intention-to-treat</u>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						7.4 mo vs 7.4 mo; HR 0.86 (95% CI 0.36- 2.04)  <u>BRCA</u> <u>subgroup</u>  <u>Intention-</u> <u>to-treat</u>  7.5 mo vs 7.4 mo; HR 0.75 (95% CI 0.27-2.1)  <u>ATM</u> <u>subgroup</u>  4.8 mo vs 11 mo; HR 5.9 (95% CI 0.07- 535.35)  <b>OS (interim                      analysis at                      62 mo)</b>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>Intention-to-treat</u></p> <p>23.6 mo vs 20.9 mo; HR 0.94 (95% CI 0.72-1.32)</p> <p><u>BRCA subgroup</u></p> <p>24.3 mo vs 20.8 mo; HR 0.81 (95% CI 0.58-1.12) p=0.21</p> <p><u>ATM subgroup</u></p> <p>21.1 mo vs 21.7 mo; HR 1.2 (95% CI 0.74-1.95)</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>Any adverse event</b></p> <p><b>Grade <math>\geq 3</math></b></p> <p>Rucaparid: 161/270 (60%)</p> <p>Docetaxel: 43/71 (61%)</p> <p>Second- Generation ARPI: 26/59 (44%)</p> <p><b>Most common adverse events</b></p> <p>Rucaparid: fatigue, nausea, anemia, decreased hemoglobin</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						Control group: fatigue, diarrhea, and neuropathy		
[470]	RCT NCT01682772(TOP ARP-B) 1-	The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in mCRPC.	n=98 men with mCRPC previously treated with one or two taxane chemotherapy regimens  and with an Eastern Cooperative Oncology Group performance status of 2 or less  2015-2018	olaparib (300 mg twice daily) n=49 Age: 67.3 y (61.2-72.1 y)	olaparib (400 mg twice daily) n=49 Age: 67.6 y (63.2-72.7 y)	<b>Composite overall response</b>  300 mg: 18/46 (39.1%; 95% CI 25.1-54.6)  400 mg: 25/46 (54.3%; 95% CI 39-69.1)  <b>Radiologic response</b>  300 mg: 6/37	Olaparib has antitumour activity against mCRPC with DDR gene aberrations, supporting the implementation of genomic stratification of metastatic castration-resistant prostate	multicentre, open-label, investigator-initiated, randomised phase 2 trial, blinding of outcome assessment unclear,  Detailed list of conflict of interest reported in the paper.  Funding: Cancer Research UK, AstraZeneca, Prostate Cancer

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			United Kingdom (17 hospitals)  Median  follow-up: 24.8 mo (IQR 16.7-35.9)			(16.2%; 95% CI 6.2-32)  400 mg: 8/33 (24.2%; 95% CI 11.1- 42.3)  <b>Median PFS</b>  300 mg: 5.4 mo (95% CI 3- 5.6)  400 mg: 5.5 (95% CI 3.6-6.5)  <b>Median OS</b>  300 mg: 10.1 mo (95% CI 9- 17.7)  400 mg: 14.3 (95% CI 9.7-18.9)	cancer in clinical practice.	UK, the Prostate Cancer Foundation, the Experimental Cancer Medicine Centres Network, and the National Institute for Health Research Biomedical Research Centres.

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><b>Serious adverse events</b></p> <p>300 mg: 49 events in 22 patients</p> <p>400 mg: 58 events in 24 patients</p> <p>most common grade 3-4 adverse event: in both cohorts was anaemia</p> <p>death possibly related to treatment: 1 in the 300 mg group</p>		

Referenz	Studiencharakteristika LoE	Studienziel	Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						(myocardial infarction)		

## 2.8 Welche neu zugelassenen Medikamente/Medikamentenkombinationen sind den Standardtherapien in der Therapie des mCRPC überlegen?

Literaturreferenzen: [\[466\]](#), [\[471\]](#), [\[472\]](#), [\[473\]](#), [\[474\]](#), [\[475\]](#), [\[450\]](#), [\[476\]](#), [\[477\]](#), [\[478\]](#), [\[479\]](#), [\[467\]](#)

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
<b>Systematische Reviews</b>								
<a href="#">[466]</a>	Systematic review with meta-analysis 1+	We aim to better characterize the PFS and OS in mCRPC patients treated with PARPis and determine the subgroup of patients with this disease who can benefit from these medications	n=7 RCTs patients with mCRPC Search date: 30 May 2023	PARP with or without ARPI (abiraterone acetate or enzalutamide)	standard care (ARPI or docetaxel)	<b>PARPi vs. Standard care OS (n=5)</b> HR: 0.855 (95% CI 0.752-0.974) p=0.018 I <sup>2</sup> =0% <b>PFS (n=7)</b> HR: 0.626 (95% CI 0.566-0.692) p=0.00 I <sup>2</sup> =45% <b>PFS in patients without HRR gene</b>	Our meta-analysis of seven RCTs showed that PARPis significantly increased PFS and OS when used with or without antihormonal agents like abiraterone or enzalutamide.	The study protocol was not registered. No reported sources of funding for the studies included in the review. Results are reported from fixed-effect models, although random-effect

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		at maximum.				<b>mutation</b> (n=4)  HR: 0.747 (95% CI 0.637-0.877) p=0.00 I <sup>2</sup> =0%		models were planned.  The authors declare no conflict of interest.  This research received no external funding.
<b>Randomisierte kontrollierte Studien</b>								
<b>Apalutamide/Abiraterone+Prednisone vs. Abiraterone+Prednisone</b>								
[471]	RCT NCT02257736 (ACIS)  1++	The current phase 3 trial evaluated clinical benefit of apalutamide plus abiraterone-prednisone	n=982 chemotherapy-naive men with mCRPC  2014-2016  17 countries in North America Europe	apalutamide (240 mg once daily) plus abiraterone (1000 mg once daily) + prednisone	placebo plus abiraterone (1000 mg once daily) + prednisone (5 mg twice daily)	<b>Apalutamid vs. placebo</b>  <b>Median OS</b> 54.8 mo (IQR 51.5-58.4 mo)  <b>radiographic PFS</b>	Despite comparison against an active therapy and the use as first-line treatment, the apalutamide plus	double-blind multicenter study  Detailed list of conflict of interest reported in the paper.

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		versus placebo and abiraterone-prednisone (hereafter abiraterone-prednisone) in patients with chemotherapy-naive mCRPC.	the Asia-Pacific region, Africa South America Median follow-up: 54.8 mo (IQR 51.5-58.4 mo)	(5 mg twice daily) n=492 Median age: 71 y (66-78 y)	n=490 Median age: 71 y (65-77 y)	<u>Median follow-up: 25.7 mo</u> apalutamide: 22,6 (95% CI 19,5-27,4) placebo: 16,6 (95% CI 13,9-19,3) HR 0.69 (95% CI 0.58-0.83) p<0.0001 <u>Median follow-up: 54.8 mo</u> apalutamide: 24 (95% CI 19,7-27,5) placebo: 16,6 (95% CI 13,9-19,3)	abiraterone-prednisone combination consistently improved rPFS in chemotherapy-naive mCRPC patients versus abiraterone-prednisone while maintaining quality of life. As survival benefit is limited with non-targeted therapies in mCRPC, we aimed to identify subgroups of patients who might benefit from therapy,	Funded by Janssen Research & Development.

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						HR 0.70 (95% CI 0.60-0.83) p<0.0001  <b>Grade 3 or 4 TEAE</b>  apalutamide: 60% (294/490)  placebo: 51% (250/489)  <b>TEAE associated with dead</b>  apalutamide: 3% (17/490)  placebo: 37% (37/489)	such as those at an older age.	
<b>Cabazitaxel vs. Abiraterone/Enzalutamide</b>								
[472]	RCT NCT02254785	We report final study results for the primary	n=95 ARPI-naive men with poor prognosis mCRPC	cabazitaxel (25 mg/m <sup>2</sup> )	enzalutamide (160 mg p.o. daily) or	<b>Cabazitaxel vs. ARPI First-line</b>	Cabazitaxel was associated with a higher clinical benefit	Investigators

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
	1-	endpoint of first-line clinical benefit rate, as well as other endpoints including overall survival and time to progression on first- and second-line therapy.	2014-2017 15 sites in Canada Australia Median follow-up: 21.9 mo	intravenous every 3 weeks) plus prednisone (5 mg orally) n=45  Median age: 68.0 y (IQR 59.0-73.0 y)	abiraterone (1000 mg p.o. daily) plus prednisone (5 mg twice daily) (physician's choice)  n=50 (27 abiraterone, 23 enzalutamide)  Median age: 67.5 y (IQR 60.3-71.0 y)	<u>radiographic response rate</u> 22% vs. 21% (p=1.00)  <u>PSA response ≥50%</u> 57% vs. 54% (p=0.84)  <u>PFS</u> 5.3 mo vs. 2.8 mo; HR: 0.87 (0.56-1.35) p=0.52  <u>Time to PSA progression</u> 6.6 mo vs. 5.0 mo; HR: 1.01 (0.61-1.66) p=0.98  <u>Stable disease ≥12 wks</u>	rate in patients with ARPI-naive poor prognosis mCRPC.	and participants were not masked to treatment allocation, median PSA level at baseline significantly different in both groups  Detailed list of conflict of interest reported in the paper.  This work was supported by Sanofi, Laval, Quebec, Canada. Data

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						75% vs. 56% p=0.083 <u>Clinical benefit</u> 80% vs. 62% p=0.039 <b>Second-line</b> <u>radiographic response rate</u> 38% vs. 34% <u>PSA response ≥50%</u> 0% vs. 25% <u>Stable disease ≥12 wks</u> 42% vs. 63% <u>Clinical benefit</u> 54% vs. 63% p=0.58		analysis and correlative studies were funded through research grants from Prostate Cancer Canada, CIHR, Movember Foundation, Prostate Cancer Foundation, Terry Fox New Frontiers Program Project Grant [TFF116129], Jane and Aatos Erkko

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>Time to progression</u></p> <p>2.7 mo vs. 3.7 mo; HR: 1.11 (0.60-2.03) p=0.74</p> <p><u>Time to PSA progression</u></p> <p>3.5 mo vs. 4.3 mo; HR: 0.87 (0.42-1.81) p=0.72</p> <p><b>most common first-line treatment-related grade <math>\geq 3</math> adverse events</b></p> <p>neutropenia (32 vs. 0%)</p> <p>diarrhoea (9 vs. 0%)</p>		Foundation, and the Academy of Finland.

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						infection (9 vs. 0%) fatigue (7 vs. 5%) <b>OS</b> 37 mo vs. 15.5 mo; HR: 0.58 (0.32-1.05) p=0.073		
[473]	RCT NCT02485691 (CARD) 1-	To assess cabazitaxel versus abiraterone/enzalutamide in older ( $\geq 70$ y) and younger ( $< 70$ y) patients in CARD.	n=135 men ( $\geq 70$ y) with mCRPC 2015-2018 62 clinical sites across 13 European countries Median follow-up: 9.2 mo (IQR 5.6-13.1 mo)	cabazitaxel (25 mg/m <sup>2</sup> intravenously over 1 h every 3 weeks) and prednisone (10 mg daily) n=66 ( $\geq 70$ y) n=63 ( $< 70$ y) <u>Median age</u>	Abiraterone (1000 mg orally once daily) with prednisone (5 mg twice daily) or enzalutamide (160 mg given orally once daily)	<b>Cabazitaxel vs. Abiraterone/Enzalutamide <math>\geq 70</math> y</b> <u>Median radiographic PFS</u> 8.2 vs 4.5 mo; HR 0.58; (95% CI 0.38-0.89) p=0.012) <u>Median PFS</u>	Cabazitaxel improved efficacy outcomes vs. abiraterone/enzalutamide in patients with mCRPC after prior docetaxel and abiraterone/enzalutamide, regardless of age. TEAEs were more	The study was open label and participants and investigators were not masked to treatment allocation. Analyses of radiographic PFS (primary endpoint) and safety

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
				<p>≥70 y: 76 y (range 70-85 y)</p> <p>&lt;70 y: 65 y (range 46-69 y)</p>	<p>n=69 (≥70 y)</p> <p>n=57 (&lt;70 y)</p> <p><u>Median age</u></p> <p>≥70 y: 74 y (range 70-88 y)</p> <p>&lt;70 y: 63 y (range 45-69 y)</p>	<p>4.5 vs 2.8 mo; HR 0.57; (95% CI 0.39-0.84) p=0.003)</p> <p><u>Median OS</u></p> <p>13.9 vs. 9.4 mo; HR 0.66 (95% CI = 0.41-1.06) p=0.084</p> <p><u>Pain response</u></p> <p>55 vs. 17% p&lt;0.001</p> <p><u>Any TEAE (Grade ≥3)</u></p> <p>58 vs. 49 %</p> <p><u>Any serious TEAE (Grade ≥3)</u></p> <p>38 vs. 45 %</p> <p><b>&lt;70 y</b></p>	<p>frequent among older patients. The cabazitaxel safety profile was manageable across age groups.</p>	<p>by age were prespecified ; others were post hoc.</p> <p>Detailed list of conflict of interest reported in the paper.</p> <p>Funding Sanofi</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<p><u>Median radiographic PFS</u></p> <p>7.4 vs 3.2 mo; HR 0.47; (95% CI 0.3-0.74) p&lt;0.001)</p> <p><u>Median PFS</u></p> <p>4.4 vs 2.5 mo; HR 0.45; (95% CI 0.3-0.68) p=0.001)</p> <p><u>Median OS</u></p> <p>13.6 vs. 11.8 mo; HR 0.66 (95% CI = 0.41-1.08) p=0.093</p> <p><u>Pain response</u></p> <p>61 vs. 35% p=0.041</p> <p><u>Any TEAE (Grade ≥3)</u></p>		

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						48 vs. 42 % <u>Any serious TEAE (Grade <math>\geq 3</math>)</u> 26 vs. 30 %		
[474]	RCT NCT02485691 (CARD) 1-	Here, we report the quality-of-life outcomes from the CARD study.	n=255 men with mCRPC 2015-2018 62 clinical sites across 13 European countries Median follow-up: 9.2 mo (IQR 5.6-13.1 mo)	cabazitaxel (25 mg/m <sup>2</sup> intravenously over 1 h every 3 weeks) and prednisone (10 mg daily) n=129 Median age: 70 y (65-76 y)	Abiraterone (1000 mg orally once daily) with prednisone (5 mg twice daily) or enzalutamide (160 mg given orally once daily) n=126 (58 abiraterone, 66 enzalutamide, 2 loss)	<b>Cabazitaxel vs. Abiraterone/Enzalutamide</b> <b>Median OS</b> 13.6 vs. 11 mo HR 0.64 (95% CI, 0.46-0.89) p= 0.008 <b>Median time to pain progression</b> not estimable vs. 8.5 mo (95% CI 4.9-not estimable)	Since cabazitaxel improved pain response, time to pain progression, time to symptomatic skeletal events, and EQ-5D-5L utility index, clinicians and patients with metastatic castration-resistant prostate cancer can be reassured that cabazitaxel will	The study was open label and participants and investigators were not masked to treatment allocation.  Detailed list of conflict of interest reported in the paper.  Funding Sanofi

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
					to follow-up) Median age: 71 y (64-75 y)	HR 0.55 (95% CI, 0.32-0.97) p= 0.035 <b>Median time to symptomatic skeletal events</b> not estimable vs. 16.7 mo (95% CI 10.8-not estimable) HR 0.59 (95% CI, 0.35-1.01) p= 0.05 <b>Median time to FACT-P total score deterioration</b> 14.8 mo (95% CI 6.3-not estimable) vs. 8.9 mo (95%	not reduce quality of life when compared with treatment with a second androgen signalling-targeted inhibitor.	

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						CI 0.63-not estimable) HR 0.72 (95% CI, 0.44-1.20) p= 0.21 <b>Physical wellbeing</b> 14.8 mo (95% CI 4.9-not estimable) vs. 8.9 mo (95% CI 4.3-not estimable) HR 0.282 (95% CI, 0.51-1.30) <b>Social or family wellbeing</b> 14.8 mo (95% CI 7.9-14.8) vs. 8.9 mo (95% CI 6.3-not estimable)		

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						HR 1.03 (95% CI, 0.61-1.73)  <b>Emotional wellbeing</b>  not estimable vs. 13.7 mo (95% CI 6.3-not estimable)  HR 0.46 (95% CI, 0.25-0.87)  <b>Functional wellbeing</b>  not estimable vs. 8.9 mo (95% CI 4.8-not estimable)  HR 0.81 (95% CI, 0.51-1.28)  <b>Prostate-specific concerns</b>  14.8 (95% CI 9.8-not		

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						estimable) vs. 8.9 mo (95% CI 4.8-not estimable)  HR 0.68 (95% CI, 0.42-1.08)  <b>EQ-5D-5L</b> significant treatment effect seen in changes from baseline favour of cabazitaxel over abiraterone or enzalutamide (p=0.030)  no difference between treatment groups for change from baseline in EQ-5D-5L		

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						visual analogue scale (p=0.060).		
<b>Enzalutamide, Docetaxel + Prednisolone vs. Docetaxel plus Prednisolone</b>								
[475]	RCT NCT02288247 (PRESIDE) 1++	We aimed to evaluate the efficacy of continuing enzalutamide after progression in controlling mCRPC treated with docetaxel and prednisolone.	n=271 patient with mCRPC with enzalutamide after progression 2014-2016 123 sites in Europe: Austria Belgium Czech Republic France Germany Greece Italy Netherlands, Norway	enzalutamide (160 mg: oral four 40 mg capsules per day) plus docetaxel (intravenous 75 mg/m <sup>2</sup> every 3 weeks) + prednisolone (oral 10 mg/day as two 5 mg tablets) n=136	placebo (oral four 40 mg capsules per day) plus intravenous docetaxel (75 mg/m <sup>2</sup> every 3 weeks) + prednisolone (oral 10 mg/day as two 5 mg tablets) n=135	<b>Enzalutamide vs. placebo Median PFS</b> 9.5 mo (95% CI 8.3-10.9 mo) vs. 8.3 mo (6.3-8.7 mo); HR 0.72 (95% CI 0.53-0.96) p=0.027 <b>Median time to PSA progression</b> 8.4 mo (95% CI 8.2-9.0) vs. 6.2 m (95% CI 5.4-8.3)	The combination of enzalutamide plus docetaxel and prednisolone in men with mCRPC who progressed on enzalutamide therapy alone significantly reduced the risk of disease progression and could serve as an effective treatment option for this	All patients, investigators, clinical staff, and the sponsor's management team were masked to treatment assignment.  Detailed list of conflict of interest reported in the paper.  This study was funded by Astellas

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			Poland Russia Spain Sweden Switzerland Turkey United Kingdom The median follow-up: enzaklutamide: 8.1 mo (IQR 3.2-11.1) placebo: 6.3 mo (IQR 3.1-10.5 mo)	Age: 71.5 y (65-75 y)	Age: 69 y (65-74 y)	risk of PSA progression: HR 0.58 (95% CI 0.41-0.82) p=0.0021 <b>ORR</b> 21/51 (41%) vs. 23/59 (39%) p=0.74 <b>TEAE</b> 133 (98%) vs. 131 (97%) <b>Drug-related treatment-emergent adverse events</b> 63 (46%) vs. 56 (41%) <b>Serious treatment-emergent</b>	subset of patients.	Pharma and Pfizer, the co-developers of enzalutamide.

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<b>adverse events</b> 67 (49%) vs. 52 (39%) <b>Deaths</b> 13 (10%) vs. 7 (5%)		
<b>177Lu-PSMA-617+Standard Care vs. Standard Care</b>								
[450]	RCT NCT0351166 (VISION) 1-	We report the results of VISION, a phase 3 trial investigating the efficacy and safety of 177Lu-PSMA-617 plus protocol-permitted standard care in a specific	n=831 men with mCRPC 2018-2019 84 sites 52 in North America 32 in Europe Median follow-up: 20.9 mo	177Lu-PSMA-617 (maximum of six cycles every six weeks) plus standard care n=551 Median age: 70 y (range 48-94 y)	standard care n=280 Median age: 71.5 y (range 40-89 y)	<b>177Lu-PSMA-617 vs. standard care</b> <b>Median imaging-based PFS</b> (n=581) 8.7 vs. 3.4 mo; HR 0.40 (99.2% CI 0.29-0.57) p<0.001	Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced	open-label study, objective response and disease control not reported, conflict of interest not clearly described Standard-care therapy that was

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
		population of previously treated patients with mCRPC who were selected for PSMA positivity on the basis of positron-emission tomographic imaging.				<p><b>Median OS</b> (n=831) 15.3 vs. 11.3 mo; HR 0.62 (95% CI, 0.52-0.74) p&lt;0.001</p> <p><b>Median time to first symptomatic skeletal event</b> (n=581) 11.5 vs. 6.8 mo; HR 0.5 (95% CI 0.4-0.62) p&lt;0.001</p> <p><b>Complete response</b> (n=248) 9.2% (17/184) vs. 0% (0/64)</p> <p><b>Partial response</b> (n=248)</p>	PSMA-positive metastatic castration-resistant prostate cancer.	permitted by the trial protocol had to be agreed on and assigned by the physician-investigator before randomization, but it could be modified at the discretion of the treating physician. Standard-care therapies could not

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						41.8% (77/184) vs. 3% (2/64) <b>Incidence of adverse events of grade 3 or above (n=831)</b> 52.7% vs. 38.0%		include cytotoxic chemotherapy, systemic radioisotopes (e.g. radium-223), immunotherapy, or drugs that were investigational when the trial was designed (e.g. olaparib). Supported by Endocyte, a Novartis company.
<b>Radium-223+Enzalutamide vs. Enzalutamide</b>								

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[476]	RCT NCT02199197 1- !supportAnnotations> !endif>	Final Safety and Efficacy Results	n=47 men with mCRPC Median follow-up: 22 mo	Radium-223 (intravenous 55 kBq/kg IV every 4 weeks for six doses) + Enzalutamide (160 mg p.o. daily) n=35 Median age: 71 y	Enzalutamide (160 mg p. o. daily) n=12 Median age: 71 y	<b>Radium-223+Enzalutamide vs. Enzalutamide</b> <b>Median OS</b> 30.8 vs. 20.6 mo, p=0.73 <b>PSA-PFS</b> 8.9 vs. 3.38 mo, p=0.97 <b>radiographic PFS</b> 11.5 vs. 7.35 mo, p=0.96 <b>Adverse events</b> There was no difference in any adverse events	Long-term safety of radium-223 with enzalutamide was confirmed in this clinical trial.	small sample size (phase II trial), open-label design, randomization and allocation process not clearly described, econdary endpoints were not included in this paper CAVE: patient flow chart shows 41 randomized patients, text described 47 patients

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						or any incidence of bone marrow disorders.		Detailed list of conflict of interest reported in the paper.  Sponsor: University of Utah
<b>Enzalutamide vs. Enzalutamide and Abiraterone + Prednisone</b>								
[477]	RCT NCT01949337 (Alliance A031201) 1-	We sought to determine whether the addition of AAP to enzalutamide prolongs OS in patients with mCRPC in the first-line setting.	n=1311 men with mCRPC 2014-2016 324 sites participating in the National Cancer Institute-funded National Clinical Trials Network Median follow-up: 60.6 mo (IQR 38.9-63 mo)	enzalutamide (160 mg once daily by mouth) n=657 Age: <65 y: 141 (21%) 65-75 y: 281 (43%)	enzalutamide (160 mg once daily by mouth) plus AAP (abiraterone 1,000 mg once daily and prednisone 5 mg twice daily by mouth)	<b>Enzalutamide vs. Enzalutamide , Abiraterone+ prednisone</b>  <b>Median OS</b> 32.7 mo (95% CI 30.5-35.4 mo) vs. 34.2 mo (95% CI 31.4-37.3 mo)	The addition of AAP to enzalutamide for first-line treatment of mCRPC was not associated with a statistically significant benefit in OS. Drug-drug interactions between the two agents	Trial register describes further outcomes (e. g. ORR) that are not reported in this paper, open label, different withdrawal before treatment start

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
				≥75 y: 235 (36)	n=654 Age: <65 y: 153 (23%) 65-75 y: 266 (41%) ≥75 y: 235 (36%)	HR 0.89 (95% CI 0.78-1.01) p=0.03 <b>Median radiographic PFS</b> 21.3 mo (95% CI 19.4-22.9 mo) vs. 24.3 mo (95% CI 22.3-26.7 mo) HR 0.86 (95% CI 0.76-0.97) p=0.02 <b>Adverse events</b> higher in the combination arm: high-grade nonhematologic toxicity: 55% vs. 69%	resulting in increased abiraterone clearance may partly account for this result, although these interactions did not prevent the combination regimen from having more nonhematologic toxicity.	(enzalutamide: 6; combination: 22)  Detailed list of conflict of interest reported in the paper.  Supported by the National Cancer Institute of the National Institutes of Health. Also supported in part by funds from Astellas.

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						fatigue: 6% vs. 11% hypertension: 22% vs. 31% all-grade atrial fibrillation: 1% vs. 2% transaminitis: 19% vs. 43% higher in the enzalutamide arm: arthralgia: 45% vs. 36%		
<b>Olaparib + Abiraterone vs. Abiraterone</b>								
[478]	RCT NCT03732820 (PROpel) 1++	We report the final prespecified overall survival analysis.	n=796 men with mCRPC 2018-2020 126 centres in 17 countries worldwide	olaparib (300 mg twice daily taken approximately 12 h apart) +	placebo (twice daily) plus abiraterone (once daily 1000 mg taken	<b>Olaparib vs. Placebo Median OS</b> 42.1 mo (95% CI 38.4–not reached) vs.	Overall survival was not significantly different between treatment groups at this	The patients, the investigator, and study centre staff were masked to

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			Median follow-up: 36.6 mo (IQR 34.1- 40.3 mo)	abiraterone (once daily 1000 mg taken on an empty stomach) n=399  Age: 69 y (63-74 y)	on an empty stomach)  n=397  Age: 70 y (65-76 y)	34.7 mo (95% CI 31-39.3 mo)  HR 0.81 (95% CI 0.67-1) p=0.054  <b>Most common grade 3-4 adverse event</b>  anaemia: 64/398 (16%) vs. 13/396 (3%)  <b>Serious adverse events</b>  161/398 (40%) vs. 126/396 (32%)  <b>Death</b>	final prespecified analysis.	drug allocation.  Detailed list of conflict of interest reported in the paper.  Funding AstraZeneca and Merck Sharp & Dohme.

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						One treatment-related death in the placebo group (interstitial lung disease)		
<b>Olaparib vs. Enzalutamide/Abiraterone+Prednisone</b>								
[479]	RCT NCT02987543 (PROfound) 1-	We aimed to assess pain and patient-centric HRQOL measures in patients in the trial.	n=245 men with mCRPC who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations  2017-2019  206 medical centres and hospitals in 20 different countries	olaparib (300 mg orally twice daily)  n=162	enzalutamide (160 mg orally once daily) or abiraterone tablets (1000 mg orally once daily) + prednisone tablets (5 mg orally twice daily)  n=83	<b>Olaparib vs. Control group OS</b> HR 0.69 (95% CI 0.50-0.97) p=0.02  <b>Median time to pain progression</b> HR 0.44 (95% CI 0.22-0.91) p=0.02	Olaparib was associated with reduced pain burden and better-preserved HRQOL compared with the two control drugs in men with metastatic castration-resistant prostate cancer and homologous recombination	The study was open label; thus, patients and participating health-care professionals were not masked to treatment allocation.  AstraZeneca, as part of an alliance between AstraZeneca

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			<p>Median follow-up: Olaparib: 6.2 m (IQR 2.2-10.4 mo)</p> <p>Control: 3.5 mo (1.7-4.9 mo)</p>			<p><b>Time to deterioration in health-related quality of life</b></p> <p><u>FACT-P total score</u></p> <p>HR 0.85 (95% CI 0.54-1.4) p=0.49</p> <p><u>Functional wellbeing</u></p> <p>HR 0.88 (95% CI 0.56-1.42) p=0.54</p> <p><u>Physical wellbeing</u></p> <p>HR 0.95 (95% CI 0.59-1.59) p=0.78</p> <p><b>First symptomatic</b></p>	<p>repair gene alterations who had disease progression after a previous next-generation hormonal drug. Our findings support the clinical benefit of improved radiographical PFS and OS identified in PROfound.</p>	<p>and Merck Sharp &amp; Dohme, a subsidiary of Merck, designed the trial and was responsible for overseeing the collection, analysis, and interpretation of the data. The manuscript was written by the authors with medical writing support, funded by AstraZeneca</p>

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
						<b>skeletal-related event</b> HR 0.37 (95% CI 0.2-0.7) p=0.0013  <b>FACT-P total score during treatment</b> OR 8.32 (95% CI 1.64-151.84) p=0.0065		and Merck Sharp & Dohme.  OS results are included in the meta-analysis above (Alameddine, 2023)  Detailed list of conflict of interest reported in the paper.  Funding AstraZeneca and Merck Sharp & Dohme.
<b>Talazoparib plus Enzalutamide vs. Enzalutamide</b> <a href="#">[LJ2]</a>								

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
[467]	RCT NCT03395197 (TALAPRO-2) 1+	We aimed to compare the efficacy and safety of talazoparib plus enzalutamide versus enzalutamide alone in patients with mCRPC.	n= 805 patients with mCRPC <u>HRR-deficient:</u> n= 169 (21%) <u>HRR-non-eficient:</u> n= 636 (79%) <u>BRCA alterations:</u> Talazoparib: n= 27 (7%) Placebo: n= 32 (8%) 2019- 2020 223 hospitals, cancer centres, medical centres in 26 countries. <u>Median follow-up:</u> rPFS:	n= 402 patients (0.5mg Talazoparib plus 160mg enzalutamide orally once daily) <u>Mean age:</u> 71 y (66–76 y) <b>Median duration of treatment:</b> <u>Talazoparib:</u> 19.8 mo (IQR 8.8–26.9 mo) <u>Enzalutamide in the talazoparib group:</u> 22.2	n= 403 patients (placebo plus 160mg enzalutamide orally once daily) <u>Mean age:</u> 71 y (65–76 y) <b>Median duration of treatment:</b> <u>Placebo:</u> 16.1 mo (6.5–25.0 mo) <u>Enzalutamide in the placebo group:</u> 16.6 mo	<b>All patients</b> <b>Median rPFS:</b> <u>talazoparib plus enzalutamide</u> (95% CI 27.5 months–not reached) <u>placebo plus enzalutamide</u> 21.9 months (16.6–25.1) Stratified - HR: 0.63; 95% CI 0.51–0.78; p<0.0001.	Talazoparib plus enzalutamide resulted in clinically meaningful and statistically significant improvement in rPFS versus standard of care enzalutamide as first-line treatment for patients with mCRPC. Final overall survival data and additional long-term safety follow-up will further clarify the clinical	Sponsor, patients, and investigators were masked to talazoparib or placebo, while enzalutamide was open-label. <u>Conflicts of interest and funding:</u> NA has received an honorarium for consultancy since May, 2020, from diverse pharmaceutical companies

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
			Talazoparib:24.9 months (IQR 21.9–30.2)  Placebo: 24.6 months (14.4–30.2)	mo (9.9–28.1 mo)	(6.7–25.1 mo)		benefit of the treatment combination in patients with and without tumour HRR gene alterations.	(detailed list in the paper).  Study was sponsored by Pfizer. Astellas Pharma provided enzalutamide. Editorial and medical writing support was provided by Emily Messina and Annette Smith, on behalf of CMC AFFINITY, a division of IPG Health Medical Communications, and

Referenz	Studiencharakteristika LoE	Studienziel	Studien-/Patientenmerkmale	Intervention	Kontrolle	Ergebnisse	Schlussfolgerungen des Autors	Methodische Bemerkungen
								was funded by Pfizer.

## 3 Literaturverzeichnis

2. Eastham JA, Aufferberg GB, Barocas DA, Chou R, Crispino T, Davis JW, Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. *J Urol*. 2022 Jul;208(1):10-18. doi: 10.1097/JU.0000000000002757. Epub 2022 May 10. PMID: 35536144.
3. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671- EAU Guidelines Office, Arnhem, The Netherlands.  
<http://uroweb.org/guidelines/compilations-of-all-guidelines/>
4. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2023 Oct;21(10):1067-1096. doi: 10.6004/jnccn.2023.0050. PMID: 37856213.
5. National Institute for Health and Care Excellence (NICE) (2021). Prostate cancer: diagnosis and management. <https://www.nice.org.uk/guidance/ng131>
6. Calof O, Singh A, Lee M, Kenny A, Urban R, Tenover J, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. *J Gerontol. A Biol Sci Med Sci*. 2005;60:1451-1457. URL: <https://www.ncbi.nlm.nih.gov/pubmed/16339333>
7. Gerstenbluth R, Maniam P, Corty E, Seftel A. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. *J Androl*. 2002;23:922-926. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12399540>
8. Hajjar R, Kaiser F, Morley J. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. *J Clin Endocrinol. Metab*. 1997;82:3793-3796. URL: <http://www.ncbi.nlm.nih.gov/pubmed/9360543>
9. Marks L, Mazer N, Mostaghel E, Hess D, Dorey F, Epstein J, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. *JAMA*. 2006;296:2351-2361. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17105798>
10. Rhoden E, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. *J Urol*. 2003;170:2348-2351. URL: <http://www.ncbi.nlm.nih.gov/pubmed/14634413>
11. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto A, Snyder P, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. *J Clin Endocrinol. Metab*. 2004;89:2085-2098. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15126525>
12. Boyle P, Koechlin A, Bota M, d'Onofrio A, Zaridze D, Perrin P, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis. *BJU Int*. 2016; URL: <http://www.ncbi.nlm.nih.gov/pubmed/26779889>

13. Kang D, Li H. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2015;94:e410. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25621688>
14. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2014;17:132-143. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24445948>
15. Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med*. 2003;349:215-224. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12824459>
16. Thompson I, Lucia M, Redman M, Darke A, La Rosa F, Parnes H, et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. *J Urol*. 2007;178:107-109. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17499284>
17. Wilt T, MacDonald R, Hagerty K, Schellhammer P, Kramer B. Five-alpha-reductase Inhibitors for prostate cancer prevention. *Cochrane Database Syst Rev*. 2008;CD007091. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18425978>
18. Kramer B, Hagerty K, Justman S, Somerfield M, Albertsen P, Blot W, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. *J Clin Oncol*. 2009;27:1502-1516. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19252137>
19. Harris R, Lohr K. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. *Ann Intern Med*. 2002;137:917-929. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12458993>
20. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. *J Am Board Fam Pract*. 2003;16:95-101. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12665174>
21. Auvinen A, Maattanen L, Finne P, Stenman U, Aro J, Juusela H, et al. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. *Int J Cancer*. 2004;111:940-943. URL: <https://www.ncbi.nlm.nih.gov/pubmed/15300807>
22. Maattanen L, Hakama M, Tammela T, Ruutu M, Ia-Opas M, Juusela H, et al. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. *Br J Cancer*. 2007;96:56-60. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17213825>
23. McLernon D, Donnan P, Gray M, Weller D, Sullivan F. Receiver operating characteristics of the prostate specific antigen test in an unselected population. *J Med Screen*. 2006;13:102-107. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16792835>
24. Halpern J, Shoag J, Mittal S, Oromendia C, Ballman K, Hershman D, et al. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm. *J Urol*. 2017;197:363-368. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27569432>
25. Cui T, Kovell R, Terlecki R. Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature. *Curr Med Res Opin*. 2016;1-7. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27264113>
26. Belbase N, Agrawal C, Pokharel P, Agrawal S, Lamsal M, Shakya V. Prostate cancer screening in a healthy population cohort in eastern Nepal: an explanatory trial study.

- Asian Pac J Cancer Prev. 2013;14:2835-2838. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23803040>
27. Rabah D, Arafa M. Prostate cancer screening in a Saudi population: an explanatory trial study. *Prostate Cancer Prostatic Dis.* 2010;13:191-194. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20066007>
  28. Candas B, Cusan L, Gomez J, Diamond P, Suburu R, Levesque J, et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. *Prostate.* 2000;45:19-35. URL: <http://www.ncbi.nlm.nih.gov/pubmed/10960839>
  29. Lilja H, Cronin A, Dahlin A, Manjer J, Nilsson P, Eastham J, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. *Cancer.* 2011;117:1210-1219. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20960520>
  30. Heidenreich A, Aus G, Abbou C, Bolla M, Joniau S, Matveev V, et al. EAU guidelines on prostate cancer. 2007
  31. National Comprehensive Cancer Network (NCCN). Prostate Cancer Early Detection Clinical Practice Guidelines in Oncology V22007. 2007
  32. Turkeri L, Tarcan T, Biren T, Kullu S, Akdas A. Transrectal ultrasonography versus digitally guided prostate biopsies in patients with palpable lesions on digital rectal examination. *Br J Urol.* 1995;76:184-186. URL: <http://www.ncbi.nlm.nih.gov/pubmed/7545063>
  33. Renfer L, Schow D, Thompson I, Optenberg S. Is ultrasound guidance necessary for transrectal prostate biopsy?. *J Urol.* 1995;154:1390-1391. URL: <http://www.ncbi.nlm.nih.gov/pubmed/7658544>
  34. Hodge K, McNeal J, Terris M, Stamey T. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. *J Urol.* 1989;142:71-74. URL: <http://www.ncbi.nlm.nih.gov/pubmed/2659827>
  35. National Collaborating Centre for Cancer, National Institute for Health and Clinical Excellence (NICE). Prostate Cancer: diagnosis and treatment. 2008; URL: <http://www.nice.org.uk/Guidance/CG58>
  36. Eichler K, Hempel S, Wilby J, Myers L, Bachmann L, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. *J Urol.* 2006;175:1605-1612. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16600713>
  37. NHS Cancer Screening Programmes. Undertaking a transrectal ultrasound guided biopsy of the prostate PCRMP Guide No 1. 2006
  38. Bootsma A, Laguna Pes M, Geerlings S, Goossens A. Antibiotic prophylaxis in urologic procedures: a systematic review. *Eur Urol.* 2008;54:1270-1286. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18423974>
  39. Hergan L, Kashefi C, Parsons J. Local anesthetic reduces pain associated with transrectal ultrasound-guided prostate biopsy: a meta-analysis. *Urology.* 2007;69:520-525. URL: <https://www.ncbi.nlm.nih.gov/pubmed/17382157>
  40. Richman J, Carter H, Hanna M, Murphy J, Rowlingson A, Andrews R, et al. Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis. *Urology.* 2006;67:1224-1228. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16765183>

41. Tiong H, Liew L, Samuel M, Consigliere D, Esuvaranathan K. A meta-analysis of local anesthesia for transrectal ultrasound-guided biopsy of the prostate. *Prostate Cancer Prostatic Dis.* 2007;10:127-136. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17211441>
42. Hoogendam A, Buntinx F, de Vet H. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. *Fam Pract.* 1999;16:621-626. URL: <http://www.ncbi.nlm.nih.gov/pubmed/10625141>
43. Philip J, Dutta RS, Ballal M, Foster C, Javle P. Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?. *BJU Int.* 2005;95:969-971. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15839915>
44. Lavoipierre A, Snow R, Frydenberg M, Gunter D, Reisner G, Royce P, et al. Prostatic cancer: role of color Doppler imaging in transrectal sonography. *AJR Am J Roentgenol.* 1998;171:205-210. URL: <http://www.ncbi.nlm.nih.gov/pubmed/9648790>
45. Halpern E, Strup S. Using gray-scale and color and power Doppler sonography to detect prostatic cancer. *AJR Am J Roentgenol.* 2000;174:623-627. URL: <http://www.ncbi.nlm.nih.gov/pubmed/10701599>
46. Lee H, Lee H, Byun S, Lee S, Hong S, Kim S. Classification of focal prostatic lesions on transrectal ultrasound (TRUS) and the accuracy of TRUS to diagnose prostate cancer. *Korean J Radiol.* 2009;10:244-251. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19412512>
47. Tamsel S, Killi R, Hekimgil M, Altay B, Soydan S, Demirpolat G. Transrectal ultrasound in detecting prostate cancer compared with serum total prostate-specific antigen levels. *J Med Imaging Radiat Oncol.* 2008;52:24-28. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18373822>
48. Aigner F, Pallwein L, Mitterberger M, Pinggera G, Mikuz G, Horninger W, et al. Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate. *BJU Int.* 2009;103:458-463. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19021610>
49. Colleselli D, Bektic J, Schaefer G, Frauscher F, Mitterberger M, Brunner A, et al. The influence of prostate volume on prostate cancer detection using a combined approach of contrast-enhanced ultrasonography-targeted and systematic grey-scale biopsy. *BJU Int.* 2007;100:1264-1267. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17850369>
50. Mitterberger M, Horninger W, Pelzer A, Strasser H, Bartsch G, Moser P, et al. A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection. *Prostate.* 2007;67:1537-1542. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17705242>
51. Tang J, Yang J, Li Y, Li J, Shi H. Peripheral zone hypoechoic lesions of the prostate: evaluation with contrast-enhanced gray scale transrectal ultrasonography. *J Ultrasound Med.* 2007;26:1671-1679. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18029918>
52. Taymoorian K, Thomas A, Slowinski T, Khiabanchian M, Stephan C, Lein M, et al. Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies. *Anticancer Res.* 2007;27:4315-4320. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18214038>
53. Wink M, Frauscher F, Cosgrove D, Chapelon J, Palwein L, Mitterberger M, et al. Contrast-enhanced ultrasound and prostate cancer; a multicentre European research

- coordination project. *Eur Urol.* 2008;54:982-992. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18584944>
54. Yang J, Tang J, Li J, Luo Y, Li Y, Shi H. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels. *Acad Radiol.* 2008;15:1291-1297. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18790401>
55. Cochlin D, Ganatra R, Griffiths D. Elastography in the detection of prostatic cancer. *Clin Radiol.* 2002;57:1014-1020. URL: <https://www.ncbi.nlm.nih.gov/pubmed/12409113>
56. Eggert T, Khaled W, Wenske S, Ermert H, Noldus J. Stellenwert der Elastographie in der klinischen Diagnostik des lokalisierten Prostatakarzinoms Vergleich von Detektionsraten der B-Modus-Sonographie und der elastographieunterstützten systematischen 10fach-Biopsie. *Urologe A.* 2008;47:1212-1217. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18704361>
57. Kamoi K, Okihara K, Ochiai A, Ukimura O, Mizutani Y, Kawauchi A, et al. The utility of transrectal real-time elastography in the diagnosis of prostate cancer. *Ultrasound Med Biol.* 2008;34:1025-1032. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18255215>
58. König K, Scheipers U, Pesavento A, Lorenz A, Ermert H, Senge T. Initial experiences with real-time elastography guided biopsies of the prostate. *J Urol.* 2005;174:115-117. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15947593>
59. Miyagawa T, Tsutsumi M, Matsumura T, Kawazoe N, Ishikawa S, Shimokama T, et al. Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images. *Jpn J Clin Oncol.* 2009;39:394-398. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19359330>
60. Nelson E, Sotoroff C, Gomella L, Halpern E. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. *Urology.* 2007;70:1136-1140. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18158034>
61. Salomon G, Köllerman J, Thederan I, Chun F, Budäus L, Schlomm T, et al. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. *Eur Urol.* 2008;54:1354-1362. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18374470>
62. Tsutsumi M, Miyagawa T, Matsumura T, Kawazoe N, Ishikawa S, Shimokama T, et al. The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: clinicopathological analysis. *Int J Clin Oncol.* 2007;12:250-255. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17701002>
63. Futterer J, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. *Eur Urol.* 2015;68:1045-1053. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25656808>
64. Zhang Z, Yang J, Zhang C, Li K, Quan Q, Wang X, et al. The value of magnetic resonance imaging in the detection of prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels: a meta-analysis. *Acad Radiol.* 2014;21:578-589. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24703470>
65. Blomqvist L, Carlsson S, Gjertsson P, Heintz E, Hultcrantz M, Mejare I, et al. Limited evidence for the use of imaging to detect prostate cancer: a systematic review. *Eur J Radiol.* 2014;83:1601-1606. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25059597>

66. Wegelin O, van Melick H, Hooft L, Bosch J, Reitsma H, Barentsz J, et al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration Is There a Preferred Technique?. *Eur Urol.* 2017;71:517-531. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27568655>
67. Gayet M, van der Aa A, Beerlage H, Schrier B, Mulders P, Wijkstra H. The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review. *BJU Int.* 2016;117:392-400. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26237632>
68. Wu J, Ji A, Xie B, Wang X, Zhu Y, Wang J, et al. Is magnetic resonance/ultrasound fusion prostate biopsy better than systematic prostate biopsy? An updated meta- and trial sequential analysis. *Oncotarget.* 2015;6:43571-43580. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26498362>
69. Valerio M, Donaldson I, Emberton M, Ehdai B, Hadaschik B, Marks L, et al. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. *Eur Urol.* 2015;68:8-19. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25454618>
70. Schoots I, Roobol M, Nieboer D, Bangma C, Steyerberg E, Hunink M. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. *Eur Urol.* 2015;68:438-450. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25480312>
71. Filson C, Natarajan S, Margolis D, Huang J, Lieu P, Dorey F, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. *Cancer.* 2016;122:884-892. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26749141>
72. Klein J, de Gorski A, Benamran D, Vallee J, De PT, Wirth G, et al. Transrectal Ultrasound-Guided Prostate Biopsy for Cancer Detection: Performance of 2D-, 3D- and 3D-MRI Fusion Targeted Techniques. *Urol Int.* 2017;98:7-14. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27784024>
73. Mendhiratta N, Rosenkrantz A, Meng X, Wysock J, Fenstermaker M, Huang R, et al. Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. *J Urol.* 2015;194:1601-1606. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26100327>
74. Porpiglia F, De Luca S, Passera R, Manfredi M, Mele F, Bollito E, et al. Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score. *Anticancer Res.* 2016;36:4833-4839. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27630337>
75. Siddiqui M, Rais BS, Turkbey B, George A, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. *JAMA.* 2015;313:390-397. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25626035>
76. Rastinehad A, Waingankar N, Turkbey B, Yaskiv O, Sonstegard A, Fakhoury M, et al. Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer

- Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies. *PLoS One*. 2015;10:e0143404. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26605548>
77. Porpiglia F, Russo F, Manfredi M, Mele F, Fiori C, Regge D. Preoperative prostate biopsy and multiparametric magnetic resonance imaging: reliability in detecting prostate cancer. *Int Braz J Urol*. 2015;41:124-133. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25928518>
78. de Gorski A, Roupret M, Peyronnet B, Le CC, Granger B, Comperat E, et al. Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. *J Urol*. 2015;194:669-673. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25784374>
79. Drost FJH, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer. *Eur Urol*. 2020;77:78-94. URL: <https://pubmed.ncbi.nlm.nih.gov/31326219/>
80. Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. *Cochrane Database Syst Rev*. 2019;4:CD012663. URL: <https://pubmed.ncbi.nlm.nih.gov/31022301/>
81. Cheikh A, Girouin N, Colombel M, Marechal J, Gelet A, Bissery A, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. *Eur Radiol*. 2009;19:770-778. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18925403>
82. Labanaris A, Engelhard K, Zugor V, Nutzelt R, Kuhn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. *Prostate Cancer Prostatic Dis*. 2010;13:65-70. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19752886>
83. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. *Clin Cancer Res*. 2010;16:1875-1883. URL: <https://www.ncbi.nlm.nih.gov/pubmed/20197480>
84. Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian P, et al. Functional magnetic resonance imaging in prostate cancer. *Eur Urol*. 2009;55:801-814. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19185981>
85. Haider M, Yao X, Loblaw A, Finelli A. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review. *Clin Oncol (R Coll Radiol)*. 2016;28:550-567. URL: <https://www.ncbi.nlm.nih.gov/pubmed/27256655>
86. Delongchamps N, Portalez D, Bruguier E, Rouviere O, Malavaud B, Mozer P, et al. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer?. *J Urol*. 2016;196:1069-1075. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27079582>
87. Peltier A, Aoun F, Lemort M, Kwizera F, Paesmans M, van VR. MRI-targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naive men. *Biomed Res Int*. 2015;2015:571708. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25692142>

88. Mariotti G, Costa D, Pedrosa I, Falsarella P, Martins T, Roehrborn C, et al. Magnetic resonance/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of prostate cancer: multi-institutional retrospective analysis of 389 patients. *Urol Oncol.* 2016;34:416-416. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27197921>
89. Baco E, Rud E, Eri L, Moen G, Vlatkovic L, Svindland A, et al. A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. *Eur Urol.* 2016;69:149-156. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25862143>
90. Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino E, Papalia R, et al. Multiparametric magnetic resonance imaging vs standard care in men being evaluated for prostate cancer: a randomized study. *Urol Oncol.* 2015;33:17-17. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25443268>
91. Tonttila P, Lantto J, Paakko E, Piippo U, Kauppila S, Lammentausta E, et al. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. *Eur Urol.* 2016;69:419-425. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26033153>
92. Ahmed H, El-Shater BA, Brown L, Gabe R, Kaplan R, Parmar M, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet.* 2017;389:815-822. URL: <http://www.ncbi.nlm.nih.gov/pubmed/28110982>
93. Krause B, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivatives. *Urol Oncol.* 2011; URL: <http://www.ncbi.nlm.nih.gov/pubmed/21388835>
94. Manikandan R, Qazi H, Philip J, Mistry R, Lamb G, Woolfenden K, et al. Routine use of magnetic resonance imaging in the management of T(1c) carcinoma of the prostate: is it necessary?. *J Endourol.* 2007;21:1171-1174. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17949319>
95. Nogueira L, Wang L, Fine S, Pinochet R, Kurta J, Katz D, et al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. *Urology.* 2010;75:472-477. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19643467>
96. Turkbey B, Pinto P, Mani H, Bernardo M, Pang Y, McKinney Y, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. *Radiology.* 2010;255:89-99. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20308447>
97. Weinreb J, Blume J, Coakley F, Wheeler T, Cormack J, Sotito C, et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. *Radiology.* 2009;251:122-133. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19332850>
98. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. *J Urol.* 2004;171:2122-2127. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15126770>
99. Ayyathurai R, Mahapatra R, Rajasundaram R, Srinivasan V, Archard N, Toussi H. A study on staging bone scans in newly diagnosed prostate cancer. *Urol Int.* 2006;76:209-212. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16601380>

100. Ishizuka O, Tanabe T, Nakayama T, Kawakami M, Kinebuchi Y, Nishizawa O. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan. *Int J Urol.* 2005;12:728-732. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16174046>
101. Briganti A, Chun F, Salonia A, Gallina A, Farina E, Da Pozzo L, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. *BJU Int.* 2006;98:788-793. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16796698>
102. Steuber T, Graefen M, Haese A, Erbersdobler A, Chun F, Schlom T, et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. *J Urol.* 2006;175:939-944. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16469587>
103. Chun F, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni V, et al. Development and external validation of an extended 10-core biopsy nomogram. *Eur Urol.* 2007;52:436-444. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17010505>
104. Perera M, Papa N, Christidis D, Wetherell D, Hofman M, Murphy D, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol.* 2016; URL: <http://www.ncbi.nlm.nih.gov/pubmed/27363387>
105. Maurer T, Gschwend J, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. *J Urol.* 2016;195:1436-1443. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26682756>
106. Budaus L, Leyh-Bannurah S, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. *Eur Urol.* 2016;69:393-396. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26116958>
107. van Leeuwen P, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective Evaluation of 68Gallium-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Prostate Cancer. *BJU Int.* 2016; URL: <http://www.ncbi.nlm.nih.gov/pubmed/27207581>
108. Herlemann A, Wenter V, Kretschmer A, Thierfelder K, Bartenstein P, Faber C, et al. Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. *Eur Urol.* 2016; URL: <http://www.ncbi.nlm.nih.gov/pubmed/26810345>
109. Engelbrecht M, Jager G, Laheij R, Verbeek A, van Lier H, Barentsz J. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. *Eur Radiol.* 2002;12:2294-2302. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12195484>
110. Soulie M, Aziza R, Escourrou G, Seguin P, Tollon C, Molinier L, et al. Assessment of the risk of positive surgical margins with pelvic phased-array magnetic resonance imaging in patients with clinically localized prostate cancer: a prospective study. *Urology.* 2001;58:228-232. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11489708>
111. Nakashima J, Tanimoto A, Imai Y, Mukai M, Horiguchi Y, Nakagawa K, et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. *Urology.* 2004;64:101-105. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15245944>

112. Wang L, Hricak H, Kattan M, Schwartz L, Eberhardt S, Chen H, et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. *AJR Am J Roentgenol.* 2006;186:743-748. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16498101>
113. Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F, et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-PSMA-HBED-CC than with F-Fluoroethylcholine PET/CT. *Eur J Nucl Med Mol Imaging.* 2016; URL: <http://www.ncbi.nlm.nih.gov/pubmed/26993315>
114. Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. *Eur J Nucl Med Mol Imaging.* 2016;43:34-41. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26404016>
115. Morigi J, Stricker P, van Leeuwen P, Tang R, Ho B, Nguyen Q, et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. *J Nucl Med.* 2015;56:1185-1190. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26112024>
116. Afshar-Oromieh A, Zechmann C, Malcher A, Eder M, Eisenhut M, Linhart H, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging.* 2014;41:11-20. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24072344>
117. van Leeuwen P, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. *BJU Int.* 2016;117:732-739. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26683282>
118. Shakespeare T. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. *Radiat Oncol.* 2015;10:233. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26582424>
119. Amin M, Boccon-Gibod L, Egevad L, Epstein J, Humphrey P, Mikuz G, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. *Scand J Urol Nephrol Suppl.* 2005;20:33. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16019757>
120. Freedland S, Csathy G, Dorey F, Aronson W. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. *J Urol.* 2002;167:516-520. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11792909>
121. Kattan M, Eastham J, Wheeler T, Maru N, Scardino P, Erbersdobler A, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. *J Urol.* 2003;170:1792-1797. URL: <https://www.ncbi.nlm.nih.gov/pubmed/14532778>
122. Mosse C, Magi-Galluzzi C, Tsuzuki T, Epstein J. The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. *Am. J. Surg. Pathol.* 2004;28:394-398. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15104304>
123. Pan C, Potter S, Partin A, Epstein J. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. *Am. J. Surg. Pathol.* 2000;24:563-569. URL: <https://www.ncbi.nlm.nih.gov/pubmed/10757404>

124. Dhom G, Degro S. Therapy of prostatic cancer and histopathologic follow-up. *Prostate*. 1982;3:531-542. URL: <http://www.ncbi.nlm.nih.gov/pubmed/7155986>
125. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark J, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med*. 2011;364:1708-1717. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21542742>
126. Wilt T, Brawer M, Jones K, Barry M, Aronson W, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. *N. Engl. J Med*. 2012;367:203-213. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22808955>
127. Ip S, Dahabreh I, Chung M, Yu W, Balk E, Iovin R, et al. An evidence review of active surveillance in men with localized prostate cancer. *Evid Rep. Technol. Assess. (Full Rep. )*. 2011;1-341. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23126653>
128. Parker C. The Scandinavian Prostate Cancer Group Study: the case for conservative management. *BJU. Int*. 2005;96:952-953. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16225505>
129. Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. *Cancer*. 2005;103:943-951. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15651057>
130. Lu-Yao G, Yao S. Population-based study of long-term survival in patients with clinically localised prostate cancer. *Lancet*. 1997;349:906-910. URL: <http://www.ncbi.nlm.nih.gov/pubmed/9093251>
131. McLaren D, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. *Cancer*. 1998;82:342-348. URL: <http://www.ncbi.nlm.nih.gov/pubmed/9445192>
132. Thompson I, Thrasher J, Aus G, Burnett A, Canby-Hagino E, Cookson M, et al. Guideline for the management of clinically localized prostate cancer: 2007 update (confirmed 2009). *J Urol*. 2007;177:2106-2131. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17509297>
133. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. *J Natl Cancer Inst*. 2008;100:1144-1154. URL: <https://www.ncbi.nlm.nih.gov/pubmed/18695132>
134. Hamdy F, Donovan J, Lane J, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. *N Engl J Med*. 2016;375:1415-1424. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27626136>
135. Heidenreich A, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, et al. EAU guidelines on prostate cancer. 2011
136. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson S, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med*. 2005;352:1977-1984. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15888698>
137. Heidenreich A, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, et al. EAU guidelines on prostate cancer. 2010; URL: <https://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2010.pdf>

138. Swindle P, Eastham J, Ohori M, Kattan M, Wheeler T, Maru N, et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. *J. Urol.* 2005;174:903-907. URL: <http://www.ncbi.nlm.nih.gov/pubmed?term=16093984>
139. Nuttall M, van der MJ, Phillips N, Sharpin C, Gillatt D, McIntosh G, et al. A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures. *J. Urol.* 2004;172:2145-2152. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15538220>
140. Hollenbeck B, Dunn R, Miller D, Daignault S, Taub D, Wei J. Volume-based referral for cancer surgery: informing the debate. *J Clin Oncol.* 2007;25:91-96. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17194909>
141. Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, et al. The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. *PLoS One.* 2016;11:e0154499. URL: <https://www.ncbi.nlm.nih.gov/pubmed/27171271>
142. Bauman G, Rumble R, Chen J, Loblaw A, Warde P. Intensity-modulated radiotherapy in the treatment of prostate cancer. *Clin Oncol (R Coll Radiol).* 2012;24:461-473. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22673744>
143. Zelefsky M, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys.* 2012;84:125-129. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22330997>
144. Wortel R, Incrocci L, Pos F, van der Heide U, Lebesque J, Aluwini S, et al. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. *Int J Radiat Oncol Biol Phys.* 2016;95:680-689. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27055398>
145. Zapatero A, Roch M, Buchser D, Castro P, Fernandez-Banda L, Pozo G, et al. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. *Clin Transl. Oncol.* 2017;19:1161-1167. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28374321>
146. Sveistrup J, af Rosenschold P, Deasy J, Oh J, Pommer T, Petersen P, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. *Radiat Oncol.* 2014;9:44. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24495815>
147. 72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. *Int J Radiat Oncol Biol Phys.* 2004;58:25-33. URL: <http://www.ncbi.nlm.nih.gov/pubmed/14697417>
148. Peeters S, Lebesque J, Heemsbergen W, van Putten W, Slot A, Dielwart M, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 2006;64:1151-1161. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16414208>
149. Zietman A, DeSilvio M, Slater J, Rossi C, Miller D, Adams J, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized

- adenocarcinoma of the prostate: a randomized controlled trial. *JAMA*. 2005;294:1233-1239. URL: <https://www.ncbi.nlm.nih.gov/pubmed/16160131>
150. Dearnaley D, Sydes M, Graham J, Aird E, Bottomley D, Cowan R, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. *Lancet Oncol*. 2007;8:475-487. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17482880>
151. Kuban D, Tucker S, Dong L, Starkschall G, Huang E, Cheung M, et al. Long-term results of the M D Anderson randomized dose-escalation trial for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2008;70:67-74. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17765406>
152. Zapatero A, Valcarcel F, Calvo F, Algas R, Bejar A, Maldonado J, et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. *J Clin. Oncol*. 2005;23:6561-6568. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16170164>
153. Viani G, Stefano E, Afonso S. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. *Int J Radiat Oncol Biol Phys*. 2009;74:1405-1418. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19616743>
154. Al-Mamgani A, Heemsbergen W, Levendag P, Lebesque J. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. *Radiother Oncol*. 2010;96:13-18. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20227123>
155. Zietman A, Bae K, Slater J, Shipley W, Efsthathiou J, Coen J, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. *J Clin Oncol*. 2010;28:1106-1111. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20124169>
156. Al-Mamgani A, van Putten W, van der Wielen G, Levendag P, Incrocci L. Dose Escalation and Quality of Life in Patients With Localized Prostate Cancer Treated With Radiotherapy: Long-Term Results of the Dutch Randomized Dose-Escalation Trial (CKTO 96-10 Trial). *Int J Radiat Oncol Biol Phys*. 2011;79:1004-1012. URL: <https://www.ncbi.nlm.nih.gov/pubmed/20421153>
157. Beckendorf V, Guerif S, Le PE, Cosset J, Lefloch O, Chauvet B, et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. *Int J Radiat Oncol Biol Phys*. 2004;60:1056-1065. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15519775>
158. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol*. 2016;17:1047-1060. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27339115>
159. Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol*. 2015;16:1605-1616. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26522334>

160. Lee W, Dignam J, Amin M, Bruner D, Low D, Swanson G, et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. *J Clin Oncol.* 2016;34:2325-2332. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27044935>
161. Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn P, de JH, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. *Lancet Oncol.* 2016;17:464-474. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26968359>
162. Aluwini S, Pos F, Schimmel E, van LE, Krol S, van der Toorn P, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. *Lancet Oncol.* 2015;16:274-283. URL: [http://www.researchgate.net/publication/272079148\\_Hypofractionated\\_versus\\_conventionally\\_fractionated\\_radiotherapy\\_for\\_patients\\_with\\_prostate\\_cancer\\_HYPRO\\_Late\\_toxicity\\_results\\_from\\_a\\_randomised\\_non-inferiority\\_phase\\_3\\_trial](http://www.researchgate.net/publication/272079148_Hypofractionated_versus_conventionally_fractionated_radiotherapy_for_patients_with_prostate_cancer_HYPRO_Late_toxicity_results_from_a_randomised_non-inferiority_phase_3_trial)
163. Incrocci L, Wortel R, Alemayehu W, Aluwini S, Schimmel E, Krol S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol.* 2016;17:1061-1069. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27339116>
164. Cozzarini C, Fiorino C, Deantoni C, Briganti A, Fodor A, La MM, et al. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. *Eur Urol.* 2014;66:1024-1030. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24985964>
165. Lewis S, Patel P, Song H, Freedland S, Bynum S, Oh D, et al. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2016;94:605-611. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26867889>
166. Koontz B, Bossi A, Cozzarini C, Wiegel T, D'Amico A. A systematic review of hypofractionation for primary management of prostate cancer. *Eur Urol.* 2015;68:683-691. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25171903>
167. Pommier P, Chabaud S, Lagrange J, Richaud P, Lesaunier F, Le PE, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. *J. Clin. Oncol.* 2007;25:5366-5373. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18048817>
168. Lawton C, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. *Int J Radiat Oncol Biol Phys.* 2007;69:646-655. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17531401>
169. Morikawa L, Roach M. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. *Int. J. Radiat. Oncol. Biol. Phys.* 2011;80:6-16. URL: <https://www.ncbi.nlm.nih.gov/pubmed/21481721>
170. Gemeinsamer Bundesausschuss (G-BA). Protonentherapie Indikation: Prostatakarzinom Abschlussbericht des Unterausschusses „Methodenbewertung“ des Gemeinsamen

- Bundesausschusses (3 Update-Recherche). 2008; URL: [http://www.g-ba.de/downloads/40-268-739/2008-06-19\\_Abschluss\\_Protonen-Prostatakarzinom.pdf](http://www.g-ba.de/downloads/40-268-739/2008-06-19_Abschluss_Protonen-Prostatakarzinom.pdf)
171. Ollendorf D, Hayes J, McMahon P, Pearson S, Kuba M, Tramontano A. Brachytherapy & Proton Beam Therapy for treatment of clinically-localized, low-risk prostate cancer Institute for Clinical and Economic Review Final Appraisal Document. 2008
172. Nihei K, Ogino T, Onozawa M, Murayama S, Fuji H, Murakami M, et al. Multi-Institutional Phase II Study of Proton Beam Therapy for Organ-Confined Prostate Cancer Focusing on the Incidence of Late Rectal Toxicities. *Int J Radiat Oncol Biol Phys.* 2010; URL: <http://www.ncbi.nlm.nih.gov/pubmed/20832180>
173. Terasawa T, Dvorak T, Ip S, Raman G, Lau J, Trikalinos T. Systematic review: charged-particle radiation therapy for cancer. *Ann Intern Med.* 2009;151:556-565. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19755348>
174. Mendenhall N, Li Z, Hoppe B, Marcus R, Mendenhall W, Nichols R, et al. Early Outcomes from Three Prospective Trials of Image-guided Proton Therapy for Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2012;82:213-221. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21093164>
175. Brada M, Pijls-Johannesma M, De RD. Current clinical evidence for proton therapy. *Cancer J.* 2009;15:319-324. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19672149>
176. Fang P, Mick R, Deville C, Both S, Bekelman J, Christodouleas J, et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. *Cancer.* 2015;121:1118-1127. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25423899>
177. Yu J, Soulos P, Herrin J, Cramer L, Potosky A, Roberts K, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. *J Natl Cancer Inst.* 2013;105:25-32. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23243199>
178. Sheets N, Goldin G, Meyer A, Wu Y, Chang Y, Sturmer T, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. *JAMA.* 2012;307:1611-1620. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22511689>
179. D'Amico A, Whittington R, Malkowicz S, Schultz D, Blank K, Broderick G, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA.* 1998;280:969-974. URL: <http://www.ncbi.nlm.nih.gov/pubmed/9749478>
180. Beyer D, Brachman D. Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. *Radiother Oncol.* 2000;57:263-267. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11104883>
181. D'Amico A, Tempany C, Schultz D, Cormack R, Hurwitz M, Beard C, et al. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. *Urology.* 2003;62:1063-1067. URL: <http://www.ncbi.nlm.nih.gov/pubmed/14665356>
182. Sharkey J, Cantor A, Solc Z, Huff W, Chovnick S, Behar R, et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. *Brachytherapy.* 2005;4:34-44. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15737905>

183. Zelefsky M, Wallner K, Ling C, Raben A, Hollister T, Wolfe T, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. *J Clin. Oncol.* 1999;17:517-522. URL: <https://www.ncbi.nlm.nih.gov/pubmed/10080594>
184. Zaorsky N, Doyle L, Hurwitz M, Dicker A, Den R. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?. *Expert review of anticancer therapy.* 2014;14:39-50. URL: [www.ncbi.nlm.nih.gov/pubmed/24124755](http://www.ncbi.nlm.nih.gov/pubmed/24124755)
185. Hinnen K, Battermann J, van Roermund J, Moerland M, Jurgenliemk-Schulz I, Frank S, et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. *Int J Radiat Oncol Biol Phys.* 2010;76:1433-1438. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19540075>
186. Koukourakis G, Kelekis N, Armonis V, Kouloulis V. Brachytherapy for prostate cancer: a systematic review. *Adv Urol.* 2009;327945. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19730753>
187. Ash D, Flynn A, Battermann J, de RT, Lavagnini P, Blank L. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. *Radiother Oncol.* 2000;57:315-321. URL: <https://www.ncbi.nlm.nih.gov/pubmed/11104892>
188. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 1999;44:789-799. URL: <http://www.ncbi.nlm.nih.gov/pubmed/10386635>
189. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. *J Urol.* 2005;173:1562-1566. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15821486>
190. Merrick G, Butler W, Wallner K, Galbreath R, Allen Z, Lief J, et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. *Urology.* 2005;65:95-100. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15667872>
191. Blasko J, Grimm P, Sylsvester J, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. *Radiother Oncol.* 2000;57:273-278. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11104885>
192. Singh A, Gagnon G, Collins B, Niroomand-Rad A, McRae D, Zhang Y, et al. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis. *Prostate.* 2005;62:54-60. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15389809>
193. Jani A, Feinstein J, Pasciak R, Krengel S, Weichselbaum R. Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer. *Urology.* 2006;67:1007-1011. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16635512>
194. Valakh V, Kirichenko A, Miller R, Sunder T, Miller L, Fuhrer R. Combination of IG-IMRT and permanent source prostate brachytherapy in patients with organ-confined prostate cancer: GU and GI toxicity and effect on erectile function. *Brachytherapy.* 2010; URL: <http://www.ncbi.nlm.nih.gov/pubmed/21030319>

195. Nilsson S, Norlen B, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. *Acta Oncol.* 2004;43:316-381. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15303499>
196. Stock R, Yalamanchi S, Hall S, Stone N. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. *J Urol.* 2010;183:546-550. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20006854>
197. Koontz B, Chino J, Lee W, Hahn C, Buckley N, Huang S, et al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. *Brachytherapy.* 2009;8:191-196. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19433320>
198. Martinez A, Demanes D, Galalae R, Vargas C, Bertermann H, Rodriguez R, et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. *Int. J. Radiat. Oncol. Biol. Phys.* 2005;62:1322-1331. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16029788>
199. Galalae R, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. *Int J Radiat Oncol Biol Phys.* 2004;58:1048-1055. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15001244>
200. Deger S, Boehmer D, Roigas J, Schink T, Wernecke K, Wiegel T, et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. *Eur Urol.* 2005;47:441-448. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15774239>
201. Demanes D, Rodriguez R, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. *Int J Radiat Oncol Biol Phys.* 2005;61:1306-1316. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15817332>
202. Galalae R, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. *Int J Radiat Oncol Biol Phys.* 2002;52:81-90. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11777625>
203. Galalae R, Martinez A, Nuernberg N, Edmundson G, Gustafson G, Gonzalez J, et al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?. *Strahlenther Onkol.* 2006;182:135-141. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16520907>
204. Hoskin P, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. *Radiother Oncol.* 2007;84:114-120. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17531335>
205. Sathya J, Davis I, Julian J, Guo Q, Daya D, Dayes I, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. *J. Clin. Oncol.* 2005;23:1192-1199. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15718316>
206. Grills I, Martinez A, Hollander M, Huang R, Goldman K, Chen P, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose

- rate palladium seeds. *J Urol.* 2004;171:1098-1104. URL: <http://www.ncbi.nlm.nih.gov/pubmed/14767279>
207. Vargas C, Martinez A, Boike T, Spencer W, Goldstein N, Gustafson G, et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. *Int. J Radiat. Oncol. Biol. Phys.* 2006;66:416-423. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16879929>
208. Yoshioka Y, Nose T, Yoshida K, Inoue T, Yamazaki H, Tanaka E, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. *Int. J Radiat. Oncol. Biol. Phys.* 2000;48:675-681. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11020563>
209. Bader P, Burkhard F, Markwalder R, Studer U. Is a limited lymph node dissection an adequate staging procedure for prostate cancer?. *J Urol.* 2002;168:514-518. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12131300>
210. Briganti A, Chun F, Salonia A, Zanni G, Scattoni V, Valiquette L, et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. *Eur Urol.* 2006;49:1019-1026. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16530933>
211. Joslyn S, Konety B. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. *Urology.* 2006;68:121-125. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16806432>
212. Touijer K, Rabbani F, Otero J, Secin F, Eastham J, Scardino P, et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. *J Urol.* 2007;178:120-124. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17499306>
213. or =6, and their influence on PSA progression-free survival after radical prostatectomy. *BJU Int.* 2006;97:1173-1178. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16686707>
214. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. *J Urol.* 2007;177:916-920. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17296375>
215. DiMarco D, Zincke H, Sebo T, Slezak J, Bergstralh E, Blute M. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. *J Urol.* 2005;173:1121-1125. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15758719>
216. Allaf M, Palapattu G, Trock B, Carter H, Walsh P. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. *J Urol.* 2004;172:1840-1844. URL: <https://www.ncbi.nlm.nih.gov/pubmed/15540734>
217. Bhatta-Dhar N, Reuther A, Zippe C, Klein E. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. *Urology.* 2004;63:528-531. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15028451>
218. Ramsay C, Adewuyi T, Gray J, Hislop J, Shirley M, Jayakody S, et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. *Health Technol Assess.* 2015;19:1-490. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26140518>

219. Cordeiro E, Cathelineau X, Thuroff S, Marberger M, Crouzet S, de la Rosette J. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. *BJU Int.* 2012;110:1228-1242. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22672199>
220. Crouzet S, Chapelon J, Rouviere O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. *Eur Urol.* 2014;65:907-914. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23669165>
221. Uchida T, Tomonaga T, Kim H, Nakano M, Shoji S, Nagata Y, et al. Improved outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer. *J Urol.* 2015;193:103-110. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25079940>
222. Thuroff S, Chaussy C. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years. *J Urol.* 2013;190:702-710. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23415962>
223. Dickinson L, Arya M, Afzal N, Cathcart P, Charman S, Cornaby A, et al. Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort. *Eur Urol.* 2016;70:668-674. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26951947>
224. Ganzer R, Fritsche H, Brandtner A, Brundl J, Koch D, Wieland W, et al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. *BJU Int.* 2013;112:322-329. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23356910>
225. Berge V, Dickinson L, McCartan N, Hindley R, Diep L, Emberton M, et al. Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer. *J Urol.* 2014;191:1764-1769. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24373800>
226. Akakura K, Suzuki H, Ichikawa T, Fujimoto H, Maeda O, Usami M, et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. *Jpn J Clin Oncol.* 2006;36:789-793. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17082219>
227. White W, Sadetsky N, Waters W, Carroll P, Litwin M. Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. *J. Urol.* 2008;180:2409-2413. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18930270>
228. Carver B, Bianco F, Scardino P, Eastham J. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. *J Urol.* 2006;176:564-568. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16813890>
229. Edamura K, Saika T, Senoh T, Koizumi F, Manabe D, Ebara S, et al. Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute. *Acta Med Okayama.* 2005;59:195-199. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16286958>
230. Fletcher S, Mills S, Smolkin M, Theodorescu D. Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. *Int J Radiat Oncol Biol Phys.* 2006;66:1092-1099. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16965872>

231. Hachiya T, Akakura K, Saito S, Shinohara N, Sato K, Harada M, et al. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan. *BJU Int.* 2005;95:534-540. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15705075>
232. Johnstone P, Ward K, Goodman M, Assikis V, Petros J. Radical prostatectomy for clinical T4 prostate cancer. *Cancer.* 2006;106:2603-2609. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16700037>
233. Saito T, Kitamura Y, Komatsubara S, Matsumoto Y, Sugita T, Hara N. Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan. *Asian J. Androl.* 2006;8:555-561. URL: <https://www.ncbi.nlm.nih.gov/pubmed/16847528>
234. Ward J, Slezak J, Blute M, Bergstralh E, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. *BJU Int.* 2005;95:751-756. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15794776>
235. Namiki S, Tochigi T, Ishidoya S, Ito A, Numata I, Arai Y. Long-term quality of life following primary treatment in men with clinical stage T3 prostate cancer. *Qual. Life Res.* 2011;20:111-118. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20680687>
236. Amling C, Leibovich B, Lerner S, Bergstralh E, Blute M, Myers R, et al. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. *Semin Urol Oncol.* 1997;15:215-221. URL: <http://www.ncbi.nlm.nih.gov/pubmed/9421448>
237. Berglund R, Jones J, Ulchaker J, Fergany A, Gill I, Kaouk J, et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. *Urology.* 2006;67:1253-1256. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16678888>
238. Freedland S, Partin A, Humphreys E, Mangold L, Walsh P. Radical prostatectomy for clinical stage T3a disease. *Cancer.* 2007;109:1273-1278. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17315165>
239. Gerber G, Thisted R, Chodak G, Schroder F, Frohmuller H, Scardino P, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. *Eur Urol.* 1997;32:385-390. URL: <http://www.ncbi.nlm.nih.gov/pubmed/9412793>
240. Ham W, Park S, Rha K, Kim W, Choi Y. Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible: results of a single-institution study. *J. Laparoendosc. Adv. Surg. Tech. A.* 2009;19:329-332. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19397390>
241. Hsu C, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. *Eur Urol.* 2007;51:121-128. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16797831>
242. Hsu C, Wildhagen M, Van Poppel H, Bangma C. Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy. *BJU Int.* 2010;105:1536-1540. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19912180>
243. Riva IMdl, Belon Lopez-Tomasety J, Marrero DR, Alvarez CE, Santamaria BP. Prostatectomia radical como monoterapia en el cancer de prostata localmente avanzado T3a: 12 anos de seguimiento. *Arch Esp Urol.* 2004;57:679-692. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15536949>

244. Mearini L, Zucchi A, Costantini E, Bini V, Nunzi E, Porena M. Outcomes of radical prostatectomy in clinically locally advanced N0M0 prostate cancer. *Urol. Int.* 2010;85:166-172. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20558980>
245. Patel V, Palmer K, Coughlin G, Samavedi S. Robot-assisted laparoscopic radical prostatectomy: perioperative outcomes of 1500 cases. *J. Endourol.* 2008;22:2299-2305. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18837657>
246. Powell I, Tangen C, Miller G, Lowe B, Haas G, Carroll P, et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. *J. Urol.* 2002;168:2016-2019. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12394698>
247. Sciarra A, Gentile V, Voria G, Mariotti G, Seccareccia F, Pastore A, et al. Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10. *Urol. Int.* 2003;70:186-194. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12660455>
248. Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. *Eur. Urol.* 2000;38:372-379. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11025373>
249. Xylinas E, Drouin S, Comperat E, Vaessen C, Renard-Penna R, Misrai V, et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. *BJU. Int.* 2009;103:1173-1178. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19040530>
250. Yossepowitch O, Eggener S, Serio A, Carver B, Bianco F, Scardino P, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. *Eur. Urol.* 2008;53:950-959. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17950521>
251. Loeb S, Smith N, Roehl K, Catalona W. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. *Urology.* 2007;69:1170-1175. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17572209>
252. Van Poppel H, Vekemans K, Da PL, Bono A, Kliment J, Montironi R, et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). *Eur. J Cancer.* 2006;42:1062-1067. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16624554>
253. Bolla M, Collette L, Blank L, Warde P, Dubois J, Mirimanoff R, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. *Lancet.* 2002;360:103-106. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12126818>
254. Bolla M, de Reijke T, van Tienhoven G, Van Den Bergh A, Oddens J, Poortmans P, et al. Duration of androgen suppression in the treatment of prostate cancer. *N Engl J Med.* 2009;360:2516-2527. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19516032>
255. Denham J, Steigler A, Lamb D, Joseph D, Mameghan H, Turner S, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 9601 randomised controlled trial. *Lancet Oncol.* 2005;6:841-850. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16257791>
256. Pilepich M, Winter K, John M, Mesic J, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive

- radiotherapy in locally advanced carcinoma of the prostate. *Int J Radiat Oncol Biol Phys.* 2001;50:1243-1252. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11483335>
257. Laverdiere J, Nabid A, De Bedoya L, Ebacher A, Fortin A, Wang C, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. *J Urol.* 2004;171:1137-1140. URL: <http://www.ncbi.nlm.nih.gov/pubmed/14767287>
258. Kumar S, Shelley M, Harrison C, Coles B, Wilt T, Mason M. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. *Cochrane Database Syst Rev.* 2006;CD006019. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17054269>
259. Pilepich M, Winter K, Lawton C, Krisch R, Wolkov H, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. *Int. J. Radiat. Oncol. Biol. Phys.* 2005;61:1285-1290. URL: <https://www.ncbi.nlm.nih.gov/pubmed/15817329>
260. Zagars G, Johnson D, von Eschenbach A, Hussey D. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. *Int. J. Radiat. Oncol. Biol. Phys.* 1988;14:1085-1091. URL: <https://www.ncbi.nlm.nih.gov/pubmed/3133327>
261. Tyrrell C, Payne H, See W, McLeod D, Wirth M, Iversen P, et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. *Radiother. Oncol.* 2005;76:4-10. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16145740>
262. Granfors T, Modig H, Damber J, Tomic R. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. *J Urol.* 2006;176:544-547. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16813885>
263. See W, Tyrrell C. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. *J. Cancer Res. Clin. Oncol.* 2006;132 Suppl 1:S7-16. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16896884>
264. Shelley M, Kumar S, Wilt T, Staffurth J, Coles B, Mason M. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. *Cancer Treat Rev.* 2009;35:9-17. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18926640>
265. Widmark A, Klepp O, Solberg A, Damber J, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. *Lancet.* 2009;373:301-308. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19091394>
266. Shelley M, Kumar S, Coles B, Wilt T, Staffurth J, Mason M. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. *Cancer Treat. Rev.* 2009;35:540-546. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19493624>
267. Roach M, Bae K, Speight J, Wolkov H, Rubin P, Lee R, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. *J. Clin. Oncol.* 2008;26:585-591. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18172188>

268. Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nistico C, et al. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. *BMC Cancer*. 2010;10:675. URL: <https://www.ncbi.nlm.nih.gov/pubmed/21143897>
269. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri E, Sperduti I, et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. *Cancer*. 2009;115:3446-3456. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19484790>
270. Denham J, Steigler A, Lamb D, Joseph D, Turner S, Matthews J, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 9601 randomised trial. *Lancet Oncol*. 2011;12:451-459. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21440505>
271. Efsthathiou J, Bae K, Shipley W, Hanks G, Pilepich M, Sandler H, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. *J Clin Oncol*. 2009;27:92-99. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19047297>
272. Kumar S, Shelley M, Harrison C, Coles B, Wilt T, Mason M. Neo-adjuvant and adjuvant hormone therapy for localised prostate cancer. *Cochrane Database Syst Rev*. 2006;CD006018. URL: <https://pubmed.ncbi.nlm.nih.gov/17054269/>
273. Bolla M, Van TG, Warde P, Dubois J, Mirimanoff R, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. *Lancet Oncol*. 2010;11:1066-1073. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20933466>
274. Pilepich M, Krall J, Johnson R, Sause W, Perez C, Zininger M, et al. Extended field (periaortic) irradiation in carcinoma of the prostate--analysis of RTOG 75-06. *Int. J. Radiat. Oncol. Biol. Phys*. 1986;12:345-351. URL: <http://www.ncbi.nlm.nih.gov/pubmed/3514555>
275. Asbell S, Martz K, Shin K, Sause W, Doggett R, Perez C, et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BNOM0 (A2) and T2NOM0 (B) prostate carcinoma. *Int J Radiat Oncol Biol Phys*. 1998;40:769-782. URL: <http://www.ncbi.nlm.nih.gov/pubmed/9531360>
276. Deger S, Boehmer D, Turk I, Roigas J, Wernecke K, Wiegel T, et al. High dose rate brachytherapy of localized prostate cancer. *Eur Urol*. 2002;41:420-426. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12074814>
277. Kalkner K, Wahlgren T, Ryberg M, Cohn-Cedermark G, Castellanos E, Zimmerman R, et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. *Acta Oncol*. 2007;46:909-917. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17917823>
278. Shelley M, Wilt T, Coles B, Mason M. Cryotherapy for localised prostate cancer. *Cochrane. Database. Syst. Rev*. 2007;CD005010. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17636783>
279. Chin J, Ng C, Touma N, Pus N, Hardie R, Abdelhady M, et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. *Prostate Cancer Prostatic Dis*. 2008;11:40-45. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17579613>

280. Cohen J, Miller R, Ahmed S, Lotz M, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. *Urology*. 2008;71:515-518. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18342200>
281. Tilly W, Gellermann J, Graf R, Hildebrandt B, Weissbach L, Budach V, et al. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. *Strahlenther. Onkol.* 2005;181:35-41. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15660191>
282. Maluta S, Dall'Oglio S, Romano M, Marciali N, Pioli F, Giri M, et al. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study. *Int. J. Hyperthermia*. 2007;23:451-456. URL: <https://www.ncbi.nlm.nih.gov/pubmed/17701536>
283. Algan O, Fosmire H, Hynynen K, Dalkin B, Cui H, Drach G, et al. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma. *Cancer*. 2000;89:399-403. URL: <http://www.ncbi.nlm.nih.gov/pubmed/10918172>
284. Thompson I, Tangen C, Paradelo J, Lucia M, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. *JAMA*. 2006;296:2329-2335. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17105795>
285. Thompson I, Tangen C, Paradelo J, Lucia M, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. *J Urol*. 2009;181:956-962. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19167731>
286. Bolla M, Van Poppel H, Collette L, van Cangh P, Vekemans K, Da PL, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). *Lancet*. 2005;366:572-578. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16099293>
287. Swanson G, Goldman B, Tangen C, Chin J, Messing E, Canby-Hagino E, et al. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. *J. Urol*. 2008;180:2453-2457. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18930488>
288. van der Kwast T, Bolla M, Van Poppel H, van Cangh P, Vekemans K, Da PL, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. *J Clin. Oncol.* 2007;25:4178-4186. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17878474>
289. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. *J Clin Oncol*. 2009;27:2924-2930. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19433689>
290. Moinpour C, Hayden K, Unger J, Thompson I, Redman M, Canby-Hagino E, et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. *J Clin Oncol*. 2008;26:112-120. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18165645>

291. Leibovich B, Engen D, Patterson D, Pisansky T, Alexander E, Blute M, et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. *J Urol.* 2000;163:1178-1182. URL: <http://www.ncbi.nlm.nih.gov/pubmed/10737490>
292. Swanson G, Thompson I, Basler J. Treatment options in lymph node-positive prostate cancer. *Cancer.* 2006;106:2531-2539. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16700035>
293. Horwitz E, Bae K, Hanks G, Porter A, Grignon D, Brereton H, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. *J Clin Oncol.* 2008;26:2497-2504. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18413638>
294. Fossati N, Willemse P, Van den Broeck T, van den Bergh R, Yuan C, Briers E, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. *Eur Urol.* 2017;72:84-109. URL: <http://www.ncbi.nlm.nih.gov/pubmed/28126351>
295. Da Pozzo L, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. *Eur Urol.* 2009;55:1003-1011. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19211184>
296. Briganti A, Karnes R, Da Pozzo L, Cozzarini C, Capitanio U, Gallina A, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. *Eur Urol.* 2011;59:832-840. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21354694>
297. Abdollah F, Karnes R, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. *J Clin Oncol.* 2014;32:3939-3947. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25245445>
298. Tilki D, Preisser F, Tennstedt P, Tober P, Mandel P, Schlomm T, et al. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. *BJU Int.* 2016; URL: <http://www.ncbi.nlm.nih.gov/pubmed/27743493>
299. Jegadeesh N, Liu Y, Zhang C, Zhong J, Cassidy R, Gillespie T, et al. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer. *Cancer.* 2017;123:512-520. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27859018>
300. Aus G, Abrahamsson P, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. *BJU Int.* 2002;90:561-566. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12230618>
301. Klotz L, Goldenberg S, Jewett M, Fradet Y, Nam R, Barkin J, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. *J Urol.* 2003;170:791-794. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12913699>
302. Schulman C, Debruyne F, Forster G, Selvaggi F, Zlotta A, Witjes W. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer European Study Group on Neoadjuvant Treatment of Prostate Cancer. *Eur. Urol.* 2000;38:706-713. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11111188>

303. Messing E, Manola J, Sarosdy M, Wilding G, Crawford E, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. *N. Engl. J. Med.* 1999;341:1781-1788. URL: <http://www.ncbi.nlm.nih.gov/pubmed/10588962>
304. Wirth M, Weissbach L, Marx F, Heckl W, Jellinghaus W, Riedmiller H, et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. *Eur. Urol.* 2004;45:267-270. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15036669>
305. McLeod D, Iversen P, See W, Morris T, Armstrong J, Wirth M. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. *BJU. Int.* 2006;97:247-254. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16430622>
306. Jones C, Hunt D, McGowan D, Amin M, Chetner M, Bruner D, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. *N Engl J Med.* 2011;365:107-118. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21751904>
307. Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N. Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses. *Clin Oncol (R Coll Radiol).* 2014;26:e21-e46. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25059922>
308. D'Amico A, Manola J, Loffredo M, Renshaw A, DellaCroce A, Kantoff P. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. *JAMA.* 2004;292:821-827. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15315996>
309. Hu J, Xu H, Zhu W, Wu F, Wang J, Ding Q, et al. Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients. *World J Surg Oncol.* 2015;13:73. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25884478>
310. Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans P, et al. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. *J Clin Oncol.* 2016;34:1748-1756. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26976418>
311. McPartlin A, Glicksman R, Pintilie M, Tsuji D, Mok G, Bayley A, et al. PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer. *Cancer.* 2016;122:2595-2603. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27219522>
312. Zhou Z, Zhu X, Xia J, Zou Z, Qu S, Zeng X, et al. Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis. *J Cancer Res Clin Oncol.* 2013;139:783-796. URL: <https://www.ncbi.nlm.nih.gov/pubmed/23380891>
313. Leal F, Figueiredo M, Sasse A. Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysis. *Int Braz J Urol.* 2015;41:425-434. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26200535>
314. Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San SC, Cabeza Rodriguez M, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

- Lancet Oncol. 2015;16:320-327. URL:  
<https://www.ncbi.nlm.nih.gov/pubmed/25702876>
315. Denham J, Joseph D, Lamb D, Spry N, Duchesne G, Matthews J, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 0304 RADAR): an open-label, randomised, phase 3 factorial trial. *Lancet Oncol.* 2014;15:1076-1089. URL:  
<http://www.ncbi.nlm.nih.gov/pubmed/25130995>
316. D'Amico A, Chen M, Renshaw A, Loffredo M, Kantoff P. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. *JAMA.* 2008;299:289-295. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18212313>
317. Dutch Urological Association. Prostate Cancer Nation-wide guideline Version 10. 2007
318. Iversen P, Johansson J, Lodding P, Kylmala T, Lundmo P, Klarskov P, et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 71 years. *Scand J Urol Nephrol.* 2006;40:441-452. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17130095>
319. Studer U, Whelan P, Albrecht W, Casselman J, de RT, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. *J. Clin. Oncol.* 2006;24:1868-1876. URL:  
<http://www.ncbi.nlm.nih.gov/pubmed/16622261>
320. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. *Br. J. Urol.* 1997;79:235-246. URL:  
<http://www.ncbi.nlm.nih.gov/pubmed/9052476>
321. Parker M, Cook A, Riddle P, Fryatt I, O'Sullivan J, Shearer R. Is delayed treatment justified in carcinoma of the prostate?. *Br. J. Urol.* 1985;57:724-728. URL:  
<http://www.ncbi.nlm.nih.gov/pubmed/4084734>
322. Herr H, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. *J Urol.* 2000;163:1743-1746. URL:  
<http://www.ncbi.nlm.nih.gov/pubmed/10799173>
323. Boustead G, Edwards S. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials. *BJU Int.* 2007;99:1383-1389. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17346269>
324. Wilt T, air B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. *Cochrane. Database. Syst. Rev.* 2001;CD003506. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11869665>
325. Amling C, Bergstralh E, Blute M, Slezak J, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. *J Urol.* 2001;165:1146-1151. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11257657>
326. Stephenson A, Kattan M, Eastham J, Dotan Z, Bianco F, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. *J. Clin. Oncol.* 2006;24:3973-3978. URL:  
<http://www.ncbi.nlm.nih.gov/pubmed/16921049>

327. Freedland S, Sutter M, Dorey F, Aronson W. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy Prostate-specific antigen. *Urology*. 2003;61:365-369. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12597949>
328. Roach M, Hanks G, Thames H, Schellhammer P, Shipley W, Sokol G, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int. J. Radiat. Oncol. Biol. Phys.* 2006;65:965-974. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16798415>
329. Foster L, Jajodia P, Fournier G, Shinohara K, Carroll P, Narayan P. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. *J Urol.* 1993;149:1024-1028. URL: <http://www.ncbi.nlm.nih.gov/pubmed/7683341>
330. Fowler J, Brooks J, Pandey P, Seaver L. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. *J Urol.* 1995;153:1011-1014. URL: <http://www.ncbi.nlm.nih.gov/pubmed/7531783>
331. Heidenreich A, Bolla M, Joniau S, van der Kwast T, Matveev V, Mason M, et al. EAU guidelines on prostate cancer. 2009
332. Nguyen P, D'Amico A, Lee A, Suh W. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. *Cancer.* 2007;110:1417-1428. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17694553>
333. Freedland S, Humphreys E, Mangold L, Eisenberger M, Dorey F, Walsh P, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. *JAMA.* 2005;294:433-439. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16046649>
334. Jerezek-Fossa B, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. *Radiother Oncol.* 2007;84:197-215. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17532494>
335. Loeb S, Roehl K, Viprakasit D, Catalona W. Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. *Eur. Urol.* 2008;54:88-94. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18400368>
336. Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. *Int. J. Radiat. Oncol. Biol. Phys.* 2008;72:972-979. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18954710>
337. Heidenreich A, Richter S, Thuer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. *Eur Urol.* 2010;57:437-443. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19303197>
338. Parekh A, Graham P, Nguyen P. Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review. *Semin Radiat Oncol.* 2013;23:222-234. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23763889>
339. Crouzet S, Blana A, Murat F, Pasticier G, Brown S, Conti G, et al. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. *BJU Int.* 2017;119:896-904. URL: <http://www.ncbi.nlm.nih.gov/pubmed/28063191>

340. Kanthabalan A, Peters M, van Vulpen M, McCartan N, Hindley R, Emara A, et al. Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. *BJU Int*. 2017;120:246-256. URL: <http://www.ncbi.nlm.nih.gov/pubmed/28258616>
341. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2013;14:149-158. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23306100>
342. Sweeney C, Chen Y, Carducci M, Liu G, Jarrard D, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. *N Engl J Med*. 2015;373:737-746. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26244877>
343. James N, Sydes M, Clarke N, Mason M, Dearnaley D, Spears M, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. *Lancet*. 2016;387:1163-1177. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26719232>
344. Kunath F, Jensen K, Pinart M, Kahlmeyer A, Schmidt S, Price CL, et al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. *The Cochrane database of systematic reviews*. 2019;6:CD003506. URL: <https://pubmed.ncbi.nlm.nih.gov/31194882/>
345. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med*. 2019;381:13-24. URL: <https://pubmed.ncbi.nlm.nih.gov/31150574/>
346. Armstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. *J Clin Oncol*. 2019;37:2974-2986. URL: <https://pubmed.ncbi.nlm.nih.gov/31329516/>
347. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE). *Lancet Oncol*. 2019;20:686-700. URL: <https://pubmed.ncbi.nlm.nih.gov/30987939/>
348. Fizazi K, Tran NP, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *The New England journal of medicine*. 2017;377:352-360. URL: <https://pubmed.ncbi.nlm.nih.gov/28578607/>
349. Smith M, Hussain M, Saad F, Fizazi K, Sternberg C, Crawford E, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. *N Engl J Med*. 2022;386(12):1132-1142. URL: <https://pubmed.ncbi.nlm.nih.gov/35179323/>
350. Hussain M, Tombal B, Saad F, Fizazi K, Sternberg C, Crawford E, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. *J Clin Oncol*. 2023;41(20):3595-3607. URL: <https://pubmed.ncbi.nlm.nih.gov/36795843/>
351. Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. *Lancet*. 2022;399(10336):1695-1707. URL: <https://pubmed.ncbi.nlm.nih.gov/35405085/>

352. Loblaw D, Virgo K, Nam R, Somerfield M, Ben-Josef E, Mendelson D, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. *J Clin Oncol*. 2007;25:1596-1605. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17404365>
353. Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2019;30:1992-2003. URL: <https://pubmed.ncbi.nlm.nih.gov/31560068/>
354. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. *Lancet*. 2000;355:1491-1498. URL: <http://www.ncbi.nlm.nih.gov/pubmed/10801170>
355. Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2015;1:1261-1269. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26378418>
356. Niraula S, Le L, Tannock I. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. *J Clin Oncol*. 2013;31:2029-2036. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23630216>
357. Cookson M, Roth B, Dahm P, Engstrom C, Freedland S, Hussain M, et al. Castration-Resistant Prostate Cancer: AUA Guideline. *J Urol*. 2013; URL: <http://www.ncbi.nlm.nih.gov/pubmed/23665272>
358. Berthold D, Pond G, Soban F, de WR, Eisenberger M, Tannock I. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. *J Clin Oncol*. 2008;26:242-245. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18182665>
359. Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de SP, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med*. 2013;368:138-148. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23228172>
360. Kantoff P, Higano C, Shore N, Berger E, Small E, Penson D, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*. 2010;363:411-422. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20818862>
361. Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med*. 2014;371:424-433. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24881730>
362. Parker C, Nilsson S, Heinrich D, Helle S, O'Sullivan J, Fossa S, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med*. 2013;369:213-223. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23863050>
363. de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med*. 2011;364:1995-2005. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21612468>
364. Fizazi K, Scher H, Molina A, Logothetis C, Chi K, Jones R, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol*. 2012;13:983-992. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22995653>

365. Logothetis C, Basch E, Molina A, Fizazi K, North S, Chi K, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. *Lancet Oncol.* 2012;13:1210-1217. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23142059>
366. Scher H, Fizazi K, Saad F, Taplin M, Sternberg C, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N. Engl. J. Med.* 2012;367:1187-1197. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22894553>
367. de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet.* 2010;376:1147-1154. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20888992>
368. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet.* 2011;377:813-822. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21353695>
369. Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J. Natl. Cancer Inst.* 2002;94:1458-1468. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12359855>
370. Yuen K, Shelley M, Sze W, Wilt T, Mason M. Bisphosphonates for advanced prostate cancer. *Cochrane Database Syst Rev.* 2006;CD006250. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17054286>
371. Fossa S, Jacobsen A, Ginman C, Jacobsen I, Overn S, Iversen J, et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. *Eur Urol.* 2007;52:1691-1698. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17306441>
372. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German Multicenter Study Investigating <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. *J Nucl Med.* 2017;58:85-90. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27765862>
373. Yadav M, Ballal S, Tripathi M, Damle N, Sahoo R, Seth A, et al. <sup>177</sup>Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. *Eur J Nucl Med Mol Imaging.* 2017;44:81-91. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27506431>
374. Kratochwil C, Giesel F, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>177</sup>Lu-Labeled PSMA-617. *J Nucl Med.* 2016;57:1170-1176. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26985056>
375. Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff C, et al. Therapeutic response and side effects of repeated radioligand therapy with <sup>177</sup>Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. *Oncotarget.* 2016;7:12477-12488. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26871285>
376. Fendler W, Reinhardt S, Ilhan H, Delker A, Boning G, Gildehaus F, et al. Preliminary experience with dosimetry, response and patient reported outcome after <sup>177</sup>Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. *Oncotarget.* 2017;8:3581-3590. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27683041>

377. Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. *EJNMMI. Res.* 2015;5:114. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26099227>
378. Baum R, Kulkarni H, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. *J Nucl Med.* 2016;57:1006-1013. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26795286>
379. Heck M, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, et al. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. *J Urol.* 2016;196:382-391. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26964917>
380. Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. *Acta Oncol.* 2003;42:620-633. URL: <http://www.ncbi.nlm.nih.gov/pubmed/14596519>
381. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. *Radiother Oncol.* 2005;75:258-270. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16299924>
382. Smith M, Coleman R, Klotz L, Pittman K, Milecki P, Ng S, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. *Ann Oncol.* 2015;26:368-374. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25425475>
383. James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, et al. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial. *JAMA Oncol.* 2016;2:493-499. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26794729>
384. Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, et al. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. *Int J Clin Oncol.* 2016;1-8. URL: <http://www.ncbi.nlm.nih.gov/pubmed/27614621>
385. Smith M, Halabi S, Ryan C, Hussain A, Vogelzang N, Stadler W, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). *J Clin Oncol.* 2014;32:1143-1150. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24590644>
386. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. *Clin Prostate Cancer.* 2005;4:31-37. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15992459>
387. Vernia P, Fracasso P, Casale V, Villotti G, Marcheggiano A, Stigliano V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. *Lancet.* 2000;356:1232-1235. URL: <http://www.ncbi.nlm.nih.gov/pubmed/11072942>
388. Sanguineti G, Franzone P, Marcenaro M, Foppiano F, Vitale V. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma A randomized study. *Strahlenther. Onkol.* 2003;179:464-470. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12835883>

389. Qaseem A, Snow V, Shekelle P, Casey D, Cross J, Owens D, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. *Ann. Intern. Med.* 2008;148:141-146. URL: <http://www.ncbi.nlm.nih.gov/pubmed/18195338>
390. Leitliniengruppe Hessen. Palliativversorgung Hausärztliche Leitlinie. 2009
391. Deutsche Krebsgesellschaft (DKG), Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Therapie und Nachsorge des Mammakarzinoms 1 Aktualisierung. 2008
392. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur Therapie von Tumorschmerzen. *Arzneiverordnung in der Praxis*; 34. 2007
393. MacDonald R, Fink H, Huckabay C, Monga M, Wilt T. Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness. *BJU. Int.* 2007;100:76-81. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17433028>
394. Manassero F, Traversi C, Ales V, Pistolesi D, Panicucci E, Valent F, et al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: results of a prospective controlled randomized trial. *Neurourol. Urodyn.* 2007;26:985-989. URL: <http://www.ncbi.nlm.nih.gov/pubmed/17487874>
395. Anderson C, Omar M, Campbell S, Hunter K, Cody J, Glazener C. Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst Rev.* 2015;1:CD001843. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25602133>
396. Wang W, Huang Q, Liu F, Mao Q. Effectiveness of preoperative pelvic floor muscle training for urinary incontinence after radical prostatectomy: a meta-analysis. *BMC Urol.* 2014;14:99. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25515968>
397. Zhu Y, Yao X, Zhang S, Dai B, Ye D. Pelvic floor electrical stimulation for postprostatectomy urinary incontinence: a meta-analysis. *Urology.* 2012;79:552-555. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22386394>
398. Geraerts I, Van PH, Devoogdt N, De GA, Fieuws S, Van KM. Pelvic floor muscle training for erectile dysfunction and climacturia 1 year after nerve sparing radical prostatectomy: a randomized controlled trial. *Int J Impot. Res.* 2016;28:9-13. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26538105>
399. Prota C, Gomes C, Ribeiro L, de BJ, Nakano E, Dall'oglio M, et al. Early postoperative pelvic-floor biofeedback improves erectile function in men undergoing radical prostatectomy: a prospective, randomized, controlled trial. *Int J Impot. Res.* 2012;24:174-178. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22573231>
400. Zippe C, Pahlajani G. Penile rehabilitation following radical prostatectomy: role of early intervention and chronic therapy. *Urol Clin. North Am.* 2007;34:601-18, viii. URL: <https://www.ncbi.nlm.nih.gov/pubmed/17983900>
401. Bo Y, Jiansheng W. Effects of Exercise on Cancer-related Fatigue and Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Meta-analysis of Randomized Clinical Trials. *Chin Med Sci J.* 2017;32:13-21. URL: <http://www.ncbi.nlm.nih.gov/pubmed/28399980>
402. Teleni L, Chan R, Chan A, Isenring E, Vela I, Inder W, et al. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of

- randomised controlled trials. *Endocr. Relat Cancer*. 2016;23:101-112. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26584972>
403. Hasenoeuhl T, Keilani M, Sedghi Komanadj T, Mickel M, Margreiter M, Marhold M, et al. The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review. *Support Care Cancer*. 2015;23:2479-2497. URL: <http://www.ncbi.nlm.nih.gov/pubmed/26003426>
404. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer. *Lancet*. 2012;380:2018-2027. URL: <https://pubmed.ncbi.nlm.nih.gov/23084481/>
405. Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT). *Lancet*. 2020;396:1413-1421. URL: <https://pubmed.ncbi.nlm.nih.gov/33002429/>
406. Vale C, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer. *Lancet*. 2020;396:1422-1431. URL: <https://pubmed.ncbi.nlm.nih.gov/33002431/>
407. Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 0803/ANZUP RAVES). *Lancet Oncol*. 2020;21:1331-1340. URL: <https://pubmed.ncbi.nlm.nih.gov/33002437/>
408. Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17). *Lancet Oncol*. 2020;21:1341-1352. URL: <https://pubmed.ncbi.nlm.nih.gov/33002438/>
409. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy. *European urology*. 2014;66:243-250. URL: [www.ncbi.nlm.nih.gov/pubmed/24680359](http://www.ncbi.nlm.nih.gov/pubmed/24680359)
410. Sachdev S, Carroll P, Sandler H, Nguyen P, Wafford E, Aufferberg G, et al. Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. *JAMA Oncol*. 2020;[Epub ahead of print]. URL: <https://pubmed.ncbi.nlm.nih.gov/32852528/>
411. Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN). *Lancet Oncol*. 2019;20:1518-1530. URL: <https://pubmed.ncbi.nlm.nih.gov/31578173/>
412. 70 years): The PEACE-1 trial. *ASCO GU*. 2023
413. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA). *Lancet*. 2020;395:1208-1216. URL: <https://pubmed.ncbi.nlm.nih.gov/32209449/>
414. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management. NICE Guideline; 175. 2014; URL: <http://www.nice.org.uk/guidance/cg175/resources/prostate-cancer-diagnosis-and-management-pdf-35109753913285>

415. Azzouzi A, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel H, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. *Lancet Oncol.* 2017;18:181-191. URL: <http://www.ncbi.nlm.nih.gov/pubmed/28007457>
416. Gill IS, Azzouzi AR, Emberton M, Coleman JA, Coeytaux E, Scherz A, et al. Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer. *The Journal of urology.* 2018;200:786-793. URL: <https://pubmed.ncbi.nlm.nih.gov/29864437/>
417. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med.* 2017;377:352-360. URL: <http://www.ncbi.nlm.nih.gov/pubmed/28578607>
418. Saad F, Cella D, Basch E, Hadaschik B, Mainwaring P, Oudard S, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer. *Lancet Oncol.* 2018;19:1404-1416. URL: <https://pubmed.ncbi.nlm.nih.gov/30213449/>
419. Small E, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff J, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. *Ann Oncol.* 2019;30:1813-1820. URL: <https://pubmed.ncbi.nlm.nih.gov/31560066/>
420. Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff J, et al. Apalutamide and Overall Survival in Prostate Cancer. *Eur Urol.* 2020;79:150-158. URL: <https://pubmed.ncbi.nlm.nih.gov/32907777/>
421. Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, Graff J, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med.* 2018;378:1408-1418. URL: <https://pubmed.ncbi.nlm.nih.gov/29420164/>
422. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med.* 2019;380:1235-1246. URL: <https://pubmed.ncbi.nlm.nih.gov/30763142/>
423. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. *N Engl J Med.* 2020;383:1040-1049. URL: <https://pubmed.ncbi.nlm.nih.gov/32905676/>
424. Sternberg C, Fizazi K, Saad F, Shore N, Giorgi U, Penson D, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med.* 2020;382:2197-2206. URL: <https://pubmed.ncbi.nlm.nih.gov/32469184/>
425. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med.* 2018;378:2465-2474. URL: <https://pubmed.ncbi.nlm.nih.gov/29949494/>
426. Tombal B, Saad F, Penson D, Hussain M, Sternberg C, Morlock R, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER). *Lancet Oncol.* 2019;20:556-569. URL: <https://pubmed.ncbi.nlm.nih.gov/30770294/>
427. Beer T, Armstrong A, Rathkopf D, Lortol Y, Sternberg C, Higano C, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. *European urology.* 2017;71:151-154. URL: <https://pubmed.ncbi.nlm.nih.gov/27477525/>

428. Wit R, Bono J, Sternberg C, Fizazi K, Tombal B, Wülfing C, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. *N Engl J Med*. 2019;381:2506-2518. URL: [www.ncbi.nlm.nih.gov/pubmed/31566937](http://www.ncbi.nlm.nih.gov/pubmed/31566937)
429. Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020;382:2091-2102. URL: <https://pubmed.ncbi.nlm.nih.gov/32343890/>
430. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020;383:2345-2357. URL: <https://pubmed.ncbi.nlm.nih.gov/32955174/>
431. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE). *Lancet*. 2018;392:2353-2366. URL: <https://pubmed.ncbi.nlm.nih.gov/30355464/>
432. Vogelzang N, Coleman R, Michalski J, Nilsson S, O'Sullivan J, Parker C, et al. Hematologic Safety of Radium-223 Dichloride. *Clin Genitourin Cancer*. 2017;15:42-52.e8. URL: <https://pubmed.ncbi.nlm.nih.gov/27613490/>
433. Smith M, Parker C, Saad F, Miller K, Tombal B, Ng Q, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223). *Lancet Oncol*. 2019;20:408-419. URL: <https://pubmed.ncbi.nlm.nih.gov/30738780/>
434. Yadav M, Ballal S, Sahoo R, Dwivedi S, Bal C. Radioligand Therapy With (177) Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer. *AJR Am J Roentgenol*. 2019;213:275-285. URL: [www.ncbi.nlm.nih.gov/pubmed/30995089](http://www.ncbi.nlm.nih.gov/pubmed/30995089)
435. Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer. *Eur Urol*. 2019;76:115-124. URL: <https://pubmed.ncbi.nlm.nih.gov/30826218/>
436. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. *JAMA Oncol*. 2020;6:650-659. URL: <https://pubmed.ncbi.nlm.nih.gov/32215577/>
437. Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, et al. A systematic review of contemporary management of oligometastatic prostate cancer. *World J Urol*. 2019;37:2343-2353. URL: <https://pubmed.ncbi.nlm.nih.gov/30706122/>
438. Connor MJ, Smith A, Miah S, Shah TT, Winkler M, Khoo V, et al. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer. *Eur Urol Oncol*. 2020;3:582-593. URL: <https://pubmed.ncbi.nlm.nih.gov/32891600/>
439. Han S, Woo S, Kim Y, Lee J, Wibmer A, Schoder H, et al. Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. *Diagnostics (Basel)*. 2021;11(4): URL: <https://pubmed.ncbi.nlm.nih.gov/33917006/>
440. Patell K, Kurian M, Garcia J, Mendiratta P, Barata P, Jia A, et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. *Expert Rev Anticancer Ther*. 2023;23(7):731-744. URL: <https://pubmed.ncbi.nlm.nih.gov/37194261/>
441. Esen B, Herrmann K, Bavbek S, Kordan Y, Tilki D, Esen T. Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response

- in Patients with Advanced Prostate Cancer. *Eur Urol Focus*. 2023;9(4):596-605. URL: <https://pubmed.ncbi.nlm.nih.gov/36842919/>
442. Buteau J, Martin A, Emmett L, Iravani A, Sandhu S, Joshua A, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [18F]NaF. *Lancet Oncol*. 2022;23(11):1389-1397. URL: <https://pubmed.ncbi.nlm.nih.gov/36261050/>
443. Wolf S, Froukh RFI. 77Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: An Update 2022. 2023;Decision Support Document No. 118 Update
444. Nautiyal A, Jha A, Mithun S, Rangarajan V. Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review. *Nucl Med Commun*. 2022;43(4):369-377. URL: <https://pubmed.ncbi.nlm.nih.gov/35045551/>
445. Sadaghiani M, Sheikhabaei S, Werner R, Pienta K, Pomper M, Solnes L, et al. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. *Eur Urol*. 2021;80(1):82-94. URL: <https://pubmed.ncbi.nlm.nih.gov/33840558/>
446. Satapathy S, Mittal B, Sood A. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis. *Clin Nucl Med*. 2020;45(12):935-942. URL: <https://pubmed.ncbi.nlm.nih.gov/32956129/>
447. Satapathy S, Sahoo R, Bal C. [18F]NaF PET/CT in Prostate Cancer. *J Nucl Med*. 2023;64(8):1266-1271. URL: <https://pubmed.ncbi.nlm.nih.gov/37169534/>
448. von Eyben F, Bauman G, von Eyben R, Rahbar K, Soydal C, Haug A, et al. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer A Systematic Review and Meta-Analysis. *Int J Mol Sci*. 2020;21(23): URL: <https://pubmed.ncbi.nlm.nih.gov/33260535/>
449. Fizazi K, Herrmann K, Krause B, Rahbar K, Chi K, Morris M, et al. Health-related quality of life and pain outcomes with [18F]NaF PET/CT. *Lancet Oncol*. 2023;24(6):597-610. URL: <https://pubmed.ncbi.nlm.nih.gov/37269841/>
450. Satapathy S, Mittal B, Sood A, Das C, Mavuduru R, Goyal S, et al. [18F]NaF PET/CT in Prostate Cancer. *J Nucl Med*. 2023;64(11):1726-1729. URL: <https://pubmed.ncbi.nlm.nih.gov/37709534/>
451. Satapathy S, Mittal B, Sood A, Das C, Mavuduru R, Goyal S, et al. Eur J Nucl Med Mol Imaging. 2022;49(5):1754-1764. URL: <https://pubmed.ncbi.nlm.nih.gov/34842950/>
452. Sartor O, de Bono J, Chi K, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2021;385(12):1091-1103. URL: <https://pubmed.ncbi.nlm.nih.gov/34161051/>
453. Hofman M, Emmett L, Sandhu S, Iravani A, Joshua A, Goh J, et al. [18F]NaF PET/CT in Prostate Cancer. *Lancet*. 2021;397(10276):797-804. URL: <https://pubmed.ncbi.nlm.nih.gov/33581798/>
454. Afferi L, Longoni M, Moschini M, Gandaglia G, Morgans A, Cathomas R, et al. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy. *Prostate Cancer Prostatic Dis*. 2023;; URL: <https://pubmed.ncbi.nlm.nih.gov/37055663/>

455. Cao B, Kim M, Reizine N, Moreira D. Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. *Eur Urol Oncol.* 2023;6(3):237-250. URL: <https://pubmed.ncbi.nlm.nih.gov/36682938/>
456. Dou M, Liang H, Liu Y, Zhang Q, Li R, Chen S, et al. Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis. *J Cancer Res Clin Oncol.* 2023;149(10):7017-7027. URL: <https://pubmed.ncbi.nlm.nih.gov/36856851/>
457. Jian T, Zhan Y, Yu Y, Yu K, Hu R, Wang J, et al. Combination therapy for high-volume. *Front Pharmacol.* 2023;14:1148021. URL: <https://pubmed.ncbi.nlm.nih.gov/37153773/>
458. Lee Y, Kim S, Tae J, Chang I, Kim T, Myung S, et al. Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials. *Prostate Int.* 2023;11(3):159-166. URL: <https://pubmed.ncbi.nlm.nih.gov/37745904/>
459. Rajwa P, Yanagisawa T, Heidegger I, Zattoni F, Marra G, Soeterik T, et al. Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis.* 2023;26(1):170-179. URL: <https://pubmed.ncbi.nlm.nih.gov/36284192/>
460. Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Liu H, et al. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. *JAMA Oncol.* 2023;9(5):635-645. URL: <https://pubmed.ncbi.nlm.nih.gov/36862387/>
461. Yanagisawa T, Kawada T, Mori K, Shim S, Mostafaei H, Sari Motlagh R, et al. Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis. *BJU Int.* 2023;132(4):365-379. URL: <https://pubmed.ncbi.nlm.nih.gov/37395151/>
462. Yanagisawa T, Rajwa P, Kawada T, Mori K, Fukuokaya W, Petrov P, et al. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis. *J Urol.* 2023;210(3):416-429. URL: <https://pubmed.ncbi.nlm.nih.gov/37339479/>
463. Zhou Z, Liu S, Mei J, Liu T, Liu F, Zhang G. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. *Acta Oncol.* 2023;62(9):1083-1090. URL: <https://pubmed.ncbi.nlm.nih.gov/37548225/>
464. Ciccarese C, Iacovelli R, Sternberg C, Gillessen S, Tortora G, Fizazi K. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. *Eur J Cancer.* 2022;173:276-284. URL: <https://pubmed.ncbi.nlm.nih.gov/35964470/>
465. Jian T, Zhan Y, Hu K, He L, Chen S, Hu R, et al. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. *Front Pharmacol.* 2022;13:955925. URL: <https://pubmed.ncbi.nlm.nih.gov/36278154/>
466. Maiorano B, De Giorgi U, Roviello G, Messina C, Altavilla A, Cattrini C, et al. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. *ESMO Open.* 2022;7(5):100575. URL: <https://pubmed.ncbi.nlm.nih.gov/36152486/>

467. Shore N, Saad F, Cookson M, George D, Saltzstein D, Tutrone R, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. *N Engl J Med*. 2020;382(23):2187-2196. URL: <https://pubmed.ncbi.nlm.nih.gov/32469183/>
468. Alameddine Z, Niazi M, Rajavel A, Behgal J, Keesari P, Araji G, et al. A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer. *Curr Oncol*. 2023;30(10):9262-9275. URL: <https://pubmed.ncbi.nlm.nih.gov/37887569/>
469. Agarwal N, Azad A, Carles J, Fay A, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2023;402(10398):291-303. URL: <https://pubmed.ncbi.nlm.nih.gov/37285865/>
470. Chi K, Rathkopf D, Smith M, Efstathiou E, Attard G, Olmos D, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. *J Clin Oncol*. 2023;41(18):3339-3351. URL: <https://pubmed.ncbi.nlm.nih.gov/36952634/>
471. Fizazi K, Piulats J, Reaume M, Ostler P, McDermott R, Gingerich J, et al. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. *N Engl J Med*. 2023;388(8):719-732. URL: <https://pubmed.ncbi.nlm.nih.gov/36795891/>
472. Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol*. 2020;21(1):162-174. URL: <https://pubmed.ncbi.nlm.nih.gov/31806540/>
473. Saad F, Efstathiou E, Attard G, Flaig T, Franke F, Goodman O, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. *Lancet Oncol*. 2021;22(11):1541-1559. URL: <https://pubmed.ncbi.nlm.nih.gov/34600602/>
474. Annala M, Fu S, Bacon J, Sipola J, Iqbal N, Ferrario C, et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. *Ann Oncol*. 2021;32(7):896-905. URL: <https://pubmed.ncbi.nlm.nih.gov/33836265/>
475. Sternberg C, Castellano D, de Bono J, Fizazi K, Tombal B, Wülfing C, et al. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. *Eur Urol*. 2021;80(4):497-506. URL: <https://pubmed.ncbi.nlm.nih.gov/34274136/>
476. Fizazi K, Kramer G, Eymard J, Sternberg C, de Bono J, Castellano D, et al. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. *Lancet Oncol*. 2020;21(11):1513-1525. URL: <https://pubmed.ncbi.nlm.nih.gov/32926841/>
477. Merseburger A, Attard G, Åström L, Matveev V, Bracarda S, Esen A, et al. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. *Lancet Oncol*. 2022;23(11):1398-1408. URL: <https://pubmed.ncbi.nlm.nih.gov/36265504/>
478. Maughan B, Kessel A, McFarland T, Sayegh N, Nussenzeig R, Hahn A, et al. Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. *Oncologist*. 2021;26(12):1006-e2129. URL: <https://pubmed.ncbi.nlm.nih.gov/34423501/>

479. Morris M, Heller G, Hillman D, Bobek O, Ryan C, Antonarakis E, et al. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). *J Clin Oncol*. 2023;41(18):3352-3362. URL: <https://pubmed.ncbi.nlm.nih.gov/36996380/>
480. Saad F, Clarke N, Oya M, Shore N, Procopio G, Guedes J, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2023;24(10):1094-1108. URL: <https://pubmed.ncbi.nlm.nih.gov/37714168/>
481. Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, et al. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2022;23(3):393-405. URL: <https://pubmed.ncbi.nlm.nih.gov/35157830/>